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	 Autism spectrum disorder (ASD) is a complex neurodevelopmental condition 
characterized by impairments in social interaction and communication, and by the presence of 
restrictive repetitive behavior. The precise cause of ASD is largely unknown, but is thought to be 
due to genetic predisposition combined with environmental factors. Emerging epidemiological 
studies have identified several non-genetic risk factors for ASD, many of which may have their 
origins during prenatal and early postnatal periods. Among these, nutritional and metabolic 
factors during critical early life windows may be important, but they have not been well studied 
in a prospective birth cohort.  
To address some of these knowledge gaps, this dissertation focused on the prospective 
associations between: 1) maternal folate and vitamin B12 status and development of ASD in 
children (specific aim 1); and 2) child’s leptin and adiponectin levels and development of ASD 
(specific aims 2 and 3). Data from the Boston Birth Cohort (BBC), a large prospective birth 
cohort, consisting of a predominantly urban, low-income minority population, were used. The 
BBC recruited mother-child pairs at birth and followed them from birth onwards for pediatric 
outcomes including ASD. Electronic Medical Records were used to identify children with ASD 
and other neurodevelopmental disorders. 
 For specific aim 1, maternal folate status was defined using two complementary 
measures: maternal self-reported intake via questionnaire and maternal plasma biomarker of 
folate and vitamin B12 levels. Mothers’ supplement intake during pregnancy was associated 
with a ‘U-shaped’ relationship in ASD risk in their children. In addition, extremely high maternal 
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plasma folate and vitamin B12 levels were associated with a greater risk of developing ASD in 
children.  
For specific aims 2 and 3, the child’s plasma leptin and adiponectin levels were 
measured at two-time points: cord blood collected at delivery and venous blood collected in 
early childhood. Children with highest early childhood leptin levels (quartile 4), when compared 
to those with lowest levels (quartile 1), showed an increased risk of developing ASD. Extremely 
rapid weight gain during 1
st
 year of life was associated with a greater ASD risk, when compared 
to those children whose growth was on track and this association persisted after adjusting for 
pertinent confounders. Early childhood leptin partially mediated the association between 1
st
 
year weight gain and ASD. However, no association with ASD was found for fetal growth 
pattern and cord leptin levels. On the other hand, cord adiponectin levels were inversely 
associated with ASD risk and this was independent of preterm birth, early childhood 
adiponectin and other known ASD risk factors. While higher early childhood adiponectin was 
also associated with a lower risk of ASD, the association attenuated after adjusting for cord 
adiponectin.  
The findings from this dissertation, if confirmed by future studies, could have important 
clinical and public health implications. Notably, findings from specific aim 1 underscore the 
need to 1) regularly monitor folate levels in women of reproductive age (both at clinical and 
population level); and 2) identify an optimal plasma folate levels, so that adverse effects of both 
low and high levels of folate can be averted. Findings from specific aims 2 and 3 provide a basis 
to further explore whether biomarkers such as leptin and adiponectin, in combination with 
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early life growth pattern can improve our ability to detect children at high risk of developing 
ASD at the earliest possible age, to inform targets for early prevention. 
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Autism Spectrum Disorder (ASD) is a heterogeneous group of neurodevelopmental 
conditions characterized by impairments in social interaction and communication, and by the 
presence of repetitive and/or restrictive behaviors and interests (1-5). Until recently, ASD 
prevalence in the U.S. has been increasing steadily (6, 7). According to recent estimates in the 
U.S., the risk of ASD is about one in 68 individuals, with one in 42 boys (23.6 per 1,000) and one 
in 189 girls (5.3 per 1,000) diagnosed with ASD (4, 7-9). The precise cause of ASD is largely 
unknown, but is thought to be due to genetic predisposition combined with environmental 
factors (6, 10-12).  While genetic factors are implicated in the etiology of ASD, to a large extent, 
ASD is also likely to be attributed to pre-, peri- and postnatal environmental factors (13). 
Several neuropathologic changes observed in the brain hint that ASD originates in utero; 
however, considering the brain’s plasticity, postnatal factors may still influence ASD’s natural 
history (14).  
Maternal nutrition is critical for fetal neurodevelopment (15-18); yet, there is a dearth 
of research on prenatal nutritional status and ASD (13). All nutrients are important for normal 
brain functioning with some (e.g. B vitamins such as folate, vitamin B12 and minerals such as 
iodine, iron) having a greater influence than others (3, 19). Emerging research has hypothesized 
the role of folate status in ASD, but the evidence is largely inconclusive (20, 21). Also, other 
nutrients involved in one-carbon metabolism (e.g. vitamin B12) have not been assessed in the 
context of ASD (13).  
In addition to nutritional factors, maternal metabolic conditions such as overweight, 
obesity and diabetes mellitus have also been linked with ASD (22-24). In addition to being a fat 
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depot, adipose tissue also functions as an immune and endocrine organ that is involved in 
metabolic responses to insults and also orchestrates inflammatory responses. Adipokines are 
cytokines that are predominantly produced by adipose tissue and includes leptin and 
adiponectin, in addition to resistin, visfatin and others (25).  Leptin and adiponectin are known 
for their ability in mediating feeding behavior and thermogenesis; in addition, recent studies 
have suggested that they possess a neurotrophic role during critical developmental periods (26) 
with elevated levels of leptin (27-31) and decreased levels of adiponectin observed in children 
with ASD compared to typically developing children (32). While emerging evidence may suggest 
a possible association, more research is needed to understand the prospective relationships 
between cord blood, early childhood plasma leptin and adiponectin and ASD risk (27). Leptin 
and adiponectin are associated with other prenatal/postnatal conditions, such as preterm birth 
(33-40), fetal growth and rapid growth in infancy (28, 41) and these factors are also 
independently associated with ASD (42-54). However, the potential role of cord and early 
childhood adipokines, prenatal/postnatal growth pattern, and preterm birth has not been 
jointly evaluated in the context of ASD.  
The timing of nutritional and metabolic insults may have a profound effect on the brain 
development and function (55, 56). The developing brain is especially sensitive to nutritional 
imbalances during late fetal/ neonatal periods and early childhood, during which there is a 
rapid development of several neurologic processes (19, 57). Similarly, metabolic insults during 
critical windows of development can have an impact on subcutaneous fat mass, insulin 
signaling pathways and may increase leptin expression (58). Given the importance of timing, 
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there is an urgent need to examine the ramifications of sub-optimal nutritional and metabolic 
states (58) during different critical developmental windows on ASD.  
In summary, although the field of early life origins of ASD is brimming with new 
research, only few studies have explored the relationship between maternal nutritional status, 
offspring metabolic status and their association with ASD (59). The timing of these insults 
during critical periods of development (e.g. fetal vs. early childhood period) is also unknown. 
Among a small number of studies that have researched nutritional and metabolic biomarkers in 
children, most were done after ASD diagnosis (27, 28).   As such, existing studies cannot 
determine if sub-optimal levels reflect active determinants in the development of ASD or a 
secondary phenomenon to the disease onset (27, 60).  
To address these knowledge gaps, this dissertation examined the relationship between: 
1) maternal nutritional status (prenatal supplement intake; folate and vitamin B12 biomarkers) 
and risk of developing ASD; and 2) child’s metabolic biomarkers (leptin and adiponectin) 
measured in cord blood and venous blood during early childhood and risk of developing ASD. 
The existing data from the Boston Birth Cohort (BBC) were used to test the study hypotheses on 
the nutritional and metabolic factors implicated in ASD. The BBC is an ongoing prospective birth 
cohort funded continuously by the National Institutes of Health over the past 16 years. Since its 
inception in 1998, the BBC has been recruiting mother-infant pairs at birth and following them 
longitudinally to study child growth, development and health.  
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1.2  Specific Aims 
Aim 1: To evaluate the associations between maternal multivitamin supplement intake, B-
vitamin biomarkers (plasma folate and vitamin B12), and risk of developing ASD in children  
Sub-aim 1a: To assess the association between maternal multivitamin supplement intake 
during preconception and each trimester of pregnancy and risk of developing ASD 
• Hypothesis: Sub-optimal intake of maternal multivitamin supplements is associated with 
an increased risk of ASD.  
Sub-aim 1b: To assess the association between maternal B-vitamin biomarkers measured at 
delivery and risk of developing ASD  
• Hypothesis: Sub-optimal (both deficiency and excess) levels of B-vitamin biomarkers in 
mothers are associated with an increased risk of developing ASD in children. 
Aim 2: To evaluate the association between cord blood, early childhood plasma leptin, and 
risk of developing ASD in children  
Sub-aim 2a: To assess the association between cord blood, early childhood plasma leptin, and 
subsequent ASD risk  
• Hypothesis: Higher levels of leptin in cord blood and venous blood measured in early 
childhood are associated with an increased ASD risk.  
Sub-aim 2b: To assess the association between fetal growth, first year weight gain pattern, and 
subsequent ASD risk  
• Hypothesis: Abnormal fetal growth and rapid first year weight gain pattern are 
associated with an increased ASD risk. 
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Sub-aim 2c: To investigate whether the association between fetal growth, first year weight gain 
pattern, and ASD risk is mediated by cord and early childhood leptin 
• Hypothesis: Cord and early childhood leptin mediates the relationship between fetal 
growth and first year weight gain pattern and ASD.  
Aim 3: To evaluate the association between cord blood, early childhood plasma adiponectin, 
and risk of developing ASD in children  
Sub-aim 3a: To assess the association between adiponectin in cord blood and in early childhood 
plasma and subsequent ASD risk  
• Hypothesis: Higher levels of adiponectin in cord blood and in early childhood plasma are 
associated with a decreased ASD risk.  
Sub-aim 3b: To investigate the joint effects of preterm birth and cord/early childhood 
adiponectin on ASD risk 
• Hypothesis: Cord/early childhood adiponectin and preterm birth have joint effects on 
ASD risk. 
1.3 Conceptual Framework 
 Figure 1-1 presents the conceptual framework that guided this dissertation. The 
framework utilizes a life-course perspective to illustrate the early life origins of ASD and 
highlights specific time periods including pregnancy, delivery/birth and infancy/early childhood. 
For the purposes of this dissertation, the time period spans from conception until ASD 
diagnosis.  
The conceptual framework is organized by specific aims. Specific aim 1 (represented in 
orange color) illustrates the associations between 1) prenatal multivitamin supplement intake, 
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2) maternal plasma folate and vitamin B12, and ASD. Although the study explored the 
relationship between prenatal supplement intake and maternal biomarkers, that was not the 
primary focus of the dissertation (as signified by the dotted line).  
Specific aim 2 (represented in blue color) has multiple components. This specific aim 
independently studied the associations between 1) cord leptin, 2) early childhood leptin, 3) 
fetal growth, and 4) first year weight gain, and ASD. This dissertation also assessed the 
mediating role of early childhood leptin in the relationship between growth during infancy and 
ASD (specified by the bold blue line). The interrelationship between many of the predictors is 
previously known (shown in dotted line), thus is not a focus of this dissertation.  
Specific aim 3 (represented in green color) assesses the relationship between 1) cord 
blood adiponectin, 2) early childhood plasma adiponectin, and ASD risk. Preterm birth is a well-
known risk factor of ASD. Yet, the joint effects of adiponectin and preterm birth in the context 
of ASD have not been examined and the role of adiponectin in mediating the relationship 
between preterm birth and ASD has not been explored (specified in bold green line) and thus 
will be assessed as part of this dissertation. Although, the study evaluated the relationship 
between cord and early adiponectin, it was not a primary focus of this dissertation (shown in 
dotted line). 
 
1.4 Dissertation Overview 
This dissertation is organized in a manuscript format. Chapter 1 serves as an overall 
introduction to the entire project and presents the research aims, hypotheses, description of 
the conceptual framework and an overview of the dissertation. In Chapter 2, the literature 
relevant to this dissertation is elaborated. Chapter 3 describes the study population, the 
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measures and methods used to address each specific aim. Chapter 4 addresses Specific aim 1 
with a manuscript titled “Maternal Multivitamin Intake, Plasma Folate and Vitamin B12 levels 
and Autism Spectrum Disorder Risk in Offspring.” Chapter 5 addresses Specific aim 2, with a 
manuscript titled “Cord and early childhood plasma leptin, fetal and infancy growth pattern, 
and development of Autism Spectrum Disorder in the Boston Birth Cohort.” Chapter 6 
addresses Specific aim 3, with a manuscript titled “Cord and early childhood plasma 
adiponectin levels and autism risk.” Chapter 7 elaborates the public health, clinical and research 
implications of this dissertation. Chapter 8 summarizes the key findings and the contributions of 
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2.1 Background and Significance 
2.1.1 Definition and Diagnosis 
ASD is a complex neurodevelopmental disorder affecting about 1.5% of the population 
(1). According to the Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th edition, 
ASD is characterized by deficits in 1) social communication and social interaction, and 2) 
restricted repetitive patterns of behavior, interests, and activities (2-5). The recent DSM-5 
definition encompasses the previous DSM-IV definition of autistic disorder (autism), Asperger’s 
disorder, childhood disintegrative disorder, Rett’s disorder, and pervasive developmental 
disorder not otherwise specified as a single diagnosis (5). However, for the purposes of this 
study, ASD will continue to be defined as described in DSM-IV since ASD cases in the BBC were 
diagnosed before DSM-5 was implemented (6-8). 
One challenge to study ASD is the heterogeneity of impairments and co-morbidities, 
especially since autistic individuals often exhibit additional behavioral problems such as self-
injury, aggression, tantrum, stereotypies, anxiety, sleep disturbances, feeding problems, non-
compliance with instructions, and odd, repetitive behaviors such as hand flapping, echolalia, 
spinning objects, tip-toe walking and body rocking (4). National estimates suggest that 30% 
(historically 70%) of the children with ASD have intellectual disability (ID) and boys have a 
greater likelihood to have co-occurring ID when compared to girls (1, 5). Few studies to date 
were able to study refined subgroups of ASD due to lack of well-established approaches and 
sample size constraints.    
Differential detection of ASD across populations due to parental awareness, and access 
to care has been an important concern.  Several studies have shown that children who receive 
an early ASD diagnosis (between 18-24 months) and intervention have better outcomes with 
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communication, social interaction and cognitive development (9-15). However, the average age 
of formal diagnosis is 4 years, with economically disadvantaged and minority children identified 
even later (12, 16). To date, studies of ASD in urban, low income, minority children are quite 
limited, an important research gap to fill.  
Diagnosing ASD is challenging given the lack of pathognomonic signs or biological 
biomarkers and is further complicated by the variety of common co-morbidities such as 
attention deficit hyperactivity disorder (ADHD), seizures and ID (16-18). As a result, the 
procedure for receiving ASD diagnosis involves a two-step process (19, 20). Level 1 universal 
screening is used to identify children with any type of developmental delays and assess a 
possibility of ASD (20). A few examples of level 1 screening instruments are Ages and Stages 
Questionnaire and BRIGANCE (19, 21). The American Academy of Pediatrics has recommended 
universal ASD screening for children between 18 and 24 months, in addition to a routine 
developmental surveillance (22). Level 2 screening is mainly for those that are already identified 
as at risk for developmental disabilities. It is also used for differentiating children with ASD from 
those with other type of neurodevelopmental disorders (19, 23). The discovery and utility of 
biomarkers to help early detection and diagnosis of ASD is increasingly becoming possible by 
rapid advancement in biomedical research and biotechnology and is emerging to be an exciting 
field to explore.  
2.1.2 Prevalence and Public Health Implications 
The dramatic increase in the number of children with ASD in the past few decades in the 
U.S. has justifiably raised concerns. The prevalence of ASD was about five per 10,000 individuals 
in 1980s, which increased to 4.2 per 1,000 in 1996 and eventually to about 14.6 per 1,000 in 
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2010 (one in 68) (1, 24-26).  This average annual increase of 9.3% and cumulative increase of 
269% (from 4.2/1,000 in 1996 to 15.5/1,000 in 2010) in prevalence has been attributed to a 
greater awareness, increase in risk factors, differences in methodologies used for estimating 
prevalence, changes in diagnostic practice or service availability, but true increase in ASD cases 
cannot be completely ruled out (2, 25-27). Much of the spike in ASD was observed in milder 
cases, with less drastic changes in prevalence noted in ASD cases with ID (26). ASD mostly is a 
life-long impairment and can have significant implications on parents, siblings, teachers and 
society as a whole (28). Financial burden of ASD can be tremendous on families. Recent 
estimates suggest that the annual direct medical, non-medical and productivity costs amounts 
to $268 billion in 2015 and is projected to be $461 billion for 2025 (29). The lifetime cost of 
supporting an individual with ASD and ID is $2.4 million and ASD without ID is $1.4 million (28). 
2.1.3 Theory and Etiology 
Several theories on ASD have been proposed ever since Leo Kanner (1943) and Hans 
Asperger (1944) described it independently and almost simultaneously (30). Most of the 
theories in the past explained ASD using the lens of behavioral psychology (31, 32). This slowly 
expanded to include underlying determinants of behavioral manifestations such as brain 
anatomy and physiology, genetics, prenatal factors and their interplay, although these factors 
have not been completely integrated with what is known about ASD behavior (30, 32). While 
the proposed theories are useful in understanding one aspect of ASD, not many attempts have 
been made to construct theories that postulate the complex pathological processes to explain 
the pathogenesis of ASD from its root causes to changes in the brain and resulting cognitive 
mechanisms, and the resulting behavior (33, 34).  
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Heterogeneity in clinical manifestation of ASD has long been an obstacle in explicating 
the underlying pathophysiology (35). The key to understanding the heterogeneity is elucidating 
how behavioral phenotypes are related to neurodevelopment, anatomical abnormalities and 
autism’s fundamental causes. Ideally, a full account of the neurobiological basis of ASD and its 
manifestation in behavior across different levels of development would be desirable (36). 
However, even with the current state of limited knowledge, there is a critical need for a unified 
model that links neurodevelopmental and behavioral manifestations implicated in ASD, so as to 
properly understand the disorder as well as design treatment programs (36, 37). To fill this gap, 
an integrated model has been adapted from the ones proposed by Frith (2012) and Niculea and 
Paval (2016) (33, 38).  It is important to note that this overarching model is merely a tool that 
“connect the dots” between different levels of deterministic factors and is not meant to be 
comprehensive in listing all the factors involved or provide definitive explanation (38).  
 
Behavioral factors: ASD is primarily diagnosed based on behavioral criteria, rather than 
biochemical, neuroanatomical or physiological indices (39). As observed in figure 2-1, there is a 
high degree of “fanning-out” or divergence of clinical manifestations at the behavioral level 
from the cognitive level (32). Separating behavior from the underlying mechanism is an 
important goal of this model. One of the interesting issues with measuring behavior alone is 
that, no matter how reliably measured, it doesn’t reveal its cause (38). Considering the variety 
of factors involved in ASD etiology, it is not surprising to observe a whole range of behavioral 
manifestations that may seem unrelated at the first glance (40). The timing of exposure, type of 
risk factors involved, alterations in brain connectivity can all have a role to play in the 
	 19	
manifestation of behavioral symptoms (33). Behaviors with same underlying cause may look 
different when manifested in different individuals (38) and further,  ASD is associated with co-
morbidities such as ADHD, motor incoordination and psychiatric symptoms that further 
complicates linking the behavior to neurobiological causes (30).  
 
Cognitive factors: The next tier in the model is cognition, which serves as an interface between 
core dysfunction in the brain and behavior and this bridge may be critical in explaining 
heterogeneity in ASD (30, 40). Cognitively, ASD is perceived as a disorder with impairment in 
central coherence, executive functioning, theory of mind and empathizing – with none of these 
theories being mutually exclusive or mutually dependent (32). The following section provides a 
broad overview of well-accepted cognitive theories in the context of ASD- 
• Mindblindness Theory or lack of theory of mind model posits that individuals with ASD 
have difficulty in understanding the minds of other people, specifically their emotions, 
feelings, beliefs and thoughts (41). Cognitive capacity to infer other’s mental states is 
fundamental for social competence and profound difficulties in social interaction and 
communications observed in those with ASD is believed to stem from impairment of 
theory of mind (42). Research studies have repeatedly shown that children with ASD 
typically fail the theory of mind tasks, whereas their neurotypical counterparts or those 
with Down’s syndrome pass the test. This has helped to further the understanding that 
ASD is not simple lack of sociability, rather a condition characterized by sociocognitive 
impairments (43). Theory of mind deficits may have their origins early in life and are 
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thought to explain language abnormalities in autism (e.g. muteness, language delays, 
echolalia and idiosyncratic use of language) (44, 45). 
• Weak Central Coherence Theory is characterized by imbalance in information 
integration and lack of tendency to draw together diverse information to create higher-
level meaning (46).  The notion of lack of central coherence highlights a cognitive style in 
some with ASD who have a tendency to miss the “big picture” and rather focus on 
extreme details of information (47, 48). Further, individuals with ASD may also have 
difficulty integrating information in the realms of surrounding context (49). 
• Executive function is an overarching term for functions such as working memory, 
impulse control, set-shifting, initiation and monitoring of action and all of these 
functions primarily involve activity in the prefrontal cortex of the brain (30). The deficit 
of executive function in ASD is characterized by the need for sameness, difficulty in 
switching attention, tendency to perseverate and lack of impulse control and these 
symptoms draw parallel to frontal lobe damage and frontal dementia (40, 50). While 
executive function impairment is common in ASD, it is not a universal feature thus 
limiting its potential to be used as a diagnostic marker (30). 
 
Anatomical factors: This tier in the model illustrates many-to-one mapping from anatomical to 
cognitive level, where few core dysfunctions feed into a single node at the cognitive level. 
Earlier studies on brain anatomy and ASD expected to find a dramatic lesion in an otherwise 
normally developed brain. However, it was soon recognized that looking for anatomical 
anomalies specific and universal across ASD and identifying a localized lesion, such as in brain 
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areas associated with social/attention deficits, was inappropriate and unfruitful (32, 40). 
Subsequently, there was a paradigm shift with studies starting to focus on “systems-level neural 
system abnormalities.” In line with this, cortical underconnectivity theory was proposed, which 
posited that the functional connectivity between frontal and posterior brain regions was lower 
in those with ASD (4, 48, 51). This has been proposed as a unifying theory that explains a range 
of deficits at the levels of psychological function, cortical function and cortical anatomy (52). 
Beyond cortical underconnectivity, other anatomical abnormalities are noted in cerebellum and 
cerebral cortex, however there is variability in direction and magnitude (5). Further, increased 
brain size – both in weight and volume, is often observed with ASD and is thought to be due to 
lack of pruning (i.e. elimination of faulty connections to optimize neural functioning) that occurs 
during normal reorganization of brain structure in childhood (30, 40).  
 
Genetic, epigenetic and environmental factors: Epidemiological studies have shown that both 
genetic and environmental factors play a crucial role in ASD etiology (18). In the model 
described in figure 2-1, the farthest tier is the multitude of genetic, epigenetic factors that may 
be causally linked to ASD. The constellation of symptoms, its severity, and its inconsistent 
response to treatment across individuals with autism is suggestive that a multitude of genetic 
factors and multiple pathways are involved in ASD (53, 54). ASD is a complex trait with many 
different genetic, non-genetic risk factors at this level that converges to a limited number of 
core dysfunctions and therefore is unlikely to have one-to-one mapping (32, 35).  
Genetics: The role of genetic factors in ASD has strongly been supported with heritability 
estimates ranging between 50% and 95% (5). In the past decade, several studies have identified 
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rare genetic variations, suggesting that polygenic and epistatic genetic factors may predispose a 
person to ASD (5). However, a lack of full concordance in monozygotic twins and varying 
concordance rates by diagnosis (55, 56) implies that genetic factors may not be sole cause of 
ASD (18).  Further, genetic factors alone could not have driven the prevalence to epidemic 
proportions in just 10-20 years (57).  
Epigenetics: The mechanism for the interaction of multiple early life factors with underlying 
genetics is unclear, but, it is postulated that epigenetics might play a role (18). Epigenetic 
mechanisms allow for heritable changes in the phenotype or gene expression without 
alteration in the primary DNA sequence and are hypothesized to be the link between gene and 
environment interaction (18, 58, 59). Both epigenetic and individual risk factors are necessary 
to allow the expression of an individual’s genetic liability (60). Most critical periods associated 
with epigenetic regulation in ASD are believed to occur during 1) prenatal period, when active 
cellular proliferation and differentiation occurs; and 2) during early postnatal period, when 
methylation patterns are necessary to establish normal neuron network (2). DNA methylation is 
a commonly studied epigenetic modification that influences neurobiological processes and is 
important for regulating gene expression (59, 61). Studies have observed epigenetic 
modifications (both hypo- and hypermethylation) in brains of those with ASD (5).  DNA 
methylation depends on the dietary sources of essential nutrients, especially folate and vitamin 
B12, during prenatal and early postnatal periods (18, 59, 62, 63) and recent evidence suggests 
that metabolic disturbances in one-carbon pathways (figure 2-2) are often observed in ASD (64, 
65). As such, compared to other nutrients, folate and vitamin B12 status are worthy of 
particular attention. 
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Environmental factors: For the purposes of this model, environmental factors are described 
broadly to include non-genetic, biological, toxic, infectious and/or immune, and social factors 
(66). The absence of a single genetic cause and incomplete penetrance of known genetic 
factors, provides a hint that environmental factors are important for ASD risk (67). Many of 
these genetic risk factors are present in individuals without ASD, suggesting that while these 
mutations may increase ASD risk, it is likely that other risk factors are also necessary (67). 
Similarly, exposure to high risk environmental factors does not always result in ASD (68).  
A pool of biological factors has been considered in the context of ASD. These include, 
but are not limited to, candidate risk factors such as advanced maternal age (69-77), advanced 
paternal age (78-80), maternal metabolic risk factors such as obesity (81), diabetes (82, 83), 
nutritional status (84-87), and prenatal maternal inflammatory disease (56, 88, 89). 
Environmental toxicants including exposure to air pollution (90-92) and pesticides (93, 94) have 
also been implicated in some studies.  
It is notable to mention that social factors have been implicated in ASD. Studies in the 
U.S. have demonstrated preponderance towards those from a higher social class as evidenced 
by high socio-economic status, parental education and intellect level (71, 75, 95-98); on the 
other hand, some studies (mainly from Europe) have shown the contrary (99-101). Place of 
residence has also been linked to ASD risk, with urbanites having a greater likelihood of having 
ASD compared to the rural population (70, 102). Racial/ethnic disparities have been observed in 
many studies, with some reporting that blacks have greater rates (71, 74, 95), whereas others 
reporting whites/Asians having greater prevalence (25, 26, 74, 75, 97). 
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Linking the tiers of an integrated multilevel model: In summary, this integrated model (figure 
2-1) demonstrates the involvement and interaction of predisposing factors across multiple 
levels and developmental periods leading to abnormal brain development and subsequent 
altered cognition and behavior. The model is a visual depiction of how small perturbations in 
genetic and epigenetic processes along with a complex interplay of multiple early life risk 
factors can have a downstream impact on developing brains, potentially giving rise to a 
spectrum of behavioral syndromes. The effect sizes for each of these factors may be small; 
however, an individual’s genetic predisposition combined with environmental triggers may 
possibly create a ‘perfect storm’ to disrupt normal neurodevelopment (18).  
The advantage of this model is that it provides an overview of pathological processes 
involved as opposed to focusing on one aspect of the deficit. Conducting studies using the 
multilevel integrated model in a life-course framework will shed light on developmental 
processes and will inform how genetic/epigenetic/environmental factors and morphological 
findings links to behavioral correlates (103). One challenge however, is that designing a study 
with multiple tiers may require elaborate models based on genetic, environmental, 
neurochemical, neurophysiological and behavioral manipulations, which may be beyond the 
scope of many studies – including this study.  
Hence considering the availability of data, resources and time, the current study will 
focus on several important, yet understudied preconceptional/prenatal influences in ASD, 
namely nutritional (specifically folate and vitamin B12) and metabolic biomarkers (especially 
adipokines such as leptin and adiponectin). If one were to fit in the key components of this 
dissertation into the stated model (figure 2-1), it will feature in the bottom most tier along with 
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genetic influences. Anatomical and cognitive factors, although important, was beyond the 
scope of this dissertation; however, their implicit roles have been acknowledged when 
extrapolating the relationship between nutrition, metabolic factors and ASD. The next section 
will expand further on nutritional and metabolic predictors of ASD.  
2.2 Nutrition in growth and neurodevelopment 
Maternal and early postnatal nutrition affects the structure and function of offspring’s 
brain development as well as later cognitive performance (65). Compared to the rest of the 
body, the brain develops at a rapid pace in utero and during the first 2 years of life making it 
more vulnerable to sub-optimal nutritional status (104, 105). While almost all nutrients have a 
role to play in ensuring proper brain development, some are more intricately involved than 
others. Specifically, nutrients in one-carbon metabolism, often dubbed “epi-nutrients,” act as a 
primary methyl donor for DNA synthesis and methylation (figure 2-2) (65, 106) and are 
intricately involved during critical periods of brain development (107, 108). Exposure to 
deficient or excess levels of these nutrients during critical windows can permanently alter the 
brain structure thereby having a lasting impact on cognitive development (108, 109).  A host of 
transporters and regulators play an important role in safeguarding the brain such that it does 
not receive too much or too little of each nutrient (107, 108). 
2.2.1 Folate and vitamin B12 metabolism 
Folate, vitamin B12, along with vitamins B6 and B2, are sources of co-enzymes that are 
involved in one carbon metabolism (110). Folate is a water-soluble vitamin that occurs naturally 
in foods such as leafy vegetables, legumes and red meat (111, 112). It is also produced 
synthetically as folic acid, which is used in supplements and food fortification programs (58). 
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The bioavailability of folic acid is ~70% greater than naturally available folate (113) and folic 
acid has to be reduced to tetrahydrofolate before it can be utilized by the body (114). As a 
methyl donor, folate is intricately involved in major cellular pathways including DNA synthesis 
and maintenance, DNA, RNA and protein methylation (58, 115).  The metabolic demand for 
folate is high especially during pregnancy due to rapid cellular growth and development (116, 
117). Placental folate transfer begins early in pregnancy and is actively transported, as 
evidenced by markedly higher levels of folate in cord blood when compared to maternal levels 
(117, 118).  
Vitamin B12 is obtained by consuming animal source foods such as meat and dairy 
(119). Vitamin B12 (also called cobalamin) is a cobalt-containing compound that is transported 
by transcobalamin II, produced by liver and placenta (120).  It is a co-factor for the enzyme 
methionine synthase in one-carbon metabolism (121). Vitamin B12 is critical for brain 
development and has a variety of functions such as transmethylation and maintenance of 
equilibrium between neurotrophic and neurotoxic factors in the central nervous system (122). 
Vitamin B12 also plays an important role in the formation of S-adenosylethionine (SAM) (figure 
2-2) and evidence suggests that low dietary vitamin B12 is linked to developmental and 
neurological disorders (122). During pregnancy, vitamin B12 requirements are increased (123), 
while the plasma vitamin B12 level drops, possibly as a physiological response to pregnancy 
(124). Similar to folate, vitamin B12 is actively transported using specific-receptor carriers (120). 
In the U.S., the prevalence of vitamin B12 deficiency in pregnant women is relatively low 
(~6.6%) (125).  
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2.2.1.1 Role of folate in neurodevelopmental conditions 
 
The incidence of both global and gene-specific changes in methylation patterns has 
instigated a lot of interest in understanding the primary pathways for one-carbon metabolites 
such as folate, vitamin B12 and homocysteine (2). Suboptimal folate status during the prenatal 
period has been associated with neurodevelopmental impairments such as neural tube defects 
(NTD), ID and other adverse health outcomes such as congenital heart defects, fetal growth 
retardation, low birth weight and preterm delivery - although the underlying mechanism for 
any of these conditions have not been elucidated (65, 84, 126, 127).  
2.2.1.1.1 Folate and NTD 
 NTD are complex multifactorial disorders that impact neurulation of the brain and spinal 
cord, occurring between 21-28 days post-conception. While the etiology of NTD is still unclear, 
it is believed that both genetic and non-genetic (e.g. maternal nutrition status) factors may be 
implicated (128, 129). Genetic polymorphisms affecting critical components of folate 
metabolism have also shown to be associated with an increased the risk of NTD (130). Several 
trials in the 1980s and 1990s showed that exogenous supplementation of folic acid prevents 
NTD (128, 129). Based on this evidence the U.S. Food and Drug Administration (FDA) 
implemented mandatory flour fortification of folic acid in 1998. Since then, approximately 
1,300 NTD births have been averted every year (131). Subsequently, there has been a sizeable 
increase in the intake of folic acid, which has drastically improved the folate status in the 
general population (129, 132). Vitamin B12 deficiency has also been shown to be associated 
with NTD, independent of folate (133, 134). Several studies have shown that mothers with 
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lowest vitamin B12 concentration have higher odds of having NTD-affected infants when 
compared to those with the highest levels (135, 136). 
2.2.1.1.2 Folate and Down’s Syndrome 
There is some evidence that suggests that abnormal folate metabolism may be 
implicated in Down’s Syndrome (137).  Specifically, studies have shown that mothers of infants 
with Down’s Syndrome have elevated plasma homocysteine when compared to the controls 
(138). Homocysteine is inversely correlated to folate status and is a sensitive marker of folate 
status. Higher frequency of polymorphisms in genes encoding the folate metabolizing enzymes 
(methylene tetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR)) 
was observed in mothers of Down’s Syndrome babies (139, 140). However, not all studies have 
confirmed these findings (141-143).  
2.2.1.1.3 Folate and ASD 
In the past decade, there has been a great interest in assessing the impact of maternal 
folic acid consumption and ASD risk. A number of epidemiological and animal studies have been 
published. Below is the summary of the emerging research in this field - 
Evidence from human studies: Recent epidemiological studies have shown that folic acid intake 
may be protective against ASD (84, 85, 87, 144). Specifically, mothers of children with ASD 
reported using preconception/prenatal vitamins or reported having higher levels of dietary folic 
acid intake and/or folic acid supplementation (84, 85, 87). Further, the greatest risk reduction 
was observed in subjects that were genetically susceptible to less efficient folate metabolism 
(84). On the other hand, two large studies conducted in the Danish Birth Cohort found no 
association between folic acid supplement intake before and during early pregnancy and 
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subsequent ASD risk in offspring (145, 146). Findings from the Generation R study 
demonstrated an association between folic acid supplementation and decreased ASD risk; 
however, this finding was not corroborated when biomarkers (maternal plasma folate levels) 
were assessed in the context of child’s autistic traits (147). Similarly, Braun et al. showed that 
prenatal vitamin intake, when compared to those who did not use supplements, was associated 
with reduced odds of elevated Social Responsiveness Scale (SRS) scores, a scale used to identify 
ASD-typical behaviors. However, no association was found between maternal whole blood 
folate concentration and SRS scores (148). DeSoto et al. reported a contradictory finding and 
noted that mothers of children with ASD were more likely to report folic acid supplement 
intake during pregnancy (149).   
A few authors have speculated that these incongruent associations could potentially be 
due to residual confounding (24, 146, 147). Multivitamin supplement use is closely tied to 
maternal education, which may be related to health conscious behaviors that could have 
lowered ASD risk (24, 147, 150, 151).  Further, the timing of supplement intake and biomarker 
assessment is thought to play a role in the association with ASD risk (147, 148). Other potential 
reasons for these inconsistencies are elaborated in chapter 7, including lack of consideration of 
full range of biomarker levels from insufficiency to excess in the data analyses (152).  
Evidence from ecological studies: Using Rochester Epidemiological Project data, Beard et al. 
showed that in Olmstead County, MN, the increased ASD incidence paralleled the prescription 
of high dose (1 mg) of folic acid supplementation (153).  Others, such as Rogers and Leeming et 
al., independently speculated that the number of ASD cases have increased significantly 
paralleling folic acid fortification in the U.S. and explained a potential biological plausibility 
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involving folic acid metabolism and altered natural selection by increasing survival of infants 
possessing MTHFR C677T polymorphism (154-156).  Along these lines, studies have shown that 
children diagnosed with ASD may have altered folate or methionine metabolism (157).  
Evidence from animal models: Animal models have supported the hypothesis that elevated 
folic acid may be associated with adverse neurodevelopmental outcomes. Barua et al. showed 
that there is altered expression of several genes in the frontal cortex and cerebral hemisphere 
of pups, when the mothers were exposed to very high folic acid supplementation during 
pregnancy (158, 159). Similarly, high maternal folic acid exposure also resulted in altered DNA 
methylation and gene expression in offspring’s cerebellum (160). Continuing such high doses 
through post-weaning periods resulted in behavior alterations, when compared to the offspring 
whose mothers were not supplemented such high doses (158). The authors hypothesized that 
behavior change may be possible because of altered gene expression and aberrant methylation 
that is potentially linked to folate over-supplementation (158).  
Similarly, Girotto et al. showed that large doses of folic acid can alter brain synaptic 
transmission and increase offspring’s susceptibility to seizures (161). Research in the chick 
embryo showed that folic acid potentially inhibits neurite extension, synaptogenesis and 
growth cone motility (162, 163). Bahous et al. demonstrated that high dietary folate is linked to 
pseudo-MTHFR deficiency, embryonic growth delay and offspring memory impairment (164).  
2.2.1.2 Role of Vitamin B12 in ASD 
It is well known that vitamin B12 is intimately involved in one-carbon metabolism along 
with folate; yet, there is a dearth of research on the role of vitamin B12 status on the 
developing brain (165). Several studies have shown that vitamin B12 deficiency can 
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detrimentally impact intracerebral functioning and is known to be associated with reduced 
levels of neurotrophins such as nerve growth factor and brain-derived neurotrophic factor 
(BDNF). The deficiency of the latter has been linked to increased oxidative stress (166) and 
severe retardation of myelination in the nervous system (167, 168).  
A few studies have looked at biomarkers of one-carbon metabolites (e.g. homocysteine, 
methylmalonic acid, S-adenosylmethionine, S-adenosylhomocysteine) in children with ASD and, 
the methodologies and findings have been largely inconsistent (2, 169, 170). For example, some 
studies have shown a decline in serum folate and/or vitamin B12 (171, 172) among ASD 
children, while others have not confirmed a particular trend for these biomarkers (64, 169, 173-
175). Nevertheless, lack of research on the association between vitamin B12 and ASD has been 
identified as an important research gap (24).  
2.2.1.3 MTHFR genotype and ASD 
MTHFR, an enzyme involved in one-carbon metabolism is at the crossroads of DNA 
methylation and synthesis (176). While some frequency of T allele and TT homozygosity exists 
in every population, the prevalence is highest among Hispanics and lowest in African Americans 
(177). One of the widely studied polymorphisms of MTHFR that affects neurodevelopment is 
MTHFR C677T (60). Human carriers of MTHFR C677T polymorphisms have reduced enzyme 
activity (by about 60%) and they are frequently seen to have increased plasma homocysteine 
(62, 176, 178) and decreased folate levels in circulation (179). Several studies have observed 
higher frequency of the C677T allele in children with ASD (174, 180). In a meta-analysis 
conducted by Pu et al., MTHFR C677T polymorphism was associated with increased risk among 
children, however, only in countries without folic acid fortification (60). Along these lines, 
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Schmidt et al., showed that an increased ASD risk was observed with MTHFR 677TT maternal 
genotype, only when mothers did not use preconception/prenatal supplements (84).  
2.3 Role of Metabolic factors in ASD risk 
Adipose tissue is a highly active endocrine organ that produces signaling molecules 
called adipokines, which are implicated in adiposity, inflammation, food intake and insulin 
sensitivity (181, 182). Emerging evidence suggests that adipose tissue may play an important 
role linking poor fetal growth and subsequent development of adverse conditions (183). 
Adipose tissue programming has its origins in prenatal and postnatal periods. There are 20 
different types of adipokines that are broadly categorized into the following: 1) primarily 
produced in the adipose tissue (e.g. leptin, resistin); 2) exclusively produced in the adipose 
tissue (e.g. adiponectin); 3) mainly produced in other tissues or organs, but is also produced by 
adipose tissue (e.g. TNF-α) (182, 184). The source of adipokines may change over the course of 
the lifespan as observed in the case of adiponectin that is secreted in multiple tissues in fetal 
life (e.g. skeletal muscle fibers, small intestine and arterial walls) (185), whereas produced 
exclusively by adipose tissue in adulthood (184).   
The role of adipokines in neurological dysfunction is increasingly recognized and is 
thought to facilitate the cross-communication between immune system and nervous system 
(66).  Adipokines are pleiotropic and can influence the development and function of the 
nervous system. Specifically, they are involved in progenitor cell differentiation, cellular 
migration within the nervous system, synaptic formation, as well as higher order neurological 
function such as cognition and memory (66). They have the ability to control the nature, 
duration and intensity of the immune response (66).   
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Adipokines are intricately involved in metabolic conditions (such as obesity and 
diabetes) and are important risk factors for adverse outcomes that are often accompanied by 
other complications such as hyperglycemia, insulin resistance and untoward fetal consequences 
(186, 187). While there are several adipokines, for the purposes of this study, two of these were 
mainly considered: leptin, a pro-inflammatory cytokine; and adiponectin, an anti-inflammatory 
cytokine. Leptin and adiponectin are metabolic counterparts, which act in parallel yet in 
opposing directions (188). Both leptin and adiponectin are critical for fetal and postnatal 
development (189, 190). They have a multitude of other functions such as energy homeostasis 
and are associated with insulin resistance and BMI (191, 192).  
The next section begins with a discussion of fetal and infant growth, followed by the 
physiology of adipokines in early life, as well as other factors that perturb the balances of these 
adipokines. Given that adipokines are intricately involved in growth and maturation, the 
discussion on prenatal and postnatal growth is placed first to provide some context, before 
delving deep into subsequent discussions on adipokines. 
2.3.1 Fetal and infant growth 
2.3.1.1 Fetal growth 
 
Intrauterine growth restriction (IUGR) is defined as the failure of the fetus to achieve its 
intrinsic growth potential, possibly attributed to anatomical and/or functional disorders and 
diseases in the feto-placental-maternal unit (190, 193, 194). Small for gestational age (SGA), 
defined as birth weight <10
th
 percentile of the population, is often used as a proxy for IUGR 
(194). IUGR can be categorized into: 1) symmetrical IUGR with weight, length and head 
circumference diminished, usually indicative of a process originating early in pregnancy; 2) 
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asymmetrical IUGR, characterized by brain sparing and a normal head circumference. The latter 
process may occur much later in pregnancy and is often related to impaired uteroplacental 
function or nutrient deficiency (190). IUGR represents a tremendous heterogeneity in terms of 
etiology, severity, body proportionality and the prognosis of IUGR infants may vary depending 
on the cause (195). In developed countries like the U.S., IUGR is mostly a manifestation of 
maternal, fetal and uterine factors that may have led to poor placental function (194). The 
metabolic conditions associated with IUGR may have an endocrine origin, which may be 
accompanied by alteration in subsequent hormonal bioavailability (190). Further, IUGR may 
initiate changes in fetal metabolism in order to provide immediate survival advantage, which 
may or may not be beneficial in the long-term (196). IUGR is known to compromise fetal 
adipose tissue development with IUGR infants having a marked reduction in body fat mass 
(190).  
IUGR and neurodevelopment: Compromised neurodevelopment is one of the notable 
outcomes observed in IUGR. Compared to children that are appropriate for gestational age 
(AGA), those with SGA may have impaired neurodevelopment and are often associated with 
immature neurobehavioral scores, lower IQ and language problems, executive function, visual 
motor skills, poor academic outcomes and behaviours problems (193, 194, 197-199). SGA 
infants may also have reduced head circumference and diminished total and regional brain 
volumes compared to normal infants (194).  
IUGR and ASD: Emerging research suggests that SGA could be a risk factor for ASD (200-203). 
While the underlying mechanism is yet to be elucidated, the association is thought to be due to 
an insult that could have limited fetal growth as well as impacted neurological development 
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(202).  Specifically, studies have hypothesized that genetic polymorphism, prenatal risk factors 
such as fetal hypoxia, placental pathology, pre-eclampsia or infections during pregnancy or 
maternal risk factors such as smoking and substance abuse could have links to both SGA and 
neuropsychiatric morbidity (201, 202).  
While the association between SGA and ASD may seem biologically plausible, some 
studies have not replicated these findings or have reported inconsistent associations (72, 204-
206). For example, Langridge et al. demonstrated that the percentage of optimal birth weight, a 
measure of fetal growth (207), was not associated with ASD, especially among those without ID 
(204). Glasson et al. also showed no association between SGA and ASD (72), while Schnedel et 
al., noted that the relationship was observed only in girls and not in boys (206). Similarly, 
Larrson et al. observed that the association between fetal growth and ASD attenuated after 
adjusting for other covariates (205). The reason for this inconsistency may be due to 
methodological differences, lack of control for both prenatal and postnatal confounding factors 
such as infancy rapid weight gain, and sample size variations (201, 206). Further, studies could 
have considered IUGR as one homogeneous group, which could have precluded them from 
observing associations.  
2.3.1.2 Growth in infancy 
Fetal growth restriction has short- and long-term auxological and metabolic 
consequences (208). A well-known short-term consequence of IUGR is postnatal catch-up 
growth, which is a compensatory process to the thinness or smallness at birth (208, 209). About 
70%-90% of SGA infants demonstrate catch-up growth during first few years of life, typically 
between 6 months to 2 years (210). Fetal growth restriction has been shown to correlate with 
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growth velocity at one month of age (211). However, the extent of catch-up growth that is 
related to IUGR and the exact time window when it becomes detrimental is unknown (208).  
Weight gain during infancy and ASD: Rapid weight gain during infancy and early childhood has 
been associated with the risk of ASD (212-214). Studies have shown that accelerated weight 
gain may not be an isolated phenomenon, but is suggestive of a macrosomic endophenotype 
that may include rapid increase in head circumference and length (215-217). There is a 
correlation between neural and non-neural endophenotypes, with weight strongly predicting 
head circumference at all ages (214). Post-birth macrocephaly (defined as cranial circumference 
>97
th
 percentile) is one of the characteristic anatomical features that have been linked to ASD 
in at least 14% to 36% of the subjects (212, 214, 216, 218-220). The precise time of onset of 
overgrowth is still unclear; but evidence suggests that overgrowth is noticeable between 6-12 
months, which predates the onset of any overt behavioural symptoms (215, 221). 
Early generalized overgrowth is a unique morphological feature of ASD and may not be 
observed in other developmental disabilities (215). Studies have shown that rapid overgrowth 
predicts later behavioural and cognitive development with steeper increase in body size 
associated with lower verbal and nonverbal score at 4 years of age (215) and increased head 
circumference linked to delayed onset of language (222), but this association has not been 
consistent (221). Several neurobiological factors including growth factors, neurotrophic factors, 
hormones and neurotransmitters have been hypothesized to play a role in excessive growth, 
although direct evidence is still being developed (214, 216). Since there are no known 
biomarkers for ASD, early life growth pattern alone, or in combination with neurobiological 
factors can potentially have a high predictive value in detecting ASD risk (214, 215).  
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2.3.2 Leptin  
Leptin is a peptide hormone that is predominantly secreted by adipose tissue and has 
been studied in the context of regulating satiety, energy homeostasis, body composition, and 
overall fetal growth and development (188, 223, 224). Circulating leptin levels reflects body 
weight and adiposity, during fetal as well as late infancy time points (225). Leptin has been 
identified as one of the critical hormonal factors that may mediate developmental 
malprogramming (226-228). Alterations in leptin availability during the periods of 
developmental plasticity can underlie some of the adverse developmental changes (226). Leptin 
has recently been shown to regulate neuroendocrine functions and the immune system (188, 
229, 230), making it a pleiotropic hormone (231).  
Maternal and fetal leptin: Leptin has an important role in pregnancy, as evidenced by a two-
fold increase in levels during the prenatal period, paralleling gradual increase in body mass 
index throughout gestation (224). Leptin levels are altered in pregnancy-related pathologies 
such as diabetes mellitus and placental insufficiency in preeclampsia (232, 233). Many studies 
have shown that maternal leptin levels are not correlated with cord leptin levels (234, 235).   
Leptin is produced by maternal and fetal adipose tissues as well as placenta, with most 
of the placental leptin (~95%) delivered into maternal circulation and only ~5% secreted into 
fetal circulation (224). Fetal leptin is independent of maternal levels and is produced by white 
adipose tissue (236, 237), although some studies have noted a positive correlation between 
placental and cord leptin (224). Leptin production may start very early in pregnancy, with its 
presence observed as early as 6-10 weeks of gestation (224, 236). Fetal levels may be low 
during the first half of the gestation and increase rapidly during the last part of third trimester, 
paralleling the significant increase of adipose mass (224).  
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Umbilical cord leptin is strongly correlated with gestational age, birth weight and head 
circumference (227, 238-240). Preterm babies have lower cord leptin when compared to term 
infants (224, 237, 241). Serum leptin levels dramatically increase after ~34 weeks of gestation 
(241-243), prior to which babies exhibit negligible leptin levels (241). Studies have repeatedly 
shown that umbilical cord leptin is markedly different between SGA, AGA and large for 
gestational age (LGA) babies (236), with the former group having the lowest levels of leptin 
(224, 239, 244-246). On the other hand, LGA babies have higher cord leptin levels than AGA, 
which correlates well with the ponderal index (224). The lower leptin level in IUGR has been 
attributed to reduced fat mass and/or diminished placental production (190). Other factors that 
influence cord leptin levels include gender, family history of obesity and maternal gestational 
diabetes (224). 
Cord and early childhood leptin: Cord blood leptin levels are inversely related to the rate of 
change in BMI (247, 248). In other words, lower cord leptin levels mediate faster weight and 
height gain at 6 months of age (224, 240, 249, 250). Emerging evidence suggests that leptin 
during neonatal period does not inhibit appetite, but rather promotes rapid growth and weight 
gain (224). This may be an adaptive leptin resistance response, possibly reflecting catch-up 
growth (224). The diminished leptin levels at birth may provide a cue for catch-up growth by 
reduced inhibition of satiety (251). Further, lower cord leptin levels are associated with higher 
leptin levels at 3 years of age and higher degree of obesity and linear growth (240).  
Studies have assessed leptin levels in breastfed vs. formula fed infants, however the 
evidence has been equivocal (224). Some studies have reported lower leptin (252, 253) or no 
difference (254) in breastfed infants whereas others have reported higher levels (255). In the 
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latter study, the authors had speculated that leptin’s presence in human milk might have 
contributed to higher leptin concentration in breast-fed infants (255).  There is some indication 
that breast milk leptin may play a role in growth, appetite regulation, at least during the first 
few months of life (224).  
The role of fetal leptin may be very different from that of mature leptin (236). Leptin at 
3 years of age is positively correlated with BMI and measures of overall and central adiposity 
(240), possibly indicating the onset of leptin resistance (256). In a rat-model, Coupe et al. 
demonstrated that rapid postnatal growth (subsequent to IUGR) could trigger reduced leptin 
sensitivity (257). Thus, hyperleptinemia may indeed be a consequence of adverse fetal or early 
postnatal environment (257, 258). Mechanistically, leptin resistance has been attributed to a 
variety of factors including compromised transport of leptin across the blood brain barrier, 
impaired negative feedback mechanism, endoplasmic reticulum stress or intracellular leptin 
signal saturation (230, 256). In summary, the auxological and metabolic alterations from 
prenatal to postnatal period can be recapitulated as follows: SGA children have low cord leptin 
levels, which in turn may be associated with accelerated postnatal weight gain, which could 
predispose individuals to leptin resistance and potentially subsequent adverse health outcomes 
(228). 
Leptin in neurodevelopment: Leptin has an important role in neurodevelopment and 
psychopathology of conditions including depression, anxiety, schizophrenia, ASD and Rett 
syndrome (233). Emerging research suggests that leptin is secreted in the brain where it seems 
to possess paracrine and/autocrine functions (233). Leptin can also cross the blood-brain 
barrier using a receptor-mediator transport (259). Leptin receptors are expressed in different 
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regions including, but not limited to, the midbrain, hippocampus, hindbrain, basolateral 
amygdyla, hypothalamus (231, 233) and has an important effect on proliferation, maintenance 
of glial and neuronal cells (227). Beyond its role as a metabolic regulator, leptin promotes 
establishment of hypothalamic circuitry, as well as cortical and hippocampal development (227, 
230). Rodents with leptin insensitivity have been observed to possess deficits in long-term 
potentiation and long-term depression (260). Animal model suggests that brain weight as well 
as brain protein and DNA contents are diminished in leptin deficiency (224).  
Leptin’s impact on brain development may be mediated by its role in activating 
proinflammatory cytokines, which are known to be increased in ASD (229, 233). In a leptin 
resistant state, there is increased production of leptin, which are associated with an increase in 
proinflammatory cytokines (233). Inflammatory cytokines are implicated in impaired higher 
neurological functions such as memory and cognition, in addition to being involved in impaired 
brain development, synaptic functioning including processes of differentiation, migration, 
proliferation and impairments in behavior (261). Thus, abnormal inflammatory activity and 
imbalance of cytokines during development can adversely impact brain development, neural 
activity and could contribute to behavioral and neurological dysfunction in ASD (66, 261). 
Recent studies have shown that children with ASD have significantly higher plasma 
leptin than controls, with more pronounced effects observed in those with early onset ASD 
(188, 229, 262-264). In a small subset of subjects, genetic correlation has been observed 
between ASD and leptin coding (265). A study conducted on autopsy tissues showed that there 
is a marked increase in leptin levels in anterior cingulate gyrus of the subjects with ASD (266). 
	 41	
Further, leptin is also known to suppress serotonin synthesis, which is reported in ASD, possibly 
suggesting a biological mechanism through which leptin may be involved (233).  
2.3.3 Adiponectin 
Adiponectin is a benign adipokine that possesses anti-diabetic, anti-atherogenic and 
anti-inflammatory properties (267). Adiponectin is an abundantly circulated and constitutes of 
0.01% of total serum protein (268). Adiponectin exists in three major forms: trimer, hexamer 
and high molecular weight (HMW) multimer (269, 270).  The biological functions vary by the 
type of adiponectin multimer (269) with the HMW being the most biologically active form 
(270). The anti-inflammatory properties of adiponectin are exerted by suppressing TNF-α 
secretion, by inhibiting its transcription and stimulating IL-10 and IL-1 receptor antagonist 
production. IL-10 is an anti-inflammatory cytokine that inhibits the production of pro-
inflammatory cytokines (271).  
Maternal and fetal adiponectin: Maternal adiponectin levels are altered throughout 
pregnancy, mirroring maternal insulin sensitivity (184). When compared to pregravid state, 
serum adiponectin levels are increased in early pregnancy, followed by a decline through the 
rest of the pregnancy (184). Maternal adiponectin levels are altered in conditions such as 
gestational diabetes, preeclampsia and preterm labor (181, 184, 272, 273). Maternal and fetal 
adiponectin have very different roles to play. For example, maternal adiponectin decreases 
placental insulin signaling and regulates fetal growth (274); whereas, fetal adiponectin 
increases fetal adiposity and growth (184).  
Cord adiponectin levels are 2-3 times higher than maternal adiponectin (271). However, 
the correlation between maternal and fetal adiponectin is inconclusive (184, 185, 240, 275-
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278). Emerging evidence suggests that adiponectin is mainly derived from the fetus and not 
from maternal or placenta tissues (185, 275). This is supported by the possibility that HMW 
multimer, the main form of adiponectin in the fetus, cannot pass through the placental barrier 
(278, 279). 
Adiponectin expression in brown adipose tissue is observed as early as 14 weeks. Cord 
adiponectin levels increase with gestational age, with almost a 20-fold increase observed 
between 24 and 40 weeks (185, 280). Studies have shown that beyond adipocytes, fetal 
adiponectin is expressed in multiple tissues of mesodermic origin (such as skeletal muscle 
fibers, smooth muscle cells of small intestine and arterial walls and connective tissues) and 
ectodermal origin (epidermis and lens) (185). The pattern of adiponectin expression in the fetus 
is markedly different than adults. While higher adiponectin in adults is associated with lower fat 
percentage, an opposite relationship is observed prenatally, with higher adiponectin levels 
associated with higher percentage body fat in the fetus (281) and anthropometric 
measurements (278). The higher levels of adiponectin in newborns, when compared to adults 
may be due a variety of factors including lack of adipocyte hypertrophy, relatively low 
percentage of body fat or a different distribution of fat depots in newborn (275).  
Adiponectin levels are related to both gestational age and birth weight (184, 240, 282), 
and studies have shown that preterm infants having substantially lower adiponectin when 
compared to their term counterparts (283-285). Recently, Terrazzan et al. showed that cord 
adiponectin levels are lower in very low birth weight preterm infants, when compared to full-
term infants (286). Similarly, Visentin et al. showed that adiponectin levels were lower in IUGR 
fetuses, when compared to SGA and AGA (183). Many studies have hypothesized that 
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adiponectin may play an important role in fetal growth, although the precise mechanism is 
unclear (185, 281). Higher cord adiponectin is associated with slower weight gain during the 
first six months of life (240, 278). 
Adiponectin in infancy and early childhood: Adiponectin levels begin to increase during the 
first month of life, before it begins to decline (239). Specifically, between ages 1 and 2, fasting 
adiponectin levels decrease by almost 25%, which has been attributed to increase in adiposity 
(287). Decline in adiponectin is steep for children that were SGA and that exhibited rapid catch-
up growth (287, 288). Hypoadiponetinemia in children is thought to be a consequence of 
increase in body fat with several studies showing that adiponectin is inversely associated with 
central adiposity (239, 240, 289). Studies on human milk adiponectin and infant growth has 
been conflicting with some research showing that higher adiponectin is associated with lower 
infant weight and weight-for-length z-scores during the first six months of life (290); whereas 
others demonstrating that lower adiponectin exposure were associated with lower weight by 2 
years of age (291, 292).  
Children who were born SGA have lower adiponectin levels, even when compared to 
obese children – who are known to possess lower adiponectin levels (288). Postnatal catch-up 
growth is associated with lower adiponectin levels. It has thus been speculated that 
intrauterine programming may permanently affect adiponectin secretion (288).   
Adiponectin in neurodevelopment: Earlier studies speculated that adiponectin cannot pass 
through the blood brain barrier and thus is not found in the brain (293). However, recent 
studies have demonstrated that adiponectin is detectable in the brain after an IV injection of 
full-length adiponectin in an animal model (293, 294). There is a lack of clarity on whether 
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adiponectin is synthesized intrathecally or whether it flows into the intrathecal space from 
plasma crossing the blood brain barrier (293).  
Compared to plasma, cerebrospinal fluid adiponectin is 100-times lower, but this is 
compensated by higher affinity to adiponectin receptors AdipoR1 and AdipoR2 that are found 
in the cortex, hypothalamus, pituitary glands and the cerebrospinal fluid (270, 295-297).  
Adiponectin has specific functions including regulation of neurogenesis, neurotrophic actions, 
promotion of adaptive neuroplasticity and protection of human neuroblastoma cells against 
cytotoxicity and neurotoxicity (295, 296, 298). Adiponectin deficiency is thought to curtail 
dendritic growth and spine density in hippocampal dentate gyrus in which neural progenitor 
cell proliferation and differentiation is inhibited (297).  
Adiponectin is known to exhibit neuroprotective functions with adiponectin treatment 
in mice shown to protect the integrity of blood brain barrier and improve neurobehavioral 
performance and focal cerebral neurogenesis (297). Adiponectin may also possess higher brain 
functions. For example, diminished adiponectin levels are associated with clinically significant 
affective episodes and subjects with major depressive symptoms are known to have lower 
adiponectin levels (298). In addition, adiponectin knockout mice have exhibited depressive-like 
behavior (297). Further, hypoadiponectenemia is thought to increase sympathetic nervous 
system activity – which is observed in depression (299).  
Adiponectin and ASD: Emerging evidence suggests that adiponectin levels may be altered in 
subjects diagnosed with ASD (192, 262). Fujita-Shimizu et al. noted that adiponectin levels are 
lower in children with ASD, when compared to normal controls. They also observed a negative 
correlation between adiponectin and measure of social development in children, assessed using 
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Autism Diagnostic Interview Revised (192). The authors speculated that altered serotonin 
neurotransmission, observed in children with ASD, could have impacted serum adiponectin 
levels (192). Rodrigues et al. showed that adiponectin was associated with severity of 
symptoms assessed by the Social Responsiveness Scale, although there were no differences in 
adiponectin levels between cases and controls (262).  In a longitudinal study, Blardi et al. 
observed that adiponectin levels declined in subjects with Rett syndrome over time (191); 
however, the authors did not find a difference in adiponectin levels in ASD subjects, after 
excluding those with Rett Syndrome (188). It is interesting to note that adiponectin levels are 
diminished in those with ADHD (300). 
2.5 Role of Timing in ASD  
Perinatal period, infancy and early childhood demonstrate heightened plasticity that 
paves the way for subsequent development of anatomic, physiological and behavioral 
conditions (301, 302). During this period of opportunity and vulnerability, several aspects of the 
brain undergo rapid anatomic and functional expansion (302). Studies have consistently shown 
that insults that retard or accelerate development during specific windows of the “first 1000 
days” may reprogram tissue structure and function leading to abnormal architecture of the 
brain (303). These in turn predispose an individual to future behavioral problems, learning 
difficulties, atypical or delayed cognitive development (303).   
The brain is a heterogeneous organ comprised of anatomic regions that have their own 
developmental trajectories (304). The majority of the brain’s structure and capacity is 
established during fetal life and early childhood. Maintaining a well-orchestrated 
developmental trajectory is not only important for establishing behaviors aided by these 
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regions, but it is also critical to ensure a time-coordinated development of brain areas that will 
soon start to work together as neural circuits (304).  
There are “critical periods” and “sensitive periods” along the developmental trajectory 
of brain regions (304). A sensitive period is an epoch when the brain is more vulnerable to 
environmental factors, but is not necessarily deterministic. Critical period is an early life epoch 
when an impact in the brain (or brain regions) by an environmental factor may have an 
irreversible impact (304). Given that brain is not a homogeneous organ, the vulnerability of a 
developing brain is determined by factors such as timing of the insult and the extent of impact 
(305, 306).  Among the external factors that influence early brain development, optimal 
nutrition and reduction of toxic stress and inflammation have been thought to have profound 
effects (304).  
2.5.1 Timing of ASD onset  
A centrally important question with regard to ASD is whether its onset occurs in 
prenatal period or the first few months of the postnatal life or years after birth (307, 308). 
Although the precise timing is unknown, emerging evidence is pointing to prenatal period as a 
vulnerable window for ASD onset (307-309). While earlier studies highlighted the vulnerability 
of early organogenesis (308, 310), recent studies are highlighting the importance of mid- and 
late-gestation periods (311-313). The developing brain is particularly vulnerable to insults 
between later half of gestation (24 and 42 weeks) and early postnatal period, because of the 
rapid development of several neurological processes (including synapse formation and 
myelination) (109). Despite the brain’s plasticity to recover and repair itself in early life, insults 
during this critical period may have a profound impact, which may result in brain dysfunction 
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(109). A study by Arora et al. on the timing of exposure during discrete prenatal and postnatal 
periods supported the critical role of later time periods in pregnancy (311). A study conducted 
by Beversdorf et al. noted that significant increases in stressors were reported between 21-32 
weeks of gestation among mothers of ASD children when compared to the controls (314).  
While the prenatal period is important, another viewpoint suggests that the vulnerable 
window could depend on 1) the risk factor, and 2) susceptibility for ASD at a given time, and 
this time period could stretch from conception to first years of life (315). Several postnatal 
factors have been studied in ASD, including respiratory infection, urinary infection and auditory 
deficit (316, 317). A recent study by Hazlett et al. suggested that very early postnatal hyper-
expansion of cortical surface areas may be critical for ASD development (318). Thus hyper-
expansion of cortical surface may be one of the early steps that trigger the cascade of events 
leading to brain over-growth, characteristic of ASD (318).  
From the developmental stand point, late fetal to early postnatal period marks the rapid 
differentiation of brain regions including striatum, cerebellum, and limbic system including 
hippocampus, dopaminergic and glutamatergic neurotransmission systems, and prefrontal 
cortex, which may all be implicated in ASD (302, 306). The integrity of these regions is key for 
establishing connections for maturation of structures that subsequently support complex 
behaviors, including working memory and executive function (302).  The limbic system has 
especially been of interest for ASD researchers because of the ways in which this region has 
been connected in social and emotional functioning of humans and primates (319). The critical 
brain wide processes including myelination, synaptogenesis, and development of the dopamine 
neurotransmitter system that are acutely impacted in ASD, are also spurred late in gestation 
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(302, 320-322).  In summary, the existing evidence suggests that timing matters in ASD. 
However, more research is needed to identify the critical time periods for specific 
environmental risk or protective factors in early life that are deterministic to ASD, and to 
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Figure 2-1 An integrated multilevel model depicting underlying abnormalities from genetic to 
behavioral factors in ASD 
	









(Solid green line between preconceptional, prenatal factors and genetic factors will be the focus 
of this study) 
Adapted from Frith, Niculea and Paval. The original caption from Frith: “The X-shape of the 
three-level framework illustrating a cognitive phenotype where there is multiple mapping 
between brain and behaviour via a singular node at the cognitive level. Any developmental 
disorder is likely to have more than one specific deficit, but for simplicity only one is shown in 
the diagram.” 
Source: Frith, U. (2012). Why we need cognitive explanations of autism. Q J Exp Psychol (Hove), 
65(11), 2073-2092. doi:10.1080/17470218.2012.697178 
Niculae, A. S., & Paval, D. (2016). From molecules to behavior: An integrative theory of autism 




 Figure 2-2 One-carbon metabolism 
	
 
Original caption from Yang and Vousden: “The methionine cycle produces S-
adenosylmethionine (SAM), which is a ubiquitous methyl group donor that is used by a large 
family of SAM-dependent methyltransferases for the methylation of DNA, RNA, proteins and 
lipids. Methionine is converted into SAM by S-adenosylmethionine synthase (also known as 
methionine adenosyltransferase (MAT)) in an ATP-dependent process. The folate cycle (which is 
supported by serine-derived one-carbon units) helps to maintain cellular ATP levels through de 
novo purine synthesis. The by-product of the methyltransferase reactions, S-
adenosylhomocysteine (SAH), is converted into homocysteine, a precursor for synthesis of 
cysteine and glutathione through the transsulfuration pathway. 5,10-methylene-
tetrahydrofolate (5,10-methylene-THF) derived from the folate cycle can be irreversibly 
converted by methylenetetrahydrofolate reductase (MTHFR) into 5-methyl-THF, which then 




methionine and THF, a process that uses vitamin B12 as a cofactor. Choline can also contribute 
to homocysteine remethylation via the generation of betaine, which is converted into 
dimethylglycine (DMG) through a reaction catalysed by betaine-homocysteine S-
methyltransferase (BHMT). DMG can further contribute one-carbon units to the mitochondrial 
folate cycle.” Source: Yang, M. and K.H. Vousden, Serine and one-carbon metabolism in cancer. 












































3.1 Data Source: the Boston Birth Cohort  
This dissertation used data from the Boston Birth Cohort (BBC), based at the Boston 
Medical Center (BMC). The BBC is an ongoing prospective cohort study, initiated by Dr. Xiaobin 
Wang in 1998 to study the environmental and genetic determinants of preterm delivery and 
later expanded to study pediatric outcomes. The BBC is uniquely poised to study ASD, since BBC 
is an enriched cohort due to oversampled preterm deliveries and preterm birth is a known risk 
factor for ASD. BBC is one of the largest birth cohorts that consist of predominantly urban low-
income minority population. A majority of the BBC participants received health care through 
means-tested insurance programs such as Medicaid and MassHealth (1). Data collection in the 
BBC follows two Boston University Medical Center IRB approved protocols that govern baseline 
and postnatal follow-up data collection, respectively which are discussed below.  
3.1.1 Baseline data collection 
  Between 1998 and 2015, 7,939 mother-child pairs were enrolled in the BBC. For every 
preterm (defined as <37 weeks) and/or low birth weight baby (defined as <2,500 g), 
approximately two term/normal birth weight babies (and their mothers) were enrolled in the 
study (2, 3). The preterm and/or LBW baby were matched with the full term/normal weight 
baby on delivery date, race/ethnicity and maternal age (+5 years). At the time of recruitment, a 
small percentage of pregnancies (<1%) were excluded from the study for the following reasons: 
conceived using in-vitro fertilization, multiple-gestation pregnancies, fetuses with chromosomal 
abnormalities or major birth defects, preterm delivery due to maternal trauma and women 
with congenital or acquired uterine lesions or incompetent cervix (4). Eligible women were 
invited to participate in the study 24-72 hours after delivery. Over 90% of those that were 
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approached agreed to participate and were initiated into the study (3, 5). Participants and non-
participants did not differ on characteristics such as infant birth weight, maternal ethnicity, or 
other sociodemographic characteristics (3).  
After obtaining signed informed consent from the mothers, using a standardized 
questionnaire, face-to-face interviews were conducted by trained research staff to collect 
epidemiological data. Detailed information was gathered on mother’s general health, maternal 
reproductive history, smoking status, drug use, alcohol consumption, preconception and 
prenatal supplement intake, prenatal dietary intake, physical activity during index pregnancy 
and social and demographic characteristics. Maternal and infant medical records were 
reviewed using standardized abstraction forms to collect data on pre-pregnancy weight, height, 
gestational weight gain, and pregnancy related complications such as gestational diabetes, 
preeclampsia and adverse birth outcomes. Mothers and infants were assigned the same study 
identification number in order to ensure accurate linking of data (1).  
3.1.2 Follow-up data collection 
Children that were part of the BBC at baseline were invited to participate in a follow-up 
study designed to assess postnatal growth, health and developmental outcomes (6). About 
2,932 children were eligible to participate in this postnatal follow-up study and were 
prospectively followed between 2003 and 2015 (5, 7, 8). The follow-up visits were scheduled in 
alignment with pediatric well-child visits during infancy and childhood (6-12 months, 2, 4 and 6 
years) and venous blood sample was collected during one of those visits (6, 7). Postnatal 
demographic and environmental information were collected using a standardized questionnaire 
(4, 9). Mother-infant dyads that participated in the follow-up study were similar to the non-
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participants, in terms of baseline characteristics, including maternal age, maternal education, 
household income, parity, child’s sex and mode of delivery (5, 7). Children in the follow-up 
study were pediatric patients of the BMC with an average 39.3 (range: 1-463) visits to the BMC 
(1). The unique identification number used in the baseline study of the BBC was continued in 
the follow-up study to ensure that the data can be linked. 
3.1.3 Ethical considerations 
The baseline study protocol was approved by the Institutional Review Boards (IRB) at 
the BMC and the Massachusetts Department of Public Health. Written informed consent was 
obtained from all study participants. Each participant was apprised that their participation in 
the study was voluntary and that their information will remain anonymous. The funding for the 
baseline BBC study was provided by the March of Dimes Perinatal Epidemiological Research 
Initiative (PERI) grants (PI: Wang, 20-FY02-5), the National Institute of Environmental Health 
Sciences, NIH (PI: Wang, R21 ES11666), and the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development, NIH (PI: Wang, R01 HD41702).  
The IRB at the Boston University Medical Center and Children’s Memorial Hospital in 
Chicago approved the postnatal follow-up data collection protocol. Informed consent was 
obtained prior to participation in the follow-up study (7). The funding for the follow-up study 
was provided by the Food Allergy Initiative and the National Institute of Allergy and Infectious 
Disease, NIH (PI Wang: R21 AI079872, U01 AI090727, 2R01 HD41702) and the Department of 
Defense (PI Wang: W81XWH-10-1-0123). Subsequently, the baseline and postnatal follow-up 
data collection was approved by the IRB at the Johns Hopkins Bloomberg School of Public 
Health (JHBSPH), when Dr. Wang moved to the Johns Hopkins University.  
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I have completed all the ethics training required by the JHBSPH and have completed the 
CITI certificate and obtained IRB approval as a research staff of the BBC. This study adhered to 
data procurement, management and analysis plan stipulated by the JHSPH IRB. To protect 
confidentiality of the study participants, I used the datasets without personal identifier and the 
data were stored on secure networks. Additionally, data will be reported only as aggregates.  
3.2 Analytic Sample for this dissertation 
 This dissertation used data from the postnatal follow-up study, which began in 2003 and 
had a baseline sample of 2,932. Since the transition to ICD-10-CM began on October 1 2015, an 
end date cut-off of September 30 2015 was chosen for the follow-up study. Figure 3-1 
summarizes the sample sizes for each specific aim. The sample size varied depending on the 
inclusion and exclusion criteria for each specific aim. There were two main reasons for 
excluding subjects: 1) missing data for one or more explanatory variables, and 2) competing 
diagnosis in the non-ASD subjects.  
Nutritional, metabolic biomarkers and early life growth data were the key explanatory 
variables in this study. In the baseline and follow-up studies, biomarkers were assessed in a 
random sample of mothers and children. Thus, depending on the specific aim, lack of 
appropriate biomarker data was one of the important reasons for excluding subjects. Since the 
BBC oversampled preterm babies at enrolment, there were a considerable proportion of 
children with neurodevelopmental diagnosis. To allow cleaner comparison between cases and 
control, those with competing diagnosis such as Attention Deficit Hyperactivity Disorder 
(ADHD), Intellectual Disability (ID) and other developmental disabilities were excluded from the 
neurotypical group.  
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3.2.1 Analytic sample for Specific Aim 1 
 The base sample for the analyses in Aim 1 was 2,932. A total of 896 children were 
excluded because of lack of maternal plasma folate and vitamin B12 measures. An additional 
189 were eliminated because of the missing third trimester prenatal supplement intake data. In 
the remaining 1,848 subjects, 167 had ADHD, 406 had other developmental disabilities and 8 
had ID without co-occurring ASD. One subject had Ventricular Septal Defect (VSD), but was 
miscoded as having ASD. Additionally, 9 subjects were excluded because of lack of relevant 
EMR data such as age of ASD diagnosis, date of first and last EMR visit – which was used in the 
Cox Proportional Hazards model, to account for the variability in length to follow-up. The final 
analytic sample size for specific aim 1 was 1,257. 
3.2.2 Analytic sample for Specific Aim 2 
 In the process of identifying subjects eligible for this specific aim, 1,554 children were 
excluded from the final analysis because of lack of one or more of the following explanatory 
variables: a) cord leptin, b) early childhood leptin, c) IUGR data, d) first year weight gain data. In 
addition, 534 children were eliminated since they were not neurotypical. In other words, they 
had other competing diagnosis such as ADHD (n=198) and other developmental disabilities 
(n=336) without a concurrent ASD diagnosis. Thus, the analytic sample for specific aim 2 was 
844. 
3.2.3 Analytic sample for Specific Aim 3 
 The lack of cord adiponectin and/or early childhood adiponectin resulted in exclusion of 
1,546 subjects from the base sample (n=2,932). Subsequently, 539 children were excluded 
because they had other competing diagnosis such as ADHD (n=203) and other developmental 
disabilities (n=336), leaving an analytic sample of 847 for this sub-aim.  
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3.3. Measures 
3.3.1 Outcome: Autism Spectrum Disorder 
ASD diagnosis in this dissertation was based on EMR data, which documented pediatric 
inpatient, outpatient, and emergency room visits using International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM). EMR data was collected for every postnatal 
clinical visit between October 2003 and September 30 2015. Children ever diagnosed with 
autism (ICD-9 code 299.00), Asperger syndrome (299.80) and/or pervasive developmental 
disorder not otherwise specified (299.90) were categorized as having ASD (1, 8). Neurotypical 
children were those without ASD, ADHD (314.0–314.9), other developmental disorders (315.0–
315.9), or ID (317–319). A sub-set of ASD children who were diagnosed by a specialist such as 
developmental behavioral pediatrician, pediatric neurologist and child psychologist and 
received ASD code at least on two separate occasions were identified as stringent cases and 
were used in sensitivity analysis.  
3.3.2 Major Explanatory Variables 
Considering the multifactorial etiology of ASD, this dissertation assessed the association 
between multiple explanatory variables, broadly categorized into nutritional and metabolic 
factors, and ASD. Nutritional factors were addressed from a maternal context and metabolic 
explanatory variables were addressed from the child’s context. The latter was assessed at two 
time points – at birth and early childhood (prior to ASD diagnosis).  
Specific Aim 1: Nutritional factors 
The goal of specific aim 1 was to assess the association between maternal B-vitamin 
status during third trimester and risk of ASD. The key explanatory variables for this aim were: 1) 
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maternal plasma folate and vitamin B12, and 2) preconception and prenatal supplement intake, 
especially third trimester supplement intake.  
Blood was drawn from mothers 24-72 hours after delivery. Plasma folate was 
subsequently measured using chemiluminescent immunoassay with diagnostic kits (Shenzhen 
New Industries Biomedical Engineering Co., Ltd. China), plasma vitamin B12 was measured 
using Beckman Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, Mississauga, 
Canada) and the interassay coefficient of variation was less than 4% (9). Plasma homocysteine 
levels were measured using automatic clinical analyzers (Beckman-Coulter) (9). Although the 
blood was drawn post-birth, plasma folate is a marker of recent intake and is reflective of third 
trimester levels (10).  
Maternal plasma folate levels were categorized based on the cut-offs suggested by the 
World Health Organization (WHO) (11). In addition, plasma folate and vitamin B12 levels were 
categorized in such a way that the lowest and highest deciles (bottom and top 10
th
 percentiles) 
were compared against the middle 80
th
 percentile. The joint effects of folate and vitamin B12 





 percentile, referent category), 2) Folate (<10
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 percentile), 3) Folate (≥ 90th percentile) and vitamin B12 (10th – <90th percentile), 4) 
vitamin B12  (<10th percentile) and folate  (10th – <90th percentile), 5) vitamin B12 (≥ 90th 
percentile) and folate (10th – <90th percentile).  Using an alternate approach the following 




 percentile, referent 
category), 2) Either folate or vitamin B12 (≥ 90
th
 percentile), and 3) Both folate and vitamin B12 
(≥ 90th percentile).  
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Preconception and prenatal supplement intake data was gathered from mothers using a 
standardized questionnaire administered soon after birth. Preconception multivitamin intake 
was dichotomized (no vs. yes). The frequency of prenatal supplement intake during first, 
second and third trimesters were categorized as follows: ≤2 times/week, 3–5 times/week and 
>5 times/week.   
Specific Aim 2: Leptin and early life growth pattern  
 
This specific aim assessed the relationship between ASD and the following key 
explanatory variables: 1) cord and early childhood leptin levels, 2) fetal growth and weight gain 
during 1
st
 year of life. Birth weight for gestational age, a proxy for fetal growth, was defined as 
follows: small for gestational age (<10
th





percentile) and large for gestational age (>90
th
 percentile). Child’s length (<2 years), height and 
weight measured during the well-child visits were used to assess the rate of weight of gain 
during infancy. The WHO reference values were used to calculate weight-for-age z-scores, 
defined as the changed in weight-for-age z scores from birth until the target time point. Based 
on this, the rate of weight gain was categorized as slow (weight gain z -score <-0.67), on track 
(−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely rapid (>1.28).   
 Umbilical cord blood was collected at delivery and postnatal venous blood was 
collected during a follow-up visit. The blood samples were processed immediately and plasma 
was stored in a freezer at −80°C. Using a sandwich immunoassay based on flow metric xMAP 
technology, plasma leptin levels were measured on Luminex 200 machines (Luminex Corp., 
Austin, TX) and had an interassay coefficient of variation of 4.5% (12). Plasma leptin >3 SD 
above the mean were deemed unlikely and was reassigned a value of 3SD (9). To ensure 
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temporality, childhood leptin measurements prior to ASD diagnosis were only included in the 
analysis.  
Specific Aim 3: Adiponectin  
 In this specific aim, the association between adiponectin and ASD was assessed at two 
time points. Adiponectin was assessed in umbilical cord sample drawn at delivery and venous 
blood sample collected during a subsequent early childhood follow-up visit. Adiponectin was 
measured using an immunoassay (ELISA) and had an inter-assay variation of <5.8% (9). The 
assays were run according to the manufacturer’s recommendation and were measured in 
duplicates. Children that had adiponectin assessed after ASD diagnosis were excluded from the 
follow-up analysis. Adiponectin levels greater than 3SD above the mean were re-assigned to 
3SD levels.  
3.3.3 Other explanatory variables 
 Covariates for this dissertation were chosen a priori based on the earlier work in the 
BBC (1, 5, 9, 13) as well as studies looking at the relationships between nutritional, metabolic 
factors and ASD (14-16). These covariates were gathered from maternal interviews, using 
standardized questionnaire or medical record abstraction. While most of the same covariates 
were accounted for in the three specific aims, there were a few that were specific for each aim. 
Below, is the list of covariates, broadly categorized into maternal and child factors. 
Maternal factors 
Maternal age at delivery was defined as mother’s age at delivery of the index pregnancy, 
calculated using mother’s date of birth and infant’s date of birth.  
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Parity captured the number of previous pregnancies, not including the index pregnancy and 
was categorized into zero, one, or two or more. This data was obtained from the baseline 
maternal questionnaire.  
Educational attainment was categorized into high school or less and some college or more. This 
grouping was reconciled from the original five options that the mothers chose, including: no 
school/elementary school, some secondary school (9
th
 grade and above), high school graduate 
or GED, some college, college degree and above.  
Smoking status was ascertained using one of the two responses – a) smoking 3 months before 
pregnancy or during pregnancy, or b) no smoking during preconception or pregnancy.  
Race-ethnicity was categorized into black, white, Hispanic and Other. This categorization is 
based on 8 original responses (Black/African American, White, Hispanic, Asian, Haitian, Cape 
Verdian, Pacific Islander, and Multiple responses (mixed ethnicity)) that were recoded into the 
4 categories.   
Pre-pregnancy BMI was generated using self-reported height and weight and was categorized 
into the following: underweight (<18.5 kg/m
2
), normal weight (≥ 18.5 to <25 kg/m
2
), overweight 
(25 to <29.9 kg/m
2
) and obesity (≥ 30 kg/m
2
). Since underweight comprised a very small 
proportion of BBC women, they were combined with normal weight category. Depending on 
the specific aim, pre-pregnancy BMI was considered as a continuous variable (as in the case of 
specific aim 1).   
Maternal diabetes status was categorized into the following: no pre-gestational or gestational 
diabetes, gestational diabetes and pre-gestational diabetes. Mothers ever diagnosed with 
diabetes mellitus complicating pregnancy (648.00 and 648.03) comprised gestational diabetes 
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cases and those ever diagnosed with diabetes (250.00 – 250.93) were identified as pre-
gestational diabetes cases. 
Maternal Methylene tetrahydrofolate reductase (MTHFR) C677T genotype was categorized 
into CC (wild type) vs. CT (heterozygous) vs. TT (homozygous). Considering the intimate role of 
MTHFR genotype in one-carbon metabolism (involving folate and vitamin B12), it was only 
included in specific aim 1 analyses.   
Homocysteine, an amino acid that is closely involved in folate and vitamin B12 metabolism, was 
included in specific aim 1 analyses, along with plasma folate and vitamin B12. It was considered 
as a binary variable with the top 10
th
 percentile, compared against the bottom 90
th
 percentile. 
Plasma homocysteine levels were measured using automatic clinical analyzers (Beckman-
Coulter).  
Child factors 
Sex was coded as 0 for female and 1 for male.  
Gestational age at birth was used to categorize preterm birth into full term (≥37 weeks), late 
preterm (≥34 to <37 weeks) and early preterm (<34 weeks). Gestational age was characterized 
based on the first day of the last menstrual period data and early ultrasound data (3, 5). 
Year of birth was coded as a dichotomous variable - children born between 1998-2006 vs. 
2007-2013.  
Follow-up time was captured as a continuous variable. Since BBC is a birth cohort, follow-up 
time was assessed as the age at which a child had the last EMR record (between Oct 2003 and 
Sep 2015).  
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Age of blood draw was calculated as the number of months between child’s birth and age of 
first blood draw. This variable was accounted for in the analyses that included early childhood 
biomarkers as the key explanatory variable (specific aims 2 and 3).  
Infant feeding was categorized into 1) formula feeding only, 2) both breastfeeding and formula 
feeding, and 3) breastfeeding only. This data was obtained from mothers using a standardized 
questionnaire during the first few years of study.  
Cord and early childhood insulin was used as a covariate in specific aim 3. Similar to leptin and 
adiponectin, insulin was measured in umbilical cord and during early childhood using a 
sandwich immunoassay, with an interassay coefficient of 4.0%. Cord and early childhood insulin 
were used as a continuous variable. 
Other relevant covariates: Information about paternal social characteristics might have had a 
role to play in the association with ASD, but were not included in this dissertation for the 
following reasons. First, data on paternal characteristics was added to baseline interview 
around mid-2000 and therefore, this information were unavailable for children enrolled in the 
cohort between 1998 and mid-2000. Second, the baseline and follow-up interviews were 
conducted with mothers, who may or may not have accurate data on paternal characteristics. 
Third, maternal and paternal sociodemographic characteristics are generally related and this 
was true in this dataset as well. Data showed that dad’s age correlated well with mother’s age 
(correlation coefficient: 0.74) and preliminary analysis adjusting for paternal age in specific aim 
1 (along with other covariates) did not alter the association between maternal plasma folate, 
vitamin B12 and ASD. However, including paternal age resulted in losing ~1/4
th
 of the sample 
size.  Thus, only maternal characteristics were used as the primary explanatory variable.  
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3.4 Statistical Analysis 
3.4.1 Data preparation 
This dissertation used BBC data from the following sources: 1) enrollment log, 2) 
baseline maternal questionnaire, 3) baseline medical record abstraction sheet, 4) maternal 
biomarker analysis data, 5) first follow-up child health questionnaire, 6) cord and early 
childhood biomarker analysis data, and 7) EMR data for the children that were followed. 
Several major data preparation steps were performed prior to data analysis. All preparation 
was done using Stata 13.0 statistical software (College Station, TX).  
3.4.1.1 Data Entry, Cleaning, and Management 
 The first step in the data preparation process was data entry and cleaning, which were 
done separately for each of the data source. The cleaned data from different sources were 
systematically merged and linked using the unique ID (described in sections 3.1.1 and 3.1.2). 
The baseline enrolment log was maintained as an excel file, which was converted into a Stata 
file. Records with implausible dates such as 01/01/1900 or infant’s date of birth prior to study 
inception, such as 01/01/1998, were coded as missing.  
The baseline maternal questionnaire was originally collected in paper-based forms. 
Digitization of paper-based forms began in late-2013 and was conducted using digital optical 
recognition software (Teleform). Trained data entry operators at the JHBSPH scanned the 
questionnaires and converted them into PDF using Teleform software. In order to ensure data 
quality, the original questionnaires were compared with the entry in PDF files and any 
uncertainties and errors were manually corrected. The medical record abstraction sheets were 
originally paper-based and data from selected questions (e.g. pregnancy and obstetric 
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complications) were manually entered. Maternal follow-up questionnaire data was digitized 
using Teleform (as described above).  
The EMR data corresponding to diagnosis records, inpatient prescription and outpatient 
prescription records of the study children were obtained from the BMC data warehouse. The 
diagnosis records data contained information on discharge claims and/or diagnostic 
information for a child’s clinic or hospital visit, as well as child’s identifiers. Since the follow-up 
period began only in Oct 2003, visits prior to this time period were not captured in the EMR. 
Similarly, visits after September 2015 were also not considered for this dissertation.  
3.4.1.2 Analysis and Handling of Missing Data 
 The outcome data was complete for all the participants. As described in section 3.3.2, 
subjects with missing data for the key explanatory variables were excluded from the analyses. 
These variables included biomarker data, maternal supplement intake, fetal growth pattern and 
weight gain during infancy.  The extent of missingness was minimal and ranged from 0% to 4% 
for important covariates such as pre-pregnancy BMI, diabetes status, offspring’s sex and 
gestational age.  
3.4.2. Analyses for Specific Aim 1 
 
The primary purpose of this sub-aim was to understand the relationship between 
maternal nutritional status measured during pregnancy and risk of ASD. It has 2 main 
objectives:  
• To assess the association between maternal B-vitamin biomarkers measured at delivery 
and risk of ASD in children 
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• To assess the association between preconception and prenatal supplement intake and 
risk of ASD in children 
Descriptive analyses were conducted to compare the characteristics of neurotypical 
children and those with ASD using chi-squared tests for categorical variables and ANOVA for 
continuous variables. I fitted a Cox proportional hazard regression model to estimate hazard 
ratios and account for variability in length of follow-up. Birth of the child was defined as the 
time of origin and the child’s first postnatal visit recorded in the EMR was defined as the time of 
entry. The child exited the ASD risk pool if he/she had the event (ASD diagnosis) or was 
censored after his/her recorded last postnatal visit (Sep 30, 2015). Covariates specified in the 
previous section were included in the model. The final model adjusted for maternal covariates 
such as age, parity, education status, race/ethnicity, smoking status, pre-pregnancy BMI, 
diabetes status, MTHFR, homocysteine and offspring characteristics such as sex, gestational age 
and year of birth.  
To assess robustness of results for sub-aim 1a, I used propensity score matching to 
assess similarity of distribution of observable characteristics among the exposed and 
unexposed. Matching was implemented to reduce the possibility of model extrapolations and 
misspecifications. Propensity scores were constructed using a majority of the variables used in 
the main Cox proportional hazard model, since the internal validity of propensity score 
matching depends on the covariates (17). The propensity score matching was conducted in R 
using MatchIt package (18) and used estimated average effects on “treatment on treated,” 
defined as the averaged causal effect that might be observed if everyone in the group were 
exposed verses none in the exposed group were exposed (19). The nearest neighbor matching 
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(3:1) without replacement was used, since there were a large number of controls when 
compared to cases. 
Next, I conducted a sensitivity analysis to assess the influence of potential EMR 
misclassification of ASD or neurotypical development. First, a sub-set of ASD subjects were 
identified using a stringent categorization, defined as receiving ASD codes on at least two 
separate occasions and having a diagnosis by a specialist. Similarly, a sub-set of the neurotypical 
children were identified by excluding those with any potential developmental disability 
indicators. The main analyses were repeated on this sub-set population defined based on 
stringent ASD and stringent neurotypical definitions.  
3.4.3 Analyses for Specific Aim 2  
Specific Aim 2 assessed the relationship between early life growth, leptin, and ASD risk. 
This aim had three objectives:  
• To assess the association between cord, early childhood plasma leptin and ASD risk 
• To assess the association between fetal growth, weight gain during first year of life and 
ASD risk 
• To evaluate the mediating effects of early childhood leptin in the association between 
weight gain during first year of life and ASD risk 
As discussed in specific aim 1, descriptive analyses using chi-squared tests (for categorical 
variables) and ANOVA (for continuous variables) were conducted before embarking on the 
main analysis. Correlation between cord and early childhood leptin was assessed. Since the 
distribution of cord and early childhood leptin was skewed, they were log transformed. Logistic 
regression models were constructed to assess the following relationships: 1) fetal growth and 
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ASD, 2) weight gain during first year of life and ASD, 3) cord leptin and ASD, and 4) early 
childhood plasma leptin and ASD. In each of these models, covariates were sequentially added 
to the base specification to assess the robustness of the coefficient (20).  
1. The cord leptin model adjusted for maternal age at delivery, parity, smoking, maternal 
BMI, maternal diabetes status, education, race, child's sex and follow-up time (base 
model) and in addition, adjusted for gestational age. 
2. The early childhood leptin model adjusted for child's sex, race, age of leptin 
measurement, follow-up time and breastfeeding status (base model), followed by 
sequential adjustment of gestational age, cord leptin levels and maternal age, maternal 
BMI and maternal diabetes status. Specifically, cord leptin was adjusted to tease apart 
the independent association of early childhood leptin and ASD.  
3. The fetal growth model adjusted for covariates including maternal age at delivery, 
parity, smoking, education, maternal BMI, maternal diabetes status, race, child's sex and 
follow-up time (base model). In the subsequent model, preterm birth was adjusted in 
addition to all covariates specified above. 
4. The first-year weight gain model adjusted for child’s sex, race, follow-up time and 
breastfeeding status (base model). Next, the following covariates were adjusted in 
addition to ones specified in this base model: fetal growth pattern, gestational age and 
maternal age, maternal diabetes status and maternal BMI. Fetal growth pattern was 
adjusted to delineate the independent association between first year weight gain and 
ASD.  
As described in the previous section, sensitivity analyses were conducted to assess the 
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robustness of the findings. All four models were repeated using a sub-set of subjects identified 
by stringent ASD definition. Next, the analyses were repeated using stringent control definition. 
Because of the small sample size, stringent cases and controls were not concurrently run in the 
same model.  
Mediation analysis 
 The analyses for specific aim 2 focused on understanding the extent to which early 
childhood leptin mediates the association between weight gain during first year of life and ASD 
risk.  A mediator is defined as one that is on the causal path between exposure and outcome 
and is caused by the exposure (21). Although there are several methods available for mediation 
analysis, KHB was chosen because it allowed categorical exposure and binary outcome. KHB 
model decomposes the logit coefficients into total, direct and indirect effects (22). The total 
effect is defined as the effect of treatment variable X (weight gain during infancy) on outcome 
variable Y (ASD), without mediating variable M (early childhood leptin). The direct effect is 
defined as the effect of treatment variable X on outcome Y, when controlling for mediating 
variable M. The indirect effect is defined as the effect of treatment variable X on outcome 
variable Y through mediating variable M (23). The mediation percentage is derived as the ratio 
of the indirect effect to the total effect (24).  
3.4.4 Analyses for Specific Aim 3 
	 In specific aim 3, I looked at the association between adiponectin and ASD, and assessed 
the joint effects of adiponectin and preterm birth on ASD. This aim has two main objectives: 
• To evaluate the association between cord and early childhood plasma adiponectin and 
ASD risk 
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• To assess the joint effects of cord adiponectin and preterm birth on ASD risk 
As discussed in other specific aims, descriptive statistical analysis was conducted as the first 
step. Correlation between cord and early childhood plasma adiponectin was assessed. Since the 
distribution of explanatory variables was skewed, they were log transformed prior to analysis. 
Two separate regression models (described below) were constructed and covariates were 
sequentially added. 
1. Cord adiponectin and ASD risk: The base model adjusted for covariates including 
maternal age, education, parity, smoking status, race/ethnicity, pre-pregnancy BMI, 
diabetes status, child’s sex and follow-up time. Then, the following covariates were 
individually added to the base model: 1) gestational age, 2) cord insulin, 3) cord leptin, 
and 4) weight gain during first year of life.  
2. Early childhood adiponectin and ASD risk: The base model adjusted for maternal age, 
pre-pregnancy BMI, maternal diabetes status, race/ethnicity, child’s sex, age of 
measurement of adiponectin, breast feeding status and follow-up time. The following 
covariates were adjusted sequentially: 1) gestational age, 2) early childhood insulin, 3) 
early childhood leptin, 4) weight gain during first year of life. In addition, cord 
adiponectin was adjusted to the base model, to make sure that the association between 
early childhood adiponectin and ASD, independent of cord adiponectin is captured.  
Sensitivity analysis was conducted using a sub-set sample, identified using stringent 
criteria for ASD and neurotypical children (as discussed in sections 3.4.2 and 3.4.3).  
3. Next, the joint effects of cord adiponectin and preterm birth were assessed. The 




percentile) levels. This groups was compared against the following groups – 1) preterm 
(<37 weeks) and high adiponectin, 2) term and low adiponectin (≤50
th
 percentile), and 3) 
preterm and low adiponectin. Similar to the regression model, I first ran an unadjusted 
analysis and then sequentially added relevant covariates such as maternal age, 
education, parity, smoking status, race/ethnicity, pre-pregnancy BMI, diabetes status, 
child’s sex and follow-up time.  
4. Finally, an exploratory mediation analysis was conducted. Since the temporality in the 
relationship between preterm birth and altered adiponectin levels are unclear, the 
mediation analysis was run both ways, as described below: 1) Cord adiponectin 
mediating the association between preterm birth and ASD; 2) Preterm birth mediating 
the association between cord adiponectin and ASD. Preterm was considered as a 
categorical variable (early preterm (<34 weeks), late preterm (≥34 to <37 weeks) and full 
term (≥37 weeks)), so that the impact of early vs. late preterm was captured. Cord 
adiponectin, the mediator, was treated as a continuous variable and the outcome ASD 
was a binary variable. The mediation analysis was run using Baron and Kenny mediation 
analysis. First, I adjusted for covariates that were accounted in the base regression 
model for cord adiponectin and ASD. The above analysis was then repeated to assess 
whether early childhood adiponectin is a potential mediator between preterm birth and 
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Eligible mother-infant pairs 
Enrolment period: 1998-2013 
Site: Boston Medical Center (BMC)	
N=2,932 
Children that received pediatric care 
Follow-up period: 2003-2015 
 at BMC	
N=5,007  
Excluded because postnatal pediatric 
care was not at BMC 	
N=1,343 
Children with cord or early childhood 
leptin measure	
N=822 
Children included in Specific 
Aim 2 analysis 
N=521 (ADHD =191; DD=330) 




No cord or early childhood leptin  
 	
N=1,386 
Children with cord and/or early 
childhood adiponectin measure 	
N=847 
Children included in Specific 
Aim 3 analysis 
N=539 (ADHD =203; DD=336) 




No cord and/or early childhood 
adiponectin measure  
 	
N=1,847 
Children with cord and/or 
early childhood leptin 
measure	
N=1,085 
(N=896 No biomarker) 
(N=189 No supp data) 
 	
N=1,257 
Children included in Specific 
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Background: To examine the prospective association between multivitamin supplementation 
during pregnancy and biomarker measures of maternal plasma folate and vitamin B12 levels at 
birth and child’s Autism Spectrum Disorder (ASD) risk.    
Methods: This report included 1257 mother-child pairs, who were recruited at birth and 
prospectively followed through childhood at the Boston Medical Center. ASD was defined from 
diagnostic codes in electronic medical records. Maternal multivitamin supplementation was 
assessed via questionnaire interview; maternal plasma folate and B12 were measured from 
samples taken 2-3 days after birth.  
Results: Moderate (3-5 times/week) self-reported supplementation during pregnancy was 
associated with decreased risk of ASD, consistent with previous findings. Using this as the 
reference group, low (≤2 times/week) and high (>5 times/week) supplementation was 
associated with increased risk of ASD. Very high levels of maternal plasma folate at birth (≥60.3 
nmol/L) had 2.5 times increased risk of ASD (95% confidence interval (CI) 1.3, 4.6) compared to 
folate levels in the middle 80th percentile, after adjusting for covariates including MTHFR 
genotype.  Similarly, very high B12 (≥536.8 pmol/L) showed 2.5 times increased risk (95% CI 1.4, 
4.5). 
Conclusion: There was a “U” shaped relationship between maternal multivitamin 
supplementation frequency and ASD risk. Extremely high maternal plasma folate and B12 levels 
at birth were associated with ASD risk. This hypothesis-generating study does not question the 
importance of consuming adequate folic acid and vitamin B12 during pregnancy; rather, raises 
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new questions about the impact of extremely elevated levels of plasma folate and B12 
exposure in utero on early brain development.  
 






Autism Spectrum Disorder (ASD) is a heterogeneous group of neurodevelopmental 
conditions characterized by impaired social reciprocity, abnormal communication and repetitive 
or unusual behavior (1, 2). The prevalence of ASD was about five per 10,000 individuals in 
1980s, but recent estimates in the U.S. suggest that it is now one in 68 individuals (3, 4). The 
etiology of ASD is complex, and includes the interplay of genetic and environmental factors (5, 
6). Folate is an essential B vitamin involved in nucleic acid synthesis, DNA methylation, and 
repair (7). Folic acid is a synthetic form of folate that is commonly used to fortify foods, and 
consumed as nutritional supplements (8). In light of substantial evidence that folic acid 
supplementation reduces the risk of neural tube defects (NTD) in offspring, the US Public Health 
Service recommended in 1992 that women of reproductive age consume 400 μg/d before and 
during pregnancy. Subsequently, mandatory fortification of cereal grain products at a suggested 
level of 140 μg folic acid/100 g was implemented in the US in 1998 (9). 
In the post-fortification era, serum folate levels in the US have increased 2.5 times 
across all life stages, including among pregnant women (10). A recent NHANES study showed 
that unmetabolized folic acid (either from folic acid supplementation or fortified grain 
products) has been detected in most of the U.S. population (11). Furthermore, data from the 
Boston Birth Cohort showed a wide range of individual variation in plasma folate levels ranging 
from insufficient to excessive levels (12). The association between folic acid intake during 
pregnancy and ASD risk in offspring has been equivocal. Several studies suggest that mothers 
who use a periconceptional multivitamin or folic acid supplementation are less likely to have 
offspring with ASD, (2, 13) yet, others have hypothesized an opposite relationship (14-16). 
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Preliminary studies that included both women’s report of prenatal vitamin use and maternal 
biomarker data found a protective effect of prenatal vitamins intake on ASD based on report, 
but this relationship could not be confirmed using biomarker data (17, 18). Given this 
background, in this hypothesis-generating study, we evaluated the relationship between self-
reported pregnancy multivitamin intake, and plasma folate levels in mothers at birth and ASD in 
offspring. Since both vitamin B12 and folate are intricately involved in one-carbon metabolism 
and there are very few studies on B12 status on human brain (19), we also explored the 
association between maternal B12 biomarker levels and ASD risk in offspring.  
4.3 Methods 
4.3.1 Participants and data collection procedure 
The study included mother-infant pairs who were recruited at the Boston Medical 
Center (BMC) at the time of birth from 1998 to 2013 and followed up prospectively from 2003 
to 2015 (supplemental figure 4-1), as described elsewhere (12, 20). Children who were not 
intending to receive pediatric care at the BMC were excluded. Mothers who had a post-birth 
blood sample for analyzing plasma folate and B12 and who had data on maternal multivitamin 
supplement intake during at least the third trimester were included in the analysis.  
Mothers of newborns were approached 24-72 hours postpartum to participate in the 
study. After obtaining informed consent, a standard questionnaire was used to collect relevant 
maternal data including supplement intake. Maternal and infant medical records were 
reviewed using standardized abstraction forms to collect data on pre-pregnancy weight and 
pregnancy related complications. Maternal blood samples collected 24-72 hours post-delivery 
were later analyzed for maternal plasma folate, B12 and homocysteine levels. Children were 
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followed from birth through both study visits and clinical pediatric visits at the BMC. Electronic 
Medical Records (EMR) containing clinicians’ primary and secondary diagnoses using ICD-9 
codes were obtained for every postnatal clinical visit starting in 2003. The study was approved 
by the Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health and 
Boston University Medical Center. 
 
4.3.2 Identification of children with ASD  
Based on EMR, children who were ever diagnosed with autism (ICD-9 code 299.00), 
Asperger syndrome (299.80) and/or pervasive developmental disorder not otherwise specified 
(299.90) were categorized as having ASD, as described elsewhere (21). Children who 
concomitantly had ASD and ADHD, ASD and other developmental disabilities, or ASD and 
intellectual disabilities were classified as having ASD. Children without ASD, ADHD (314.0-
314.9), other developmental (315.0 - 315.9), or intellectual disabilities (317 – 319) constituted 
the ‘neurotypical’ group. Children diagnosed with ADHD or other developmental or intellectual 
disabilities without concurrent ASD were excluded from the analysis. One subject who had 
Ventricular Septal Defect (VSD), but was miscoded as having ASD, was identified and excluded. 
For sensitivity analyses, children with ASD were restricted to those with an ASD code for at least 
2 visits and where at least one visit was with a specialist (developmental behavioral 
pediatrician, pediatric neurologist or child psychologist). Sensitivity analyses were also 
implemented restricting neurotypical children to only those that did not have other competing 
diagnoses, including congenital anomalies and psychiatric or behavioral disorders (see 




Plasma folate was measured using chemiluminescent immunoassay with diagnostic kits 
(Shenzhen New Industries Biomedical Engineering Co., Ltd. China) and plasma B12 was 
measured using the Beckman Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, 
Mississauga, Canada) using a MAGLUMI 2000 Analyzer. The interassay coefficient of variation 
was less than 4% (12). Mothers with the lowest and highest deciles (top and bottom 10th 
percentiles) of the plasma folate (<14.7 and ≥60.3 nmol/L) and B12 (<247.0 and ≥536.8 pmol/L) 
distributions were compared against the middle 80th percentile.  
Preconception multivitamin intake was dichotomized (no vs. yes) and prenatal 
multivitamin supplement intake was coded as a categorical variable (supplement ≤2 
times/week, 3-5 times/week and >5 times/week). Mothers ever diagnosed with diabetes 
(250.00-250.93) were identified as pregestational diabetes cases and those ever diagnosed with 
diabetes mellitus complicating pregnancy (648.00 and 648.03) comprised gestational diabetes 
cases. 
4.3.4 Covariates 
Plasma homocysteine levels were measured using automatic clinical analyzers 
(Beckman-Coulter). Homocysteine was considered as a binary variable with the top 10th 
percentile of the distribution compared against the bottom 90th percentile (<11.7 μmol/L). 
Other covariates were chosen a priori based on previous studies looking at maternal nutritional 
status and the risk of ASD (13, 22). Neonates who were delivered at or after 37 completed 
weeks of gestation were considered full term; those delivered <34 weeks, and ≥34 but <37 
weeks of gestation were considered early and late preterm, respectively. Race-ethnicity was 
categorized into black, white, Hispanic and Other. Other covariates assessed were: child sex 
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(female vs. male), maternal age at delivery, smoking during pregnancy (“ever smoked” 3 
months before pregnancy/during pregnancy vs. “no smoking” during preconception/ 
pregnancy), parity (not including the index pregnancy), maternal education (high school or less 
vs. some college or more), year of the baby’s birth (1998-2006 vs. 2007-2013) and Methylene 
tetrahydrofolate reductase (MTHFR) C677T genotypes (CC vs. CT vs. TT). 
4.3.5 Statistical Analyses 
The primary outcome variable was ASD and exposures were maternal vitamin 
supplementation during preconception, 1st, 2nd and 3rd trimesters or maternal plasma folate 
and B12 levels in the days after birth. Preliminary data analysis was performed to compare 
neurotypical children and those with ASD using chi-squared tests for categorical variables and 
ANOVA for continuous variables. We fitted a Cox proportional hazard regression model to 
estimate hazard ratios and account for the variability in length of follow-up. Birth of the child 
was defined as the time of origin and the child’s first postnatal visit recorded in the EMR was 
defined as the time of entry. The child exited the ASD risk pool if he/she had the event (ASD 
diagnosis) or was censored after his/her recorded last postnatal visit. In addition, the role of 
maternal MTHFR C677T genotype was examined via stratification and cross-product 
proportional hazard regression analyses. We tested the interaction of maternal folate (as a 
binary variable) and 1) B12 levels (as a binary variable) and 2) MTHFR C677T (as a categorical 
variable) on the risk of ASD. 
4.4 Results 
A total of 1257 mother-infant pairs were included in the analysis, of which 86 were ASD 
cases and 1171 were children with neurotypical development (supplemental figure 4-1). 
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Children with ASD had co-morbidities including ADHD (n=25), intellectual disabilities (n=39) and 
other developmental disabilities (n=76), that were not mutually exclusive. Table 4-1 describes 
the characteristics of mothers and children in each group. The frequency of multivitamin 
supplement intake during third trimester differed between mothers whose children had ASD 
when compared to those who had children with neurotypical development. They were also 
more likely to have higher pre-pregnancy BMI, pre-gestational/gestational diabetes and very 
high maternal B12 (≥90th percentile). The distribution of folate and B12 levels in our study 
population is consistent with the NHANES data for women of reproductive age (supplemental 
figure 4-2) and detailed comparisons are provided in supplemental tables 4-2 and 4-3. To 
understand the impact of differential follow-up, analyses were conducted on this cohort 
comparing baseline characteristics of the children included in the analyses and those excluded 
from the analyses.  
Maternal multivitamin supplement intake preconception was not statistically 
significantly associated with the risk of ASD in children (Table 4-2). Consistent with previous 
research, (13) 1st trimester supplement intake (≥ 3 times/week) was protective against ASD risk 
when compared to those who reported taking a supplement <3 times/week; or conversely, low 
levels of multivitamin supplement intake were associated with increased ASD risk. When 
supplement intake was stratified by intake frequency, a “U” shaped relationship was observed, 
with maternal supplement intake ≤2 times/week and >5 times/week during both 
demonstrating statistically significantly increased risk for ASD (Table 4-2 and Figure 4-1). This 
“U” shaped relationship was consistent across all trimesters and became stronger after 
adjusting for potential confounders. 
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 Elevated maternal plasma B12 (>600 pmol/L) compared to non-elevated (≥200 – ≤600 
pmol/L) levels was associated with increase in risk of ASD in offspring in both unadjusted and 
adjusted models (Table 4-3) (23). Deficient B12 (<200 pmol/L) compared to normal levels was 
not associated with ASD risk  (Table 4-3).  
 The risk of ASD in children along the continuum of plasma folate and B12 is presented in 
Figure 4-2 and supplemental tables 4-4 and 4-5.  Using the WHO suggested threshold, the risk 
of ASD was not significantly different between children when their mothers had possibly 
deficient (<13.5 nmol/L) or excess (>45.3 nmol/L) plasma folate levels after birth, compared to 
mothers who had normal levels (≥13.5 to ≤45.3) (Table 4-3).  However, the risk of ASD among 
mother-child pairs with higher levels of plasma folate suggests association at increasing folate 
levels.  
We categorized and compared the lowest and highest deciles with the middle 80th 
percentiles for maternal folate (<14.7 and ≥60.3 nmol/L) and B12 levels (<247.0 and ≥536.8 
pmol/L). Mothers with plasma folate levels in the highest 10th percentile, when compared with 
the middle 80th percentile, had a significant increase in the risk of children’s ASD in both 
unadjusted and adjusted models (Table 4-3). Mothers who had plasma folate levels in the 
lowest decile did not have increased ASD risk in children in the adjusted model (Table 4-3). 
Plasma B12 levels in the top decile, when compared to the middle 80%, was associated with 
about two and half times increased risk (Table 4-3). However, the risk of ASD in children whose 
mothers had lowest levels of plasma B12 was not significantly different than the referent group 
in both models. Similarly, elevated maternal plasma homocysteine when compared to non-
elevated levels did not alter ASD risk even after accounting for confounders (Table 4-3).  
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We compared self-reported maternal multivitamin supplement intake to measured 
biomarker levels after birth.  Nearly all mothers took supplements during pregnancy; the 
frequencies of use for 1st, 2nd and 3rd trimesters were 86.2%, 90.2% and 89.1% respectively. 
Within each supplement intake category, there was a range in maternal plasma folate and B12 
levels (supplemental table 4-6, supplemental figures 4-3 and 4-4). There were no differences in 
the mean plasma folate levels between non-supplement users and different levels of 
supplement users, except those who had supplements 3-5 times/week. The percentage of 
mothers with elevated plasma folate and B12 did not vary between different levels of 
supplement intake. When supplement intake was stratified by parity, a greater percentage of 
nulliparous women were likely to consume supplements >5 times/week in the 1st and 3rd 
trimesters (supplemental table 4-7). 
We assessed the joint effects of maternal plasma folate and B12 levels on the risk of 
ASD in children by considering mothers who had both biomarkers in the middle 80th percentile 
at delivery as the referent category (Table 4-3). The risk of ASD in children was not different 
between mothers with only one or the other biomarker in an extreme decile compared to 
mothers who had both biomarkers in the middle 80th percentile, after adjusting for 
confounders. For mothers who had at least one biomarker level (plasma folate and/or B12) in 
the lowest decile, the risk of ASD in children was not different, nor was it for both in the lowest 
decile (Table 4-3). Mothers who had at least one or both biomarkers in the top decile did have 
an increased risk for ASD in their offspring in adjusted models (Table 4-3). There was an 
interaction between maternal folate and B12 (P <0.01). 
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MTHFR genotype was available for 96.5% of the mothers (n=1213) of which 794 (65.9%), 
347 (28.6%) and 72 (5.9%) had CC, CT and TT genotype respectively. In this sample, maternal 
MTHFR genotype did not differ between children with neurotypical development and those 
with ASD (Supplemental Table 4-8).  No differences in genotype were observed by maternal 
folate and B12 levels (Supplemental Table 4-9). The geometric means of plasma folate were 
also not significantly different across different genotypes (Supplemental Table 4-10) and there 
was no interaction between maternal folate and MTHFR genotype status on ASD risk.  
To assess the influence of EMR misclassification of ASD or neurotypical development on 
these findings, a sensitivity analysis (Supplemental Table 4-11) was conducted applying 
stringent criteria for case diagnosis (ASD code for at least 2 visits, including a specialist) and for 
children with neurotypical development (excluding potential developmental disability 
indications) (Supplemental Table 4-1). The results demonstrate slightly stronger associations in 
this smaller sample; mothers who had plasma folate in the top decile had more than two-fold 
greater ASD risk (HR 2.4, 95% CI 1.1, 5.0) and with plasma B12 in the top decile had almost four 
times increased risk (HR 3.9, 95% CI 2.0, 7.7), after adjusting for confounders. Consistent with 
results in the full sample, the risk of ASD was highest when mothers had elevated levels of both 
plasma folate and B12 (HR 16.4, 95% CI 6.5, 41.7). Results from alternative analyses using 
propensity score matching (Supplemental Table 4-13) and logistic regression (Supplemental 





4.5.1 Main findings 
The results show that moderate intake (3-5 times/week) of multivitamin supplements 
during pregnancy is associated with decreased risk of ASD in offspring, consistent with the 
previous literature (2, 13). Upon further examination of the risk at the low and high ends of 
intake, the study results further suggest that while infrequent intake (≤2 times/week) of 
multivitamin supplements is associated with increased risk of ASD, as has been reported 
previously, high frequency of multivitamin supplement intake (>5 times/week) is also 
associated with increased risk of ASD in children in this cohort, compared to moderate intake. 
This is the first study to report on the prospective association between measured maternal 
plasma folate and B12 biomarkers at birth and risk of ASD in offspring in a large, prospective US 
birth cohort. Consistent with the “U-shaped” finding for supplement intake, the biomarker 
analyses showed that very high levels of maternal plasma folate and B12 (≥90th percentile) at 
birth were also associated with increased risk of ASD in offspring.  
With regard to post-delivery biomarkers, which are reasonably consistent with third 
trimester pregnancy levels, (24, 25) maternal plasma folate and B12 in the highest decile (≥90
th 
percentile) were each associated with increased risk of ASD in children. A moderate level of 
self-reported supplement intake (3-5 times/week) is protective against ASD, but that an 
increased risk is observed with higher and lower intake of multivitamin supplements, and with 
very high concentrations of plasma folate (≥90th percentile) and B12 (≥90th percentile) 
biomarkers at birth. This observation suggests that while deficiency is detrimental, excess 




For over a century, it has been known that the dose-response relationship for many 
micronutrients is non-monotonic: at low levels benefits increase with intake until plateauing at 
optimal concentrations, with toxicity at higher levels, as regulatory mechanisms become 
overwhelmed (26, 27). In a landmark paper, Daly et al. showed that maximum NTD risk was 
observed in mothers who had folate deficiency (0-4.4 nmol/L). There was a dose response 
relationship with risk plateauing beyond maternal folate levels of 11.3 nmol/L and no apparent 
additional benefits beyond levels of 15.9 nmol/L (28). At the other end of the spectrum, this 
study observed an increased ASD risk when mothers had plasma folate levels in the top decile 
during the third trimester (corresponding to 60.3 nmol/L), which is well beyond the highest 
level recommended by WHO (45.3 nmol/L). 
This study is not able to directly attribute the source of these high levels for the top 
decile. It is possible that adverse birth outcomes such as NTD, spontaneous abortions, stillbirths 
and developmental disabilities, (29-31) in a previous delivery might have prompted some 
pregnant women to consume higher dosages of prenatal vitamins, which could explain elevated 
biomarker levels. However, there were no significant difference in previous adverse pregnancy 
outcomes between mothers with ASD and children with neurotypical development in this 
sample. Upon further examination of EMR-based medication history for mothers of children 
with ASD, none of them were prescribed megadoses of prenatal vitamins.  
Mandatory folic acid fortification was instituted in the U.S. in January 1998 and the BBC 
began enrolling mothers in October 1998. Considering that BBC is a post-fortification study, it is 
possible that women with high folic acid intake also consumed folic acid from multiple sources 
including fortified foods, possibly creating an accumulation of folic acid, as observed in a recent 
	
	 110	
NHANES study (32). In this sample, mothers who consumed more supplements were also more 
likely to have consumed fortified foods (e.g. pasta, bread, cereal), suggesting that the 
combination of dietary folic acid along with supplement intake might have potentially resulted 
in elevated levels, although correlations between supplement intake and biomarker levels were 
not extremely high.  
This study notes that the highest ASD risk (HR 13.7, 95% CI 6.5, 28.9) was observed in 
children of mothers with both plasma folate and B12 elevated (≥90th percentile). In addition, a 
significant interaction was observed between plasma folate and B12 (p<0.001) suggesting 
possible perturbation in one-carbon metabolism, which intimately involves both 
micronutrients. 
One possible theory suggests that elevated maternal folate levels in the past few 
decades have altered natural selection, increasing the survival rates of those with the MTHFR 
C677T polymorphism by reducing miscarriage rates (15). It is also possible that genetic variation 
may interfere with folic acid absorption or metabolism to folate precluding the benefits of folic 
acid and promoting accumulation in maternal blood. In this study, there was no relationship 
between the MTHFR C677T variant, plasma folate and ASD risk. However, the study did not 
exhaustively examine variation in this gene, or other genes in the one-carbon cycle.   Also, due 
to the small number of mothers with TT genotype in this sample, the study might be 
underpowered to address this question.  
It is not surprising that some nutrients are tightly regulated within a narrow range, given 
that both deficiency and excess can induce abnormal brain development (33). The 
concentration of nutrients can have an impact on the brain development with a nutrient that 
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promotes normal development in one concentration may be toxic at another (33). Similarly, the 
timing of supplementation or deficiency can also have a role to play in brain function (33, 34). 
Pregnant women have superior absorption of folic acid and B12 compared to non-pregnant 
counterparts (35) and excrete minimal folate in urine during the third trimester (36) – all of 
which could have lead to increased plasma levels. Considering the elevated maternal levels in 
addition to fetus’s ability to actively absorb micronutrients, it is likely that some offspring may 
have accumulated high levels of these micronutrients. The fetal brain is vulnerable to 
nutritional insults especially during the third trimester, when several neurological processes 
including synaptogenesis increase in cortical volume and cortical connectivity between different 
regions, myelination and pruning are occurring at a rapid rate (33, 37-40). 
Human and animal studies have shown that sub-optimal intake of folic acid during 
pregnancy can induce persistent changes in the offspring’s genome, thereby influencing 
physiological outcomes (41-45). With regards to neurocognitive development, increase in 
maternal folate during gestation in animal models alters gene expression in cerebral and 
cerebellar hemispheres (41, 42). Specifically, key developmental genes involved in neural 
pathways, gamma-Aminobutyic acid (GABA), dopamine-serotonin and synaptic plasticity 
demonstrated altered expression and impairment in many of the pathways are linked to ASD 
(42, 46, 47). Prolonged exposure to high folic acid has been shown to alter offspring’s behavior, 
including greater anxiety-like behavior, ultrasonic vocalizations in pups (linked to autism in 
mouse models) and hyperactivity (42). B12 plays an important role in DNA methylation, in 
addition to being integrally involved in myelination, (48) cellular growth and differentiation 
(49). Yet, there is a dearth of research on the role of B12 status on developing brains (19). A 
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cross-sectional study showed that maternal B12 measured at parturition was inversely 
associated with DNA methylation of insulin-like growth factor (IGF-2) in cord blood (50).  
4.5.3 Limitations and Strengths of the study 
Case and neurotypical development classification was based on EMR, rather than using 
adjudication based on research-reliable gold standard diagnostic assessments such as the 
Autism Diagnostic Interview-Revised (ADI-R) or the Autism Diagnostic Observation Schedule 
(ADOS) (51). This approach enables consideration of all children with available administrative 
data, but may misclassify some children as ASD who have other developmental or behavioral 
problems.  The study findings were consistent even when restricting cases to those with 
multiple visits indicating an ASD diagnostic code, including by a specialist. Further, if such 
misclassification of atypical, but non-ASD children exists in the sample, the results would imply 
that elevated maternal plasma folate and B12 levels could have implications in other 
developmental disabilities beyond ASD.   
Maternal dietary intake data during preconception and pregnancy might have provided 
additional perspectives on the study results and lack of this information is a limitation. 
Maternal plasma folate and B12 were measured 24-72 hours after delivery; this may reflect 
maternal folate and B12 levels only during the third trimester and may not reflect early 
pregnancy status. Despite plasma folate being a marker of recent intake and more susceptible 
to variations in diet, it is well correlated with red blood cell folate and thus is a reliable marker 
(52). Although we had information on the frequency of maternal multivitamin supplement 
intake, lack of information on specific dosage is a limitation. A study based on NHANES data 
suggests that a majority of pregnant women consume ≥800 μg of folic acid when using 
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supplements and we assume this to be true of women in this cohort as well (53). We adjusted 
for well-recognized ASD risk factors, but there is a possibility of residual confounding.  Finally, 
the study population consists mainly of urban low-income minority women and extrapolation 
of study findings to other populations should be made with caution. 
While the study suggests that very low or very high maternal folate and B12 measured 
at delivery may be associated with ASD in offspring, further research in the following areas will 
be beneficial, beginning with replication of these findings in independent cohorts with more 
vigorous ASD phenotyping, understanding the mechanism connecting elevated folate, B12 to 
neurocognitive development and examining the source of elevated biomarkers. Further, more 
research is needed to understand if the window of exposure affects the impact of folic acid 
supplementation. 
4.6 Conclusion 
The etiology of ASD is complex and this study provides a new perspective but not a 
definitive explanation. This hypothesis-generating study does not question the importance of 
consuming adequate amounts of folic acid and B12 during pregnancy; the results confirm the 
protective effects of adequate vitamin supplementation for ASD risk, as observed in previous 
studies. Rather, it raises questions about whether excessive amounts of maternal folate and 
B12 may be harmful if a “U-shaped” risk curve is confirmed, as has been observed for other 
health-related risk (54). This result suggests further investigation of this potentially U-shaped 
risk in other cohorts and underscores the critical importance of identifying optimum maternal 
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Mothers   
Age at birth (years), mean (SD) 28.3 (6.6) 30.9 (6.5) 
Parity (%)   
   0 501 (42.8) 31 (36.1) 
   1 337 (28.8) 37 (43.0) 
   2 or more 326 (27.8) 18 (20.9) 
   Missing 7 (0.6) 0 (0.0) 
Mother's education (%)   
   High School or less 754 (64.4) 48 (55.8) 
   Some college or more 415 (35.3) 37 (43.0) 
   Missing 4 (0.3) 1 (1.2) 
Maternal BMI (SD) 26.3 (6.2) 28.1 (7.6) 
Diabetes (%)   
   No 1056 (90.2) 70 (81.4) 
   Gestational diabetes mellitus 67 (5.7) 8 (9.3) 
   Diabetes mellitus 48 (4.1) 7 (8.1) 
   Missing 0 (0.0) 1 (1.2) 
Smoking during & 3 months prior to pregnancy (%) 
   No 1000 (85.4) 69 (80.2) 
   Yes 164 (14.0) 15 (17.4) 
   Missing 7 (0.6) 2 (2.3) 
Maternal plasma folate (%)   
   <14.7 nmol/L (<10th percentile) 118 (10.1) 7 (8.1) 
   ≥14.7 to <60.3 nmol/L (10-90 percentile) 942 (80.4) 65 (75.6) 
   ≥60.3 nmol/L (≥90th percentile) 111 (9.5) 14 (16.3) 
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Maternal plasma vitamin B12 (%)   
   <247.0 pmol/L (<10th percentile) 119 (10.2) 6 (7.0) 
   ≥247.0 to <536.8 pmol/L 10-90 percentile) 945 (80.7) 62 (72.1) 
   ≥536.8 pmol/L (≥90th percentile) 107 (9.1) 18 (20.9) 
Maternal plasma homocysteine (%)   
   <11.7 μmol/L (<90th percentile) 1050 (89.7) 80 (93.0) 
   ≥11.7 μmol/L (≥90th percentile) 121 (10.3) 6 (7.0) 
Maternal supplement intake (3rd trimester) (%)  
   <2 times/week 116 (9.9) 15 (17.4) 
   3 – 5 times/week 447 (38.2) 19 (22.1) 
   >5 times/week 608 (51.9) 50 (60.5) 
Maternal MTHFR genotype   
   CC 742 (63.4) 52 (60.5) 
   CT 323 (27.6) 24 (27.9) 
   TT 65 (5.6) 7 (8.1) 
   Missing 41 (3.5) 3 (3.5) 
Offspring   
Gender (%)   
   Male 525 (44.8) 63 (73.3) 
   Female 646 (55.2) 23 (26.7) 
Gestational age (%)   
   Term 911 (77.8) 57 (66.3) 
   Late preterm (34-36 weeks) 161 (13.8) 13 (15.1) 
   Early preterm (<34 weeks) 99 (8.5) 16 (18.6) 
Year of birth (%)   
   1998-2006 526 (44.9) 38 (44.2) 
   2007-2013 645 (55.1) 48 (55.8) 
aThe Boston Birth Cohort uses a rolling enrolment and the study sample were enrolled between 
1998 and 2013, and have been followed up from birth up to the last visit recorded in the EMR 
	
	 120	
BMI, body mass index; MTHFR, methylene tetrahydrofolate reductase  
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Table 4-2 Maternal self-reported multivitamin intake during preconception and 1st, 2nd and 
3rd trimesters and ASD risk in offspring  
 
  Unadjusted Adjusteda 
Maternal Supplement intake Nb HR (95% CI) HR (95% CI) 
Preconception    
    Yes 54 0.4 (0.1, 1.8) 0.5 (0.1, 2.1) 
    No 1087 1.0 (Reference) 1.0 (Reference) 
First Trimester       
≤2 times/week 164 2.1 (1.1, 4.0) 3.4 (1.6, 7.2) 
3-5 times/week 457 1.0 (Reference) 1.0 (Reference) 
>5 times/week 628 1.9 (1.1, 3.1) 2.3 (1.2, 3.9) 
Second Trimester       
≤2 times/week 115 2.6 (1.3, 5.3) 3.8 (1.8, 8.0) 
3-5 times/week 466 1.0 (Reference) 1.0 (Reference)  
>5 times/week 674 1.8 (1.1, 3.0) 2.1 (1.2, 3.6) 
Third Trimester       
≤2 times/week 131 2.7 (1.4, 5.3) 3.5 (1.7, 7.4) 
3-5 times/week 466 1.0 (Reference) 1.0 (Reference)  
>5 times/week 660 1.8 (1.1, 3.1) 2.1 (1.2, 3.6) 
aAdjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes 
status, race and MTHFR genotype; offspring characteristics: gestational age, sex and year of 
birth  
b N may be different for preconception and each trimester periods due to missing data 




Table 4-3 Maternal plasma folate, vitamin B12 concentrations in samples obtained 24-72 hours after delivery and risk of ASD in 
offspring  
 
  Unadjusted Adjusteda 
Maternal folate - WHO cutpoints n HR (95% CI) HR (95% CI) 
<13.5 nmol/L 103 0.7 (0.3, 1.6) 1.1 (0.5, 2.8) 
≥13.5 nmol/L to ≤45.3 nmol/L 852 1.0 (Reference) 1.0 (Reference) 
>45.3 nmol/L (corresponds to 76th percentile) 302 1.2 (0.8, 2.0) 1.5 (0.9, 2.5) 
Maternal vitamin B12    
<200 pmol/L 35 1.7 (0.6, 4.8) 1.9 (0.7, 5.3) 
≥200 pmol/L to ≤600 pmol/L 1136  1.0 (Reference) 1.0 (Reference) 
>600 pmol/L (corresponds to 93.1th percentile) 86 2.7 (1.4, 4.9) 3.0 (1.6, 5.7) 
Maternal Folate – Extreme Deciles       
<14.7 nmol/L (<10th percentile) 125 0.7 (0.3, 1.5) 1.2 (0.5, 2.8) 
>14.7 to <60.3 (≥10th to <90th, middle 80th percentile) 1007 1.0 (Reference) 1.0 (Reference)  
≥60.3 nmol/L (≥90th percentile) 125 1.8 (1.0, 3.2) 2.5 (1.3, 4.6) 
Vitamin B12 – Extreme Deciles       
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<247.0pmol/L (<10th percentile) 125 0.7 (0.3, 1.6) 0.7 (0.3, 1.7) 
≥247.0 to <536.8 (≥10th to <90th, middle 80th percentile) 1007 1.0 (Reference)   1.0 (Reference) 
≥536.8pmol/L (≥90th percentile) 125 2.6 (1.6, 4.5) 2.5 (1.4, 4.5) 
Joint effects of folate & vitamin B12 Percentilesb       
Folate & vitamin B12 (10-90 percentile) 815 1.0 (Reference) 1.0 (Reference) 
Folate (<10th percentile) & vitamin B12 (10-90 percentile) 104 0.6 (0.2, 1.5) 0.8 (0.3, 2.2) 
Folate (≥90th percentile) & vitamin B12 (10-90 percentile) 88 0.6 (0.2, 1.8) 0.8 (0.2, 2.6) 
Vitamin B12 (<10th percentile) & Folate (10-90 percentile) 94 0.6 (0.2, 1.6) 0.5 (0.2, 1.6) 
Vitamin B12 (≥90th percentile) & Folate (10-90 percentile) 98 1.2 (0.6, 2.7) 1.1 (0.5, 2.4) 
Either Folate & vitamin B12 (<10 percentile)c 229 0.6 (0.3, 1.1) 0.8 (0.4, 1.5) 
Both Folate & vitamin B12 (<10 percentile) 21 1.1 (0.3, 4.5) 2.4 (0.5, 10.4) 
Either Folate or vitamin B12 (≥90 percentile)d 223 1.6 (0.9, 2.5) 1.8 (1.1, 3.1) 
Both Folate & vitamin B12 (≥90 percentile) 27 6.3 (3.3, 12.1) 13.7 (6.5, 28.9) 
Maternal Homocysteine    




a Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes status, race and MTHFR genotype; 
offspring characteristics: gestational age, sex and year of birth 
b There was interaction between maternal plasma folate and vitamin B12 (P<0.01) 
c Either folate or vitamin B12 <10th percentile compares the risk of having a ASD child in mothers who had at least one of the 
biomarkers <10th percentile versus those who had both of these biomarkers in the middle 80th percentile 
d Either folate or vitamin B12 ≥90th percentile compares the risk of having a ASD child in mothers who had at least one of the 
biomarkers ≥90th percentile versus those who had both of these biomarkers in the middle 80th percentile
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Figure 4-1 Maternal self-reported multivitamin supplement intake and ASD risk in offspring  
 
 
Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes 




























Figure 4-2 Association between maternal folate and vitamin B12 concentrations and risk of 

















Unadjusted association between maternal plasma folate (panel A) and plasma vitamin B12 
(panel B) levels at different cut-off points and risk of ASD in offspring. The unadjusted HR for 
plasma folate (panel A) was truncated at 65 nmol/L due to the small sample size beyond the 
specified cutoff point (unadjusted HR for mothers whose plasma folate ≥65 nmol/L was 1.9, 
95% CI 1.0, 3.4; n=113). The unadjusted HR for plasma vitamin B12 (panel B) was truncated at 
700 pmol/L due to declining sample sizes beyond the specified cutoff point (unadjusted HR for 
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Supplemental table 4-1: ICD-9-CM code based definitions for ASD and neurotypical 
development in the Boston Birth Cohort, 2003 - 2013 
 ICD-9-CM codes N 
ASD case definition 61 
Inclusion criteria (any one of these 
codes): 
299.0, 299.01, 299.8, 299.81, 299.9, 
299.91 
 
Definition for children with neurotypical development  601 
Exclusion criteria (any one of these codes):  
   ADHD 314.0 - 314.9  
   Conduct Disorder 312.0 - 312.9  
Emotional disturbances of 
childhood or   adolescence 
including Oppositional Defiant 
Disorder 
313.0 - 313.9  
   Developmental Delay 315.0 - 315.9  
   Intellectual Disability 317 – 319  







Supplemental table 4-2: Comparison between the Boston Birth Cohort study samplea and 
NHANES sample (2009-2010) for women of reproductive age with regard to plasma/serum 
folate levels 
 
 BBC NHANES 
Sample size N=1,257 N=1,971 
Study population Women that just delivered 
babies 
95% of the participants are women 
of reproductive age but not 
pregnant 
Age group 14 – 47 years 15 – 50 years 
Race/ethnicity Blacks – 59.4% 
White – 4.8% 
Hispanics – 25.6% 
Others – 10.3% 
Blacks – 18.3% 
White – 42.4% 
Hispanics & Mex. Am – 32.2% 
Others – 7.2% 




Mean 36.1 nmol/L 37.7 nmol/L 
Median 31.3 nmol/L 34 nmol/L 
25th percentile 21.9 nmol/L 23.8 nmol/L 
75th percentile 44.7 nmol/L 47.9 nmol.L 
Range 4.5 -135.9 nmol/L 9.3 – 175 nmol/L 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled 









Supplemental table 4-3: Comparison between the Boston Birth Cohorta study sample and 
NHANES sample (2011-2012) data for women of reproductive age with regard to 
plasma/serum vitamin B12 levels 
 
 BBC NHANES 
Sample size N=1,257 N=1,879 
Study population Women that just delivered 
babies 
95% of the participants are women 
of reproductive age but not 
pregnant 
Age group 14 – 47 years 15 – 50 years 
Race/ethnicity Blacks – 59.4% 
White – 4.8% 
Hispanics – 25.6% 
Others – 10.3% 
Blacks – 26.2% 
White – 31.6% 
Hispanics & Mex. Am – 22.6% 
Others – 19.6% 
Biomarker measured Plasma vitamin B12 Serum vitamin B12 
Assay ACCESS Immunoassay Electrochemiluminescence 
immunoassay 
Mean 380.0 pmol/L 433.9 pmol/L 
Median 359.3 pmol/L 380.8 pmol/L 
25th percentile 295.4 pmol/L 281.9 pmol/L 
75th percentile 439.5 pmol/L 519.6 pmol/L 
Range 59.8 – 750.0 pmol/L 79.7 – 4140.2 pmol/L 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled 
between 1998 and 2013, and have been followed up from birth up to the last visit recorded in 
the EMR  
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Supplemental table 4-4: Hazard ratios for unadjusted and adjusted plasma folate 
concentrations at different cutpoints in the Boston Birth Cohorta (N=1,257)  
 




n  HR 95% CI p value HR 95% CI P value 
<10 35 Ref     Ref     
≥10 1222 1.7 0.4 - 7.1 0.44 0.8 0.2 - 3.2 0.76 
<15  138 Ref     Ref     
≥15  1119 1.8 0.8 - 3.8 0.16 1.1 0.5 - 2.5 0.80 
<20 263 Ref     Ref     
≥20  994 1.5 0.9 - 2.6 0.15 1.2 0.6 - 2.1 0.60 
<25 409 Ref     Ref     
≥25  848 1.6 1.0 - 2.6 0.06 1.3 0.8 - 2.1 0.38 
<30 587 Ref     Ref     
≥30  670 1.4 0.9 - 2.1 0.14 1.1 0.7 - 1.8 0.60 
<35 732 Ref     Ref     
 ≥35  525 1.3 0.8 - 2.0 0.25 1.2 0.8 - 1.9 0.41 
<40 857 Ref     Ref     
 ≥40  400 1.3 0.9 - 2.1 0.20 1.3 0.8 - 2.2  0.25 
<45 948 Ref     Ref     
 ≥45  309 1.2 0.8 - 2.0 0.38 1.3 0.8 - 2.1 0.34 
<50 1029 Ref     Ref     
 ≥50  228 1.2 0.7 - 2.0 0.58 1.3 0.8 - 2.3 0.32 
<55 1089 Ref     Ref     
 ≥55  168 1.6 1.0 - 2.8 0.07 1.8 1.0 - 3.2 0.04 
<60 1131 Ref     Ref     
 ≥60  126 1.9 1.0 - 3.3 0.04 2.4 1.3 - 4.4 0.007 
<65 1144 Ref     Ref     
 ≥65  113 1.9 1.0 - 3.4 0.04 2.4 1.3 - 4.6 0.007 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled 
between 1998 and 2013, and have been followed up from birth up to the last visit recorded in 
the EMR 
 
b Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes 






Supplemental table 4-5: Hazard ratios for unadjusted and adjusted plasma vitamin B12 
concentrations at different cutpoints in the Boston Birth Cohorta (N=1,257) 
 




n  HR 95% CI p 
value 
HR 95% CI p 
value 
<200 35 Ref     Ref     
≥200 1222 0.6 0.2 - 1.7 0.37 0.6 0.2 - 1.7 0.37 
<250 133 Ref     Ref     
 ≥250 1124 1.8 0.8 - 4.2 0.16 1.8 0.7 - 4.4 0.23 
<300 343 Ref     Ref     
 ≥300 914 1.7 1.0 – 2.9 0.06 1.7 0.9 - 3.1 0.09 
<350 581 Ref     Ref     
 ≥350 676 1.3 0.8 - 2.0 0.22 1.1 0.7 - 1.8 0.66 
<400 794 Ref     Ref     
 ≥400 463 1.4 0.9 - 2.2 0.12 1.2 0.7 - 1.9 0.56 
<450 974 Ref     Ref     
 ≥450 283 1.7 1.1 - 2.7 0.02 1.6 1.0 - 2.7 0.07 
<500 1084 Ref     Ref     
 ≥500 173 2.2 1.3 - 3.6 0.003 1.9 1.1 - 3.3 0.02 
<550 1143 Ref     Ref     
 ≥550 114 2.8 1.6 - 4.8 <0.001 3.0 1.7 - 5.3 <0.001 
<600 1171 Ref     Ref     
 ≥600  86 2.6` 1.4 - 4.7 0.002 2.6 1.4 - 5.0 0.004 
<650 1199 Ref     Ref     
 ≥650  58 2.5 1.2 - 5.2 0.01 2.8 1.3 - 6.0 0.009 
<700 1212 Ref     Ref     
≥700  45 2.8 1.3 - 6.0 0.009 3.5 1.5 - 7.8 0.003 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled 
between 1998 and 2013, and have been followed up from birth up to the last visit recorded in 
the EMR 
 
b Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes 







Supplemental table 4-6: Maternal self-reported multivitamin supplement intake during 1st, 
2nd and 3rd trimesters and corresponding median maternal plasma folate and B12 levels 
measured 24-72 hours after delivery in the Boston Birth Cohort a (N=1,257) 
 
    Plasma Folate 
(nmol/L) 









First Trimester       
  <2 times/wk 164 29.2 19.3 – 44.1 364.6 298.5 – 438.4 
   3-5 times/wk 457 31.2 22.3 – 44.6 357.4 288.6 – 440.5 
   >5 times/wk 628 32.4 22.4 – 44.9 359.1 296.6 – 439.1 
   Missing 8 28.2 18.6 – 56.8 321.3 277.6 – 426.6 
Second Trimester      
   <2 times/wk 115 25.3 16.7 – 44.1 345.1 275.4 – 437.8 
   3-5 times/wk 466 31.6 22.4 – 45.0 358.7 291.1 – 441.1 
   >5 times/wk 674 32.2 22.5 – 44.4 360.9 297.8 – 439.6 
   Missing 2 31.5 15.6 – 47.4 419.3 341.8 – 496.7 
Third Trimester      
   <2 times/wk 131 24.5 16.4 – 38.3 351.1 289.1 – 437.4 
   3-5 times/wk 466 32.0 22.5 – 45.1 358.7 291.6 – 443.9 
   >5 times/wk 660 32.3 22.5 – 44.7 360.3 297.1 – 439.1 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled 
between 1998 and 2013, and have been followed up from birth up to the last visit recorded in 
the EMR 









Supplemental table 4-7: Maternal self-reported supplement intake for 1st, 2nd, and 3rd trimesters stratified by maternal parity 
 
Parity n Frequency of supplement intake, n (%) P value 
  ≤ 2x/wk 3-5x/wk ≥5x/wk  
First trimester     0.025 
Nulliparous 531 57 (10.7) 187 (35.2) 287 (54.1)  
Multiparous 716 107 (14.9) 270 (37.7) 339 (47.4)  
Second trimester     0.08 
Nulliparous 534 39 (7.3) 194 (36.3) 301 (56.4)  
Multiparous 719 76 (10.6) 272 (37.8) 371 (51.6)  
Third trimester     0.015 
Nulliparous 534 43 (8.1) 190 (35.6) 301 (56.4)  



















Supplemental table 4-8: Maternal MTHFR genotype stratified by offspring status (ASD vs. Neurotypical) in the Boston Birth Cohort 
a (N=1,257) 
 Offspring status  
Maternal MTHFR 
genotype 
ASD, n (%) Neurotypical, n 
(%) 
p value 
   CC 742 (63.4) 52 (60.5) 0.79 
   CT 323 (27.6) 24 (27.9) 
   TT 65 (5.6) 7 (8.1) 
   Missing 41 (3.5) 3 (3.5) 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 






Supplemental table 4-9: Maternal MTHFR genotype stratified by maternal folate, vitamin B12 levels (both middle 80% vs. both 




Folate + B12 
(middle, ≥10 to 
<90 percentile) 





elevated, ≥ 90 
percentile) 
p value 
   CC 508 (62.3) 21 (77.8) 60 (61.2) 0.51 
   CT 230 (28.2) 5 (18.5) 27 (27.6) 
   TT 49 (6.0) 1 (3.7) 9 (9.2) 
   Missing 28 (3.4) 0 (0.0) 2 (2.0) 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 









Supplemental table 4-10: Mean maternal folate (nmol/L) by maternal MTHFR genotype in the Boston Birth Cohort a (N=1,257) 
 
 Maternal folate (nmol/L) 
Maternal MTHFR 
genotype 
n Geometric Mean  (SD) 
   CC 794 30.8 (29.6 - 32.1) 
   CT  347 30.1 (28.4 - 32.0) 
   TT 72 34.2 (30.3 - 38.6) 
   Missing 44 30.3 (25.5 - 35.9) 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 























Supplemental table 4-11: Sensitivity Analyses by restricting cases (n=61) and controls (n=601) to highest confidence in the Boston 
Birth Cohort a (N=662) 
 
    Unadjusted Adjusted b 
Maternal plasma folate – WHO cutpoints n  HR 95% CI p value HR 95% CI p value 
   <13.5 nmol/L  52 0.4 0.09 - 1.5 0.15 0.8 0.2 - 3.5 0.78 
   ≥13.5 to ≤45.3 nmol/L  428 Ref   Ref    
   >45.3 nmol/L  (corresponds to 76th percentile) 182 1.1 0.7 – 1.9 0.67 1.4 0.8 - 2.6 0.29 
Maternal plasma vitamin B12                
  <200 pmol/L  25 0.9 0.2 - 3.5 0.84 1.2 0.3 – 5.0 0.85 
  ≥200 & ≤600 pmol/L  594 Ref     Ref     
  >600 pmol/L (corresponds to 93.1th percentile) 43 3.2 1.6 - 6.2 0.001 4.7 2.1 - 10.3 <0.001 
Maternal Folate – Extreme Deciles               
  <14.7 nmol/L (<10th percentile) 62 0.5 0.1 - 1.5 0.21 1.2 0.4 - 4.2 0.73 
   ≥14.7 to <60.3 (≥10th to <90th, middle 80th 
percentile) 
522 Ref     Ref     
   ≥60.3 nmol/L (≥90th percentile) 78 1.9 1.0 - 3.6 0.05 2.4 1.2 - 5.0 0.02 
Vitamin B12 – Extreme Deciles               
   <247.0 pmol/L (<10th percentile) 68 0.3 0.1 - 1.3 0.11 0.4 0.1 - 1.9 0.27 
   ≥247.0 to <536.8 pmol/L (≥10th to <90th, 
percentile) 
530 Ref     Ref     
   ≥536.8 pmol/L (≥90th percentile) 64 3.5 1.9 - 6.1 <0.001 3.9 2.0 - 7.7 <0.001 
Joint effects of folate & vitamin B12 c               
Folate & vitamin B12 (≥10th to <90th, middle 80th 
percentile) 
428 Ref     Ref     
Folate (<10th) & vitamin B12  (middle 80th 
percentile) 
47 0.6 0.2 - 2.1 0.47 1.3 0.4 - 4.4 0.66 




Vitamin B12 (<10th) & Folate  (middle 80th 
percentile) 
48 0.4 0.1 - 1.8 0.25 0.6 0.1 - 2.6 0.49 
Vitamin B12 (≥90th) & Folate  (middle 80th 
percentile) 
46 1.9 0.9 - 4.4 0.11 2.1 0.8 - 5.4 0.11 
Both Folate & vitamin B12 (<10th percentile) 5 Estimates could not be calculated because of small cell size 
Either Folate & vitamin B12 (<10th percentile) d 115 0.4 0.2 – 1.1 0.08 0.8 0.3 – 2.2 0.68 
Folate & vitamin B12 (≥90th percentile) 18 6.6 3.2 - 13.8 <0.001 17.1 6.7 – 43.9 <0.00
1 
Either folate or vitamin B12 (≥90th percentile) e 124 1.9 1.1 - 3.4 0.02 2.8 1.5 - 5.2 0.002 
 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
followed up from birth up to the last visit recorded in the EMR 
b Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes status, race and MTHFR genotype; 
offspring characteristics: gestational age, sex and year of birth 
c There was significant interaction between maternal plasma folate and vitamin B12 (p value - 0.017) 
d Either folate or vitamin B12 <10th compares the risk of having a ASD child in mothers who had at least one of the biomarkers <10th 
vs. those who had both of these biomarkers in the middle 80th percentile 
e Either folate or vitamin B12 ≥90th compares the risk of having a ASD child in mothers who had at least one of the biomarkers ≥90th 




Supplemental Table 4-13: Maternal plasma folate, vitamin B12 levels in samples obtained 24-72 hours after delivery and risk of 
ASD in offspring in the in the Boston Birth Cohort a (N=1,257)  (using Propensity Score Matching) 
Maternal folate  OR (95% CI) b, c p value 
 <90th percentile Ref  
≥90th percentile (≥60.3 nmol/L)  3.4 (1.4 – 8.3) 0.006 
Maternal vitamin B12   
<90th percentile  Ref  
≥90th percentile (≥536.8 pmol/L) 6.8 (2.7 – 17.9) <0.001 
 
Maternal Vitamin B12 OR (95% CI) b, c p value 
<90th percentile  Ref  
≥90th percentile (≥536.8 pmol/L) 3.2 (1.5 – 7.0) 0.003 
Maternal Folate   
<90th percentile Ref  
≥90th percentile (≥60.3 nmol/L)  3.0 (1.2 – 7.6) 0.02 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
followed up from birth up to the last visit recorded in the EMR 
b Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes status, race and MTHFR genotype; 
offspring characteristics: gestational age, sex and year of birth 








Supplemental table 4-14: Maternal plasma folate, vitamin B12 levels measured 24-72 hours after delivery and risk of ASD in 
offspring in the Boston Birth Cohorta (N=1,257) using Logistic Regression model 
 
    Unadjusted Adjusted b 
Classifying folate and vitamin B12 levels based on deficiency, normal and excess 
Maternal folate -  WHO cutpoints n OR 95% CI p value OR 95% CI p value 
   <13.5 nmol/L 103 0.9 0.4 - 2.1 0.77 1.3 0.5 - 3.2 0.63 
   ≥13.5 nmol/L to ≤45.3 nmol/L 852 Ref   Ref    
   >45.3 nmol/L (corresponds to 76th percentile) 302 1.2 0.7 - 2.0 0.42 1.5 0.8 - 2.6 0.19 
Maternal vitamin B12 
   <200 pmol/L 35 2.0 0.7 - 5.7 0.22 2.0 0.6 - 6.6 0.23 
   ≥200 pmol/L to ≤600 pmol/L 1136 Ref     Ref     
   >600 pmol/L (corresponds to 93.1th percentile) 86 2.5 1.3 - 4.8 0.007 3.1 1.5 - 6.5 0.002 
Maternal Folate – Extreme Deciles               
   <14.7 nmol/L (<10th percentile) 125 0.9 0.4 - 1.9 0.71 1.4 0.6 - 3.4 0.42 
    >14.7 to <60.3 (≥10th to <90th, middle 80th 
percentile) 
1007 Ref   Ref     
    ≥60.3 nmol/L (≥90th percentile) 125 1.8 1.0 - 3.4 0.05 2.3 1.1 - 4.7 0.02 
Vitamin B12 – Extreme Deciles               
   <247.0 pmol/L (<10th percentile) 125 0.8 0.3 - 1.8 0.55 0.7 0.3 - 2.0 0.50 
   ≥247.0 to <536.8 (≥10th to <90th, middle 80th 
percentile) 
1007 Ref     Ref     
   ≥536.8 pmol/L (≥90th percentile) 125 2.6 1.5 - 4.5 0.001 2.7 1.4 - 5.2 0.003 
Joint effects of folate & vitamin B12 Decilesc               
Folate & vitamin B12 (≥10th to <90th, middle 80th 
percentile) 
815 Ref     Ref     
Folate (<10th percentile) & vitamin B12  (middle 80th 
percentile) 
104 0.7 0.3 - 1.8 0.48 1.0 0.4 - 2.7 0.98 
Folate (≥90th percentile) & vitamin B12  (middle 80th 
percentile) 
88 0.5 0.2 - 1.6 0.25 0.7 0.2 - 2.3 0.54 
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Vitamin B12 (<10th percentile) & Folate  (middle 80th 
percentile) 
94 0.6 0.2 - 1.8 0.38 0.5 0.1 - 1.7 0.28 
Vitamin B12 (≥90th percentile) & Folate  (middle 80th 
percentile) 
98 1.1 0.5 - 2.5 0.85 1.0 0.4 - 2.5 0.995 
Either Folate & vitamin B12 (< 10th percentile)d 229 0.7 0.4 – 1.4 0.32 0.8 0.4 – 1.8 0.66 
Both Folate & vitamin B12 (< 10th percentile) 21 1.5 0.3 – 6.5 0.60 2.6 0.5 – 13.0 0.25 
Either Folate or vitamin B12 (≥90th percentile)e 223 1.5 0.9 - 2.5 0.16 1.8 1.0 - 3.2 0.05 
Both Folate & vitamin B12 (≥90th percentile) 27 9.7 4.3 - 21.9 <0.001 18.0 6.9 - 46.9 <0.001 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
followed up from birth up to the last visit recorded in the EMR 
b Adjusted for maternal characteristics: age, education, parity, BMI, smoking status, diabetes status, race and MTHFR genotype; 
offspring characteristics: gestational age, sex and year of birth 
c There was significant interaction between maternal plasma folate and vitamin B12 (p<0.001) 
d Either folate or vitamin B12 <10th percentile compares the risk of having a ASD child in mothers who had at least one of the 
biomarkers <10th percentile vs. those who had both of these biomarkers in the middle 80th percentile 
e Either folate or vitamin B12 ≥90th percentile compares the risk of having a ASD child in mothers who had at least one of the 








Supplemental figure 4-1: Flow chart of initial enrollment and postnatal follow-up of 







Eligible mother-infant pairs were enrolled at 
Boston; Enrollment period: 1998 - 2013 
	 
N= 2,580 
Children with maternal folate and vitamin B12  
N= 2,321 
Children with maternal folate, vitamin B12 and 
self-reported supplement intake data 
N= 1,257 
Children included in the primary analysis 
N=5,359 
Excluded because of lack of maternal folate 
and vitamin B12 measurements  
	 
N=478 
Excluded because of not receiving pediatric 
care at the Boston Medical Center 
 
N=259 
Excluded because of lack of 3rd trimester 
supplement intake data 
N=586 
Children had following diagnosis without 
concurrent ASD: 170 (ADHD); 8 (intellectual 
disabilities); 407 (other developmental 
disabilities); 1 (VSD)  
N= 1,735 
Children with ASD or neurotypical development 
N = 1,171 
Children with Neurotypical 
development	 
N = 86 
Children with ASD 
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Supplemental figure 4-2: Comparing the distributions of Boston Birth Cohort a (N=1,257) mother’s plasma folate and vitamin B12 
levels with NHANES women of reproductive ages (15-50 years) for plasma/serum folate (2009 – 2010) (N=1,971) and 




























a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
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a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
followed up from birth up to the last visit recorded in the EMR  
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a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
followed up from birth up to the last visit recorded in the EMR  
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Supplemental figure 4-5: Maternal plasma folate distribution by maternal MTHFR genotype in the Boston Birth Cohort a (N=1,257) 
 
a The Boston Birth Cohort uses a rolling enrollment and the study sample were enrolled between 1998 and 2013, and have been 
followed up from birth up to the last visit recorded in the EMR 
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Cord and Early Childhood Plasma Leptin, Fetal and Infancy Growth Pattern, and Development of 
Autism Spectrum Disorder in the Boston Birth Cohort 
 
(This paper has received a favorable peer review and is currently under revision for publication in 
Autism Research with contributions from co-authors Barry Zuckerman, Xiumei Hong, Guoying 





Leptin is a pro-inflammatory cytokine that plays an important role in energy homeostasis. 
Emerging evidence suggests that leptin levels are altered in children with autism spectrum 
disorder (ASD); however this has not been studied prospectively. Rapid growth during infancy and 
early childhood has been implicated in ASD, but the evidence is inconsistent. Since leptin is 
involved in growth and is a potential risk factor for ASD, we explored the associations between 1) 
cord, early childhood leptin and ASD; and 2) birth weight for gestational age, early childhood 
weight gain and ASD. We also assessed the mediating role of leptin in the relationship between 
weight gain during infancy and ASD.  This study was conducted in a sample of 822 subjects from 
the Boston Birth Cohort. ASD was defined from diagnostic codes in electronic medical records. 
Extremely rapid weight gain during infancy was associated with a greater ASD risk and this 
persisted after adjusting for potential confounders (aOR: 3.11; 95% CI:  1.37, 7.07). Similarly, 
children that had higher plasma leptin levels, prior to ASD diagnosis, had an increased ASD risk in 
both unadjusted and adjusted models (aOR: 7.87; 95% CI: 2.06, 30.04). Further, early childhood 
leptin indirectly mediated the relationship between rapid weight gain and ASD. No associations 
were found between birth weight for gestational age, cord leptin and risk of ASD. Our findings 
provide a basis to further explore whether the combination of early life growth pattern and a 
biomarker such as leptin can predict ASD earlier.  






Autism Spectrum Disorder (ASD) is a neurodevelopmental conditions characterized by 
impairments in sociability and communication, as well as increased repetitive and/or restrictive 
behaviors and interests (1-5).  ASD prevalence in the U.S. has increased dramatically since 1996 
and now, 1 in 68 children are diagnosed with ASD (6, 7). The precise cause of ASD is largely 
unknown (8). Numerous studies have demonstrated associations with genetic, environmental, 
perinatal and immunological risk factors, leading to a hypothesis that ASD likely has a 
multifactorial pathogenesis or is a common end point of multiple causal pathways (8, 9).  
Among the perinatal risk factors, preterm birth and small for gestational age (SGA) have 
been studied extensively in the context of ASD (8, 10-12). SGA is a proxy for intrauterine growth 
restriction (13) and studies have reported that SGA children are at increased risk of ASD (8, 14, 
15); however, the results are inconsistent (15-17). Many children that are small at birth tend to 
have rapid catch-up growth during early postnatal period (18, 19). Rapid growth during first 
year of life has been shown to be associated with ASD (20-22), although not all studies have 
confirmed these findings (23, 24). While abnormal birth weight percentiles and rapid early 
growth have been identified as independent risk factors of ASD, the combined effect of SGA 
with rapid postnatal weight gain has not been explored. Most studies previously conducted on 
SGA infants have not accounted for the rate of postnatal growth, and vice versa. Further, the 
biological mechanisms behind SGA and rapid weight gain and ASD risk have not been clearly 
elucidated (25, 26).  
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Leptin is a peptide hormone that is predominantly secreted by the white adipose tissue 
and has been studied in the context of fetal growth and early childhood weight gain (27, 28). 
Studies have found that children with SGA have lower leptin levels possibly reflecting a lower 
fat mass as a result of intrauterine restricted fetal weight gain (29-32). Metabolically, lower 
cord blood leptin levels are known to predict rapid weight gain in infancy (33-36). Beyond 
leptin’s role in prenatal and postnatal weight gain, this pleiotropic cytokine has been shown to 
be important in the regulation of the immune system, neurodevelopment including neuron 
excitability, synaptic plasticity, neural differentiation and promoting migration of neuronal 
lineage cells to the cortical plate (28, 37-40). Emerging evidence suggests that children (2-15 
years) with ASD have significantly higher plasma leptin levels than controls (28, 40-43). Among 
a few studies that have researched leptin-ASD association in children, most were done after 
ASD diagnosis (28, 40), thus unable to assess the temporal relationship. To our knowledge, 
none of the studies have assessed cord and early childhood leptin levels independently and 
simultaneously in relation to ASD in a prospective birth cohort. 
Despite studies observing cytokine involvement in ASD (41, 44-46) and the knowledge 
about the role of fetal and infant growth and ASD (20-22), existing studies have not evaluated 
the potential link between growth and leptin levels related to ASD. We set out to understand 
whether elevated leptin levels observed in people with ASD are related to rapid weight gain 
during infancy, and whether leptin has a mechanistic role in explaining the early growth-ASD 
relationship. Specifically, in this report we sought to explore the relationship between – 1) birth 
weight for gestational age, weight gain during first year of life and ASD risk; 2) cord and early 
childhood leptin and ASD risk; and 3) the potential of leptin mediating the relationship between 
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weight gain during first year and ASD risk. We analyzed the longitudinal data from the Boston 
Birth Cohort (BBC), a predominantly urban low-income minority population.  
  
5.3 Methods 
5.3.1 Participation and data collection procedure 
 As illustrated in supplemental figure 5-1, this study included 822 children from the BBC, 
who were recruited at birth (between 1998 and 2009), were followed prospectively until 2015 
and had a median length of follow-up of 7.5 years (interquartile range: 5.2 – 9.8 years). 
Mothers of newborns were invited to participate in the study 24-72 hours after birth. Over 90% 
of those that were approached agreed to participate and were initiated into the study (47, 48). 
For every preterm (defined as <37 weeks of gestation) and/or low birth weight baby (defined as 
<2,500 g), approximately two term and normal birth weight babies (and their mothers) were 
enrolled in the study (48). The exclusion criterion for initial enrolment was multiple-gestation 
pregnancies and newborns with major birth defects. Participants and non-participants did not 
differ on characteristics such as infant birth weight, maternal ethnicity, or other 
sociodemographic characteristics (48). A sub-set of the participants were enrolled in the follow-
up study that began in 2003 and children not planning to receive pediatric care at the Boston 
Medical Center were not included in the postnatal follow-up. There were no major differences 
in baseline demographic characteristics between those with and without postnatal follow-up 
(49).  
Of 2,932 that were eligible for postnatal follow-up, 2,110 were excluded for the 
following reasons: 1,589 did not have at least one of the exposure variables (cord leptin, early 
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childhood leptin) and 521 had other competing diagnosis such as ADHD, intellectual disabilities 
(ID) or other developmental disabilities (DD). Electronic Medical Records (EMR) containing 
clinicians’ primary and secondary diagnoses using ICD-9 codes were obtained for every 
postnatal clinical visit since 2003. The study was approved by the Institutional Review Boards of 
the Johns Hopkins Bloomberg School of Public Health and Boston University Medical Center. 
5.3.2 Identification of children with ASD 
Based on EMR, children that were ever diagnosed with autism (ICD-9 code 299.00), 
Asperger syndrome (299.80) and/or pervasive developmental disorder not otherwise specified 
(299.90) were categorized as having ASD. Neurotypical children were those that were never 
diagnosed with ASD, ADHD, ID and other DD. When children had concurrent diagnosis, such as 
ASD and ADHD or ASD and ID or ASD and other DD, they were classified as having ASD. Two 
separate sensitivity analyses were conducted  - 1) using a stringent criteria, defined as having 
ASD diagnosis on more than two separate occasions in the EMR and one visit to specialists such 
as behavioral pediatrician, pediatric neurologist or child psychologist; and 2) using a stringent 
control that additionally excluded children who did not have other competing diagnoses 
(Conduct disorder (312.0 - 312.9), Emotional disturbances of childhood or adolescence 
including Oppositional Defiant Disorder (313.0 - 313.9), Congenital Anomalies (740 - 759.9)).   
5.3.3 Exposure variables 
Birth weight for gestational age was defined as follows: SGA (<10th percentile), 
appropriate for gestational age (AGA) (≥10th – 90th percentile) and large for gestational age 
(LGA) (>90th percentile) (47). Child’s length (<2 years) and height and weight were measured 
during the well-child visits at the Boston Medical Center. WHO reference values was used to 
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calculate weight-for-age z-scores and was defined as the change in weight-for-age z-scores 
from birth until the target time-point. Weight-for-age z-score was categorized into the 
following groups: slow (weight gain z-score <-0.67), on track (−0.67 to 0.67), rapid (>0.67 to 
1.28), and extremely rapid (>1.28) (50).  
Umbilical cord blood sample was collected at delivery and non-fasting early childhood 
venous blood sample were collected during subsequent follow-up visits. The median age of 
early childhood leptin measurement was 18.4 months (IQR: 10.3-49.2 months). All the blood 
samples were processed immediately after collection and plasma samples were stored in a 
freezer at −80°C.  Only children with blood samples obtained prior to ASD diagnosis were 
included in the early childhood biomarker analysis. As mentioned elsewhere, plasma leptin 
levels were measured in duplicates using a sandwich immunoassay based on flow metric xMAP 
technology on Luminex 200 machines (Luminex Corp., Austin, TX). The interassay coefficient of 
variation was 4.5% (50). Unlikely leptin levels, defined as greater than 3 SD, were observed in 8 
and 7 subjects for cord and early childhood leptin, respectively and were re-assigned a value of 
3SD (51).   
5.3.4 Statistical Analyses 
The outcome variable was ASD and major exposure variables were 1) birth weight for 
gestational age and weight gain during first year of life and 2) cord blood and early childhood 
leptin levels. Correlation between cord and early childhood leptin was minimal (0.02). 
Normality of the data was assessed using Shapiro-Wilk test and both cord and early childhood 
leptin levels were log transformed because of the skewed distribution. Data analyses were 
performed to compare neurotypical children and those with ASD using chi-square tests for 
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categorical variables and ANOVA for continuous variables. Logistic regression models were 
applied to estimate the crude and adjusted associations between weight gain during first year 
of life, log-transformed leptin levels at birth and early childhood (X, independent variables) and 
ASD (Y, dependent variable). All results are presented as odds ratio. Throughout, we used 2-
sided statistical tests with a significance level of 0.05. Data were analyzed using STATA version 
13.0 (StataCorp, College Station, TX).  
Mediation analysis: The role of leptin as a potential mediator of the association 
between weight gain during infancy and ASD risk was examined. KHB command in STATA was 
used to decompose the total effect of weight gain in infancy into natural direct and indirect 
effects, mediated by early childhood leptin levels (52). The total effect (defined as the effect of 
weight gain during infancy on ASD without the mediating variable early childhood leptin) was 
decomposed into direct effect (the effect of weight gain during infancy on ASD when controlling 
for early childhood leptin, the mediator) and indirect effect (the effect of weight gain during 
infancy on ASD through early childhood leptin, the mediator). The proportion of mediating 
effect among the total effect was calculated as indirect effect divided by the total effect. 
5.3.5 Other covariates 
 Covariates were selected a priori based on the existing literature, including our own 
work in the BBC (47, 49, 51, 53). Following covariates were adjusted in the analysis: maternal 
age at delivery, smoking during pregnancy (ever smoked 3 months before pregnancy/during 
pregnancy vs. not smoked before pregnancy/during pregnancy), parity (not including the index 
pregnancy), maternal education (high school or less vs. some college or more), maternal pre-
pregnancy BMI, maternal diabetes status (defined below), maternal age at delivery, 
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race/ethnicity, child’s sex (female vs. male), gestational age at birth (defined below), year of the 
baby’s birth (1998-2006 vs. 2007-2013), mode of feeding (defined below), age at which early 
childhood blood was drawn and follow-up time for each subject.  
Maternal diabetes status was classified into the following: 1) no preexisting diabetes 
mellitus (DM) or gestational diabetes mellitus (GDM), 2) preexisting DM, and 3) GDM.  Subjects 
were categorized as having preexisting DM if any of the following criteria were met before 
pregnancy: (a) diabetes diagnosis by a physician; (b) received a ICD-9 code of “250.x” or 
“648.0x”; (c) fasting plasma glucose level ³126 mg/dl (7.0 mmol/l) or a casual plasma 
glucose³200 mg/dl (11.1 mmol/l); (d) treatment with anti-diabetes medicines (oral medicines 
or insulin). Subjects were categorized as having GDM if there was no evidence of preexisting 
diabetes (as defined above) and met any of the following criteria: (a) physician diagnoses of 
GDM; (b) received a ICD code of “648.8x”; (c) fasting plasma glucose level ³126 mg/dl (7.0 
mmol/l) or casual plasma glucose³200 mg/dl (11.1 mmol/l); (d) two or more of the following 
plasma glucose values in oral glucose tolerance test (OGTT) were met or exceeded: i) Fasting: 
95 mg/dL (5.3 mmol/L); ii) 1 h: 180 mg/dL (10.0 mmol/L); iii) 2 h: 155 mg/dL (8.6 mmol/L); iv) 3-
h 140mg/dL (7.8mmol/L); v) treatment with anti-diabetes medicines (oral medicines or insulin) 
(54-56).  
Neonates who were delivered ≥ 37 completed weeks of gestation were categorized as 
term, while those delivered <34 weeks, and ≥34 but <37 weeks of gestation were considered 
early and late preterm, respectively. Race/ethnicity was categorized into black, white, Hispanic 
and Other. Data on mode of feeding was collected from mothers using a standardized 
questionnaire during a follow-up visit in the first few years of life. Mode of feeding was 
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categorized into the following: 1) formula only, 2) both formula and breastfeeding, and 3) 
breastfeeding only. When mothers had multiple follow-up visits, data collected during the first 
visit was used (57). 
5.4 Results 
Table 5-1 describes the characteristics of mothers and children by child's case status 
(neurotypical vs. ASD). As expected, previously recognized risk factors were more prevalent 
among children with ASD compared to neurotypical children, including male sex, advanced 
maternal age, preterm birth and lower birth weight. Consistent with the literature (58, 59), girls 
had higher cord and early childhood plasma leptin levels than boys (Supplemental table 5-1). 
Children that were SGA had lower cord leptin levels and were more likely to have extremely 
rapid weight gain (Supplemental tables 5-1 and 5-2). Children with most rapid weight gain 
during infancy were also likely to have higher early childhood leptin levels, but the latter did not 
differ by birth weight for gestational age (Supplemental table 5-1).  
5.4.1 Fetal growth pattern and ASD risk 
 A total of 599 children had birth weight for gestational age data, of which 47 were later 
diagnosed with ASD (Supplemental figure 5-1). Five of these 47 ASD subjects had co-occurring 
ID. Compared to children with AGA, neither SGA children nor LGA children were at a greater 
risk of ASD, before or after the adjustment of covariates including maternal age at delivery, 
parity, smoking status, education, race, maternal BMI, maternal diabetes, child's sex, follow-up 
time and gestational age (Table 5-2).   
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5.4.2 Weight gain during infancy and ASD risk 
A total of 573 children had weight gain during infancy data, of which 46 were later 
diagnosed with ASD (Supplemental figure 5-1). Five of these 46 subjects had co-occurring ID. 
Prenatal determinants of weight gain during infancy are presented in Supplemental table 5-2, 
and preterm birth was a major determinant of infant excessive weight gain. When compared to 
children whose growth was on track based on weight gain z-scores, children that had slow 
weight gain or rapid weight gain did not have an increased ASD risk (ORslow: 1.52; 95% CI: 0.49, 
4.71, ORrapid: 1.33; 95% CI: 0.46, 3.86) (Table 5-2).  However, extremely rapid weight gain during 
infancy was associated with an increased risk of ASD (ORextremely rapid: 2.64; 95% CI: 1.20, 5.78). 
This association persisted after adjusting for covariates (child's sex, race, follow-up time and 
breastfeeding status) in model 3 (aORextremely rapid: 3.11; 95% CI:  1.37, 7.07). Next, we 
sequentially added birth weight for gestational age to model 3 covariates and observed a 
consistent association (Table 5-2). However, the significance attenuated after adjusting for 
gestational age in addition to model 3 covariates (aOR: 2.08; 95% CI: 0.84, 5.13). The 
association did not attenuate after adjusting for prenatal determinants such as maternal BMI, 
diabetes status and age at the time of delivery, in addition to covariates specified in model 3 
(Table 5-2). Sensitivity analyses using stringent comparators or cases showed a consistent 
association between birth weight for gestational age, weight gain during infancy and risk of ASD 
(Supplemental tables 5-3 and 5-4). 
5.4.3 Cord leptin and ASD risk 
 A total of 655 children had data on cord leptin levels, of which 39 were later diagnosed 
with ASD (Supplemental Figure 5-1). Two of these 39 ASD subjects had co-occurring ID. Prenatal 
and perinatal determinants of cord leptin are presented in Supplemental Table 5-1. The mean 
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cord leptin levels were 38.23 pg/mL in children with neurotypical development and 27.37 
pg/mL in children with ASD (Table 5-1). As observed in other cohorts (59), higher cord blood 
leptin levels correlated with increase in gestational age. In the unadjusted model, cord leptin 
levels (stratified into quartiles) were not associated with the risk of ASD (Table 5-3). Similarly, 
no associations were observed after adjusting for covariates in models 1 and 2. The relationship 
between cord leptin and ASD was not altered, irrespective of whether cord leptin was assessed 
as a continuous or a categorical variable (Supplement table 5-5).  
5.4.4 Early childhood leptin and ASD 
A total of 652 children were included in the analyses, of which 36 were later diagnosed 
with ASD (Supplemental Figure 5-1). Four of these 36 ASD subjects had co-occurring ID. Figure 
5-1 provides a distribution of early childhood leptin levels among neurotypical children and 
those with ASD, showing a shift in distribution towards right for children with ASD. 
Supplemental figure 5-2 provides a distribution of when early childhood leptin levels were 
measured. When compared to children that had the lowest leptin levels (quartile 1), children 
with highest leptin levels (quartile 4) had an increased ASD risk (OR: 5.41; 95% CI: 1.53, 19.05)  
(Table 5-3).  The association remained significant after adjusting for covariates (model 3) 
including child's sex, race, child’s age when leptin was measured, follow-up time and 
breastfeeding status (aOR: 7.87; 95% CI: 2.06, 30.04). Further adjusting for gestational age 
(model 4), cord leptin levels (model 5) or prenatal determinants such as maternal BMI, diabetes 
status and age at the time of delivery (model 6) did not attenuate the association between 
early childhood leptin and ASD. Analysis using early childhood plasma leptin levels as a 
continuous variable or categorical variable yielded consistent findings (Supplement table 5-5). 
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Sensitivity analyses using stringent controls or cases showed similar trends in association 
between cord, early childhood leptin and ASD risk (Supplemental tables 5-6 and 5-7). Results 
from alternative analyses using Cox proportional hazard regression for birth weight for 
gestational age, weight gain during infancy, cord and early childhood leptin, and ASD risk 
(Supplemental tables 5-8 and 5-9) were consistent in direction and statistical significance.  
5.4.5 Early childhood leptin mediating the relationship between weight gain during infancy 
and ASD risk  
A total 476 children had both weight gain during infancy data and early childhood leptin 
measurements (Table 5-4). In the unadjusted model that assessed the role of early childhood 
leptin as a mediator of the relationship between weight gain during infancy and risk of ASD, the 
total effect of extremely rapid weight gain was statistically significant (OR: 2.80; 95% CI: 1.07, 
7.28). Both direct (OR: 2.22; 95% CI: 0.84, 5.87) and indirect effects (OR: 1.26; 95% CI: 0.95, 
1.67) were non-significant. In the adjusted model, the total effect attenuated (aOR: 1.80; 95% 
CI: 0.55, 5.90). However, the indirect effect became significant (aOR: 1.56; 95% CI: 1.01, 2.42), 
suggesting an indirect-only mediation (60) and that the early childhood leptin potentially 
mediates 76.03% of the total relationship between extreme rapid weight gain and ASD, after 
adjusting for confounders. Other weight gain categories such as slow and rapid weight gain 
were not significantly associated with ASD and adjusting for early childhood leptin levels did not 
alter their association with ASD.  
5.5 Discussion 
In this prospective cohort study, our results showed that extremely rapid weight gain 
during infancy and elevated early childhood leptin levels measured prior to ASD diagnosis were 
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associated with an increased ASD risk in childhood.  Our findings are in line with several studies 
that have reported that rapid weight gain during infancy is a potential indicator of early autism 
risk (21, 22, 25, 26, 61).  We extend the previous findings and suggest that the association 
between rapid weight gain and ASD is potentially mediated, at least indirectly, by early 
childhood plasma leptin. To our knowledge, this is the first study to assess the 
interrelationships between birth weight, infancy weight gain and leptin in the context of ASD in 
a prospective birth cohort.  
Conceptual Framework of ASD risk factors from prenatal to early childhood: 
Epidemiological studies and animal models have consistently showed that an adverse in-utero 
environment may lead to altered programming of tissue structure and function, predisposing to 
later behavioral problems, learning difficulties, abnormal or delayed cognitive development and 
other conditions (62, 63). Sub-optimal prenatal environmental influences could induce 
permanent fetal adaptations that are beneficial for short-term survival, but increases the 
vulnerability to later pathogenic environmental stimuli (64, 65). As illustrated in Figure 5-2, 
based on the findings by us and others, postnatal influences such as extremely rapid weight 
gain and elevated leptin levels may not be isolated stand-alone occurrences during the first 
year of life; but could rather be a compensatory event to an adverse prenatal condition or 
deviation in biological mechanism (23, 50, 66). In support of this argument, we observed that 
children that were exposed to maternal diabetes or overweight/obesity during pregnancy and 
those that were SGA or early preterm, were more likely to have extremely rapid weight gain 
during infancy. Further, in line with the existing evidence (67), low concentrations of cord blood 
leptin were associated with rapid weight gain during the first year of life suggesting that cord 
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leptin could serve as a signal for catch-up growth. Taken together, it can be inferred that the 
incongruent prenatal (e.g. SGA) and postnatal milieu (rapid catch up growth) associated with 
endocrinologic alterations (early childhood leptin levels) may have a negative impact on the 
brain architecture and circuits, which could predispose an individual to adverse 
neurobehavioral outcomes (62, 68). Given this context, we further elaborate our findings and 
discuss how they compare to the previous studies and provide possible explanations.  
Many studies, in addition to ours, reported an inconsistent association between fetal 
growth and ASD (15-17, 69). Langridge et al. demonstrated that the percentage of optimal birth 
weight, a measure of fetal growth (70), was not associated with ASD, especially among those 
with intellectual disability (69). Glasson et al. also showed no association between SGA and ASD 
(16), while Schnedel et al., noted that the relationship was observed only in girls and not in boys 
(17). Similarly, Larrson et al. observed that the association between fetal growth and ASD 
attenuated after adjusting for other covariates (15). In contrast, a few studies showed that SGA 
children had elevated risk of ASD (8, 14, 71). A possible explanation for the lack of association 
between fetal growth and ASD is likely due to the heterogeneity in the SGA group related to the 
timing of onset. Fetal growth restriction may have different clinical manifestation and sequelae 
depending on whether the onset of growth restriction is early or late during gestation (72, 73). 
In our study, considering SGA as a homogenous group could have possibly blurred the 
association between fetal growth and ASD. We do not have data in the current study to tease 
apart this association, but can be explored further in future studies. Other potential reasons 
including methodological differences, lack of control for confounding factors, and sample size 
variations could explain some of the inconsistencies (14, 17). 
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Consistent with our findings, several studies have shown that children who are later 
diagnosed with ASD have accelerated weight gain during infancy and early childhood (21, 22, 
26, 74). This accelerated weight gain may not be a distinct morphological feature, but is 
suggestive of a broader autistic phenotype characterized by rapid increase in head 
circumference, height and weight (22, 26, 74-77).  In support of this hypothesis, studies have 
shown that head circumference is well correlated with weight and height in ASD children(20, 
26, 74). Rapid increase in head circumference in children with ASD is one of the most consistent 
findings that many studies have demonstrated (20, 22, 23, 26, 61, 76, 77). Although we did not 
analyze head circumferences due to incomplete data, weight has been shown to be the 
strongest predictor of head circumference during most of infancy (74). Taken together, our 
findings support the existing evidence that extremely rapid weight gain during infancy is 
associated with ASD, possibly indicative of an overall growth dysfunction. There are many 
speculations about why rapid weight gain is observed in children with ASD. Studies have 
posited that an abnormality in factors (such as metabolism, growth or neurotrophic factors and 
hormone levels) may predispose an individual to overall accelerated growth as well as ASD (21, 
22, 74, 76).  
Our study showed that early childhood leptin levels were altered in children with ASD. 
While prior studies assessing this relationship were mainly cross-sectional, our prospective 
study for the first time showed that elevated leptin levels are observed even prior to ASD 
diagnosis. Considering the role of leptin in neurocognition, elevated leptin and associated leptin 
resistance during the critical periods of postnatal brain development may have permanent 
adverse implications (78, 79). While the mechanism behind leptin resistance is still being 
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understood, it is believed to involve reduced transport of leptin to the brain, poor negative 
feedback mechanism, endoplasmic reticulum stress and an intracellular leptin signaling system 
that is saturable (79-81).  
Similar to other studies (36, 82), we noted that low cord leptin levels closely reflected 
birth weight and also predicted the greatest weight gain during infancy. However, cord blood 
leptin was not associated with ASD. This finding may be intriguing especially in the context that 
early childhood leptin is associated with ASD; however, our results are consistent with the 
existing evidence that cord and early childhood leptin may have different roles to play (80, 83). 
Cord blood leptin is derived primarily from the fetal tissue and is reflective of fetal 
adiposity (30, 84-86). While leptin is detectable in the fetus at around 18 weeks, rapid increase 
in leptin levels are observed after 34 weeks, in tandem with increase in fetal adipose tissues 
(85, 87). Perinatal and neonatal periods are considered to be a window of maximum leptin 
sensitivity with normal neonates having two to three times higher leptin when compared to 
adults (37, 78, 88, 89). Neonatal leptin has a different physiological response and promotes 
hyperphagia and swallowing activity in newborn and may not inhibit growth, food intake or 
energy expenditure (65, 90-92).  However, leptin sensitivity declines with age (80, 93).  
After closure of the critical window, higher leptin does not protect against adiposity and 
some children even develop leptin tolerance (80). Thus, leptin, once positively associated with 
birth weight and less adiposity during early childhood (27, 59, 80) no longer possesses the same 
effect – demonstrating that the effect of leptin in perinatal period is distinct from that of later 
life (94). One study that longitudinally measured cord and early childhood leptin showed that 
while high cord blood leptin was initially shown to be protective against adiposity, it was 
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subsequently associated with weight gain and adiposity at age 7 (80). These age-specific effects 
of leptin have been linked to developmental changes in leptin receptor expression – which are 
widely expressed in the central nervous system starting from mid-gestation (95).  While these 
findings are related to adiposity, it is plausible to believe that leptin’s role may be similar with 
neurocognitive outcomes.  
Leptin as a mediator: After establishing independent associations between ASD and 1) 
extremely rapid weight gain during infancy, and 2) early childhood leptin, we showed that 
children with extremely rapid weight gain during infancy had elevated leptin levels. In support 
of this, animal models that have shown that rapid catch-up growth in early childhood is 
associated with leptin resistance and this occurs independent of postnatal diet induced obesity 
(64, 96, 97). It has been hypothesized that proinflammatory cytokines may mediate the 
relationship between rapid postnatal growth and ASD (68). As a proof of concept, our study was 
able to demonstrate the mediating effect of leptin in the association between extremely rapid 
weight gain and ASD. However, in our dataset, cord leptin did not possess any mediating effects 
unlike early childhood leptin.  
Mechanism of leptin in ASD: Inflammation is a possible mechanism through which 
leptin may impact the psychopathology of ASD. Leptin, a pro-inflammatory cytokine may play a 
role in the pathophysiology of conditions such as schizophrenia (98, 99) and ASD (100, 101). A 
variety of independent studies have linked cytokine dysregulation to ASD (100). Cytokines act 
as immune mediators and their imbalance during development and throughout life can 
adversely impact neural activity and mediate behavioral aspect of the disorder (100). 
Inflammatory cytokines are implicated in higher neurological functions such as memory and 
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cognition, in addition to being involved in brain development, synaptic functioning including 
processes of differentiation, migration, proliferation and impairments in behavior (102). Thus, 
abnormal inflammatory activity and imbalance of cytokines during development can adversely 
impact neural activity and could contribute to behavioral and neurological dysfunction in ASD 
(100, 102).  
Altered leptin levels can also impact brain structure and function.  For example, leptin 
levels are increased at the site of inflammation in the post-mortem brain tissue (40). Leptin 
deficient and leptin resistant state is associated with lower brain weight, protein content, 
reduction in brain myelin, neuronal soma size and several synaptic proteins. Reduced brain 
weight is observed in animals that lacked leptin signaling (92). A study conducted on autopsy 
tissues showed that there is a marked increase in leptin levels in anterior cingulate gyrus among 
those that had ASD (103). In a small subset of patients, genetic correlation was observed 
between ASD and leptin coding (104). Leptin is involved in long-term potentiation and long-
term depression (105) and dysregulation of this function is implicated in ASD (105). Further, 
leptin is also known to suppress serotonin synthesis, which is reported in ASD, possibly 
suggesting another biological pathway through which leptin can be involved in ASD (78).  
In our earlier report in the BBC, we showed that maternal obesity and diabetes was 
associated with increased risk of ASD in offspring (49). Our results, along with consistent 
findings across diverse populations (106-109) raised the possibility of early metabolic 
dysfunction in the development of ASD.  Studies have posited that early life manipulations of 
leptin in animal models alter susceptibility to subsequent obesity and metabolic disorders (65, 
82). Periods of hypo- or hyperleptinemia may induce metabolic adaptations, which could be the 
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basis of developmental programming (65). In this context, the role of leptin as a potential 
mediator of the developmental programming of ASD (94) may be a novel proposition for ASD, 
but requires further investigation. Additional research is warranted on the role of other 
hormones with leptin opposing action, so as to better understand the metabolic milieu involved 
in ASD. Similarly, future studies should also examine variants in leptin and leptin receptors to 
better understand the biological pathways of leptin in ASD.  
  
5.5.1 Limitations and Strengths 
Although our study stemmed from a rigorously designed prospective birth cohort, the 
findings may be tempered due to some limitations. First, case and neurotypical development 
classification of children was based on EMR data and it is possible that there may be outcome 
misclassification. However, this misclassification may not be differential given the prospective 
study design. Second, the relatively small number of cases in our prospective cohort design 
could have resulted in wide confidence intervals and imprecise estimates. Third, although our 
models accounted for breastfeeding vs. formula feeding, more research is needed to examine 
the role of perinatal nutrition and its influences on weight gain, early childhood leptin and ASD. 
Fourth, we could not directly assess fat mass at the time of leptin measurement and this could 
have resulted in some residual confounding. Fifth, plasma leptin levels follow a circadian 
rhythm (81) and may be impacted by fasting status; although, the timing of plasma sample 
collection for leptin measurements was random, the distribution was comparable between ASD 
and neurotypical groups. Finally, our study population consisted mainly of urban low-income 
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minority populations that were also at high risk for conditions such as SGA and preterm births 
and thus, the results may not be generalizable to the U.S. population.  
Despite these limitations, our study has a number of strengths. This is one of the first 
longitudinal studies that addressed leptin levels at birth and in early childhood in the context of 
ASD. Infant weight gain was assessed as part of well-child visit during first year of life, when 
child’s ASD status was not known. By using a sample of children that have weight gain data as 
well as data on cord and early childhood leptin, we were uniquely poised to examine the inter-
relationship of these variables in the development of ASD.  
5.6 Conclusion 
In the BBC, we showed that extremely rapid weight gain during infancy and elevated 
leptin levels during early childhood were independently associated with greater ASD risk and 
early childhood plasma leptin levels at least indirectly mediated the relationship between early 
childhood weight gain and ASD.  Furthermore, the prenatal and postnatal risk factors for ASD 
are interrelated and act along a continuum from prenatal to postnatal periods.  An important 
implication of these findings is that in addition to prenatal factors, pathogenic processes 
underlying ASD likely continue during the postnatal period, including infancy and possibly 
extending to early childhood (26). Even though accelerated weight gain in early life, combined 
with elevated plasma leptin may not be a unique biomarker for ASD, our preliminary findings 
provide a basis from which to further explore the relationship between prenatal events, infancy 
rapid weight gain, leptin and ASD under a life course framework (23). Additional research is 
needed to understand if a combination of prenatal and early childhood anthropometric, 
biological, genetic variables and behavioral signs together can accurately predict ASD sooner. If 
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proven to be useful by future studies, this will provide an opportunity to start intervention 
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(n=769) ASD (n=53) p value 
Characteristics       
Mothers       
Age at birth (yrs), mean (SD) 28.21 (6.51) 30.35 (6.28) 0.02 
Parity (%)     0.92 
   0 331 (41.74) 21 (39.62)   
   1 or more 447 (58.13) 32 (60.38)   
   Missing 1 (0.13) 0 (0.0)   
Mother's education (%)     0.43 
   High School or less 498 (64.76) 31 (58.49)   
   Some college or more 266 (34.59) 21 (39.62)   
   Missing 5 (0.65) 1 (1.89)   
Maternal BMI (%)     0.16 
   Underweight (<18.5) + Normal Weight 
(≥18.5-<25)  371 (48.24) 19 (35.85)   
   Overweight (25-29.9) 235 (30.56) 18 (33.96)   
   Obesity (≥30) 163 (21.20) 16 (30.19)   
Diabetes mellitus (%)     0.19 
   No 688 (89.47) 45 (84.91)   
   Gestational  53 (6.89) 3 (5.66)   
   Pre-gestational diabetes 27 (3.51) 5 (9.43)   
   Missing 1 (0.13) 0 (0.0)  
Smoking during & 3 months prior to 
pregnancy (%)     0.17 
   No 659 (85.70) 41 (77.36)   
   Yes 105 (13.65) 12 (22.64)   
   Missing 5 (0.65) 0 (0.00)   
Offspring       
Sex (%)     <0.001 
   Male 327 (42.52) 39 (73.58)   
   Female 442 (57.48) 14 (26.42)   
Race-ethnicity (%)     0.91 
   Black 434 (56.44) 32 (60.38)   
   White 46 (5.98) 4 (7.55)   
   Hispanic 185 (24.06) 11 (20.75)   
   Other 99 (12.87) 6 (11.32)   
   Missing 5 (0.65) 0 (0.0)   
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Gestational age (%)     0.007 
   Term  579 (75.29) 32 (60.38)   
   Late preterm (≥34 - <37 weeks) 126 (16.38) 10 (18.87)   
   Early preterm (<34 weeks) 64 (8.32) 11 (20.75)   
Birthweight (g) 3009.07 (714.09) 2782.26 (886.18) 0.03 
Year of birth (%)     0.70 
   1998-2006 400 (52.02) 29 (54.72)   
   2007-2013 369 (46.98) 24 (45.28)   
Birth weight for gestational age (%)a,b     0.73 
   Appropriate for gestational age (AGA) 442 (80.07) 36 (76.60)   
   Small for gestational age (SGA) 59 (10.69) 5 (10.64)   
   Large for gestational age (LGA) 51 (9.24) 6 (12.77)   
Weight gain during infancy (%)c, d     0.06 
   On target 178 (33.78) 9 (19.57)   
   Slow 65 (12.33) 5 (10.87)   
   Rapid weight gain 89 (16.89) 6 (13.04)   
   Extremely rapid weight gain 195 (37.00) 26 (56.52)   
Cord blood leptin (SD)e 38.23 (34.01) 27.37 (19.94) 0.05 
Early childhood leptin (SD)f 4.22 (5.60) 5.88 (5.68) 0.08 
Mode of feeding (%)     0.62 
   Formula 177 (23.02) 10 (18.87)   
   Both 537 (69.83) 37 (69.81)   
   Breastfeeding 49 (6.37) 5 (9.43)   
   Missing 6 (0.78) 1 (1.89)   
a Fetal growth defined as AGA (≥10th – 90th percentile);  SGA (<10th percentile), and LGA (>90th 
percentile) 
b n =599 (Neurotypical n=552; ASD n=47) 
c Weight gain z-scores during the first year of life were defined as the change in weight-for-age 
z-scores from birth until the target time-point and was categorized into the following groups: 
slow (weight gain z-score <-0.67), on track (−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely 
rapid (>1.28) 
d n=573 (Neurotypical n=527; ASD n=46) 
e n=655 (Neurotypical n=616; ASD n=39) 









Table 5-2 Association between birth weight for gestational age, weight gain during infancy 
and ASD risk in children  
  
Total 
n ASD n OR 95% CI 
p 
value 
Birth weight for gestational agea 
Unadjusted           
  AGA 478 36 Ref   
  SGA 64 5 1.04 0.39, 2.76 0.94 
  LGA 57 6 1.44 0.58, 3.59 0.43 
Model 1      
  AGA 478 36 Ref     
  SGA 64 5 0.81 0.28, 2.34 0.70 
  LGA 57 6 1.23 0.44, 3.47 0.69 
Model 2           
  AGA 478 36 Ref     
  SGA 64 5 0.86 0.29, 2.54 0.79 
  LGA 57 6 1.37 0.48, 3.91 0.55 
Weight gain during infancyb 
Unadjusted           
  On target 187 9 Ref     
  Slow 70 5 1.52 0.49, 4.71 0.47 
  Rapid weight gain 95 6 1.33 0.46, 3.86 0.60 
  Extremely rapid weight gain 221 26 2.64 1.20, 5.78 0.02 
Model 3           
  On target 187 9 Ref     
  Slow 70 5 1.71 0.53, 5.52 0.37 
  Rapid weight gain 95 6 1.39 0.43, 4.44 0.58 
  Extremely rapid weight gain 221 26 3.11 1.37, 7.07 0.007 
Model 4 
       On target 187 9 Ref     
  Slow 70 5 1.55 0.46, 5.24 0.48 
  Rapid weight gain 95 6 1.50 0.46, 4.88 0.50 
  Extremely rapid weight gain 221 26 3.33 1.44, 7.72 0.005 
Model 5 
       On target 187 9 Ref     
  Slow 70 5 1.74 0.54, 5.66 0.36 
  Rapid weight gain 95 6 1.32 0.41, 4.24 0.64 
  Extremely rapid weight gain 221 26 2.08 0.84, 5.13 0.11 
Model 6 
       On target 187 9 Ref     
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  Slow 70 5 1.40 0.40, 4.86 0.59 
  Over growth 95 6 1.22 0.36, 4.14 0.75 
  Extremely rapid weight gain 221 26 3.33 1.40, 7.89 0.006 
 
a In-utero growth defined as Appropriate for gestational age (≥10th – 90th percentile);  Small for 
gestational age (<10th percentile), and Large for gestational age (>90th percentile) 
b Weight gain during infancy defined as the change in weight-for-age z-scores from birth until 
the target time-point and was categorized into the following groups: slow (weight gain z-score 
<-0.67), on track (−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely rapid (>1.28) 
 
Model 1: Adjusted for maternal age at delivery, parity, smoking, education, maternal BMI, 
maternal diabetes status, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, follow-up time and breastfeeding status 
Model 4: Adjusted for Model 3 + birth weight for gestational age 
Model 5: Adjusted for Model 3 + gestational age 


































n ASD n OR 95% CI 
p 
value 
Cord leptin           
Unadjusted 
        Q1 164 10 Ref     
   Q2 163 11 1.11 0.46, 2.70 0.81 
   Q3 164 11 1.11 0.46, 2.68 0.82 
   Q4 164 7 0.69 0.25, 1.85 0.46 
Model 1           
   Q1 164 10 Ref     
   Q2 163 11 1.44 0.53, 3.87 0.48 
   Q3 164 11 1.76 0.66, 4.69 0.26 
   Q4 164 7 0.96 0.31, 2.94 0.94 
Model 2 
        Q1 164 10 Ref     
   Q2 163 11 2.01 0.68, 5.92 0.21 
   Q3 164 11 2.74 0.90, 8.31 0.08 
   Q4 164 7 1.40 0.42, 4.66 0.58 
Early childhood leptin 
     Unadjusted 
        Q1 163 3 Ref   
   Q2 163 8 2.75 0.72, 10.57 0.14 
   Q3 163 10 3.49 0.94, 12.91 0.06 
   Q4 163 15 5.41 1.53, 19.05 0.009 
Model 3 
        Q1 163 3 Ref   
   Q2 163 8 3.32 0.83, 13.37 0.09 
   Q3 163 10 4.61 1.17, 18.22 0.03 
   Q4 163 15 7.87 2.06, 30.04 0.003 
Model 4 
        Q1 163 3 Ref   
   Q2 163 8 3.30 0.81, 13.41 0.10 
   Q3 163 10 4.93 1.23, 19.77 0.02 
   Q4 163 15 7.89 2.05, 30.44 0.003 
Model 5 
        Q1 163 3 Ref   
   Q2 163 8 3.59 0.68, 18.96 0.13 
   Q3 163 10 4.18 0.79, 22.19 0.09 




        Q1 163 3 Ref   
   Q2 163 8 3.43 0.84, 13.94 0.09 
   Q3 163 10 5.09 1.28, 20.21 0.02 
   Q4 163 15 7.46 1.93, 28.82 0.004 
 
 
Model 1: Adjusted for maternal characteristics such as maternal age at delivery, parity, 
smoking, maternal BMI, maternal diabetes status, education, race, child's sex and follow-up 
time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, age of leptin measurement, follow-up time and 
breastfeeding status 
Model 4: Adjusted for Model 3 + gestational age 
Model 5: Adjusted for Model 3 + cord leptin levels 









Table 5-4 Mediation analysis – Leptin as a mediator in the relationship between weight gain 
during first year of life and ASD risk 
 
   
  
Total Effect, OR  
(95% CI) 
Direct Effect, OR 
(95% CI) 
Indirect effect, 





Unadjusted (Total N=476; ASD=32) 
On track Ref    
Slow 1.92 (0.52, 7.11) 1.93 (0.52, 7.16) 0.99 (0.81, 1.22)  
Rapid weight gain 1.39 (0.38, 5.11) 1.17 (0.32, 4.32) 1.19 (0.93, 1.52)  
Extreme rapid weight 
gain 2.80 (1.08, 7.28) 2.22 (0.84, 5.87) 1.26 (0.95, 1.67)  
Model 1: Adjusted 
On track Ref    
Slow 1.80 (0.44, 7.47) 1.81 (0.44, 7.49) 1.00 (0.72, 1.39)  
Rapid weight gain 1.06 (0.23, 4.85) 0.82 (0.18, 3.78) 1.29 (0.89, 1.87)  
Extreme rapid weight 
gain 1.80 (0.55, 5.90) 1.15 (0.34, 3.88) 1.56 (1.01, 2.42) 76.03 
 
Model 1: Adjusted for child’s sex, race, breast-feeding category, age of leptin measurement, 
follow-up time and gestational age  
A causal inference framework was used to estimate ORs and 95% CI for total, direct and indirect 
effects. A logistic regression model was fit using categorical exposure (weight gain during 












Panel A: Distribution of cord leptin levels (log transformed) in neurotypical children and those to be diagnosed with ASD 
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Distribution of cord leptin levels (log transformed)
Cord leptin distribution in children with neurotypical development
Cord leptin distribution in children to be diagnosed with ASD












4 6 8 10 12
Distribution of early childhood leptin (log transformed)
Early childhood leptin distribution in children with neurotypical development


























Conceptual model characterizing the relation between in utero growth / preterm birth, cord and early childhood leptin, weight gain 
during infancy, and risk of ASD in childhood 
FGR – Fetal Growth Rate 
PTB – Preterm birth 
















Excessive weight gain 
Early childhood leptin 
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Supplemental Table 5-1: Prenatal and Perinatal determinants of cord blood and early 
childhood leptin 
 Mean cord 
leptin (pg/ml) 




Maternal factors     
BMI     
   <25 33.27 0.002 3.93 0.02 
   ≥25 to <30 39.62 3.92 
   ≥30 44.64 5.40 
Diabetes     
   No 35.77 <0.001 4.30 0.75 
   Yes 52.50 4.08 
Smoking     
   No 38.87 0.02 4.27 0.80 
   Yes 30.33 4.12 
Race     
   Black 40.32 0.05 4.69 0.05 
   White 27.71 2.27 
   Hispanic 34.21 4.15 
   Other 37.53 3.64 
Child factors     
IUGRa     
   AGA 39.08 <0.001 3.97 0.14 
   SGA 20.52 3.86 
   LGA 59.15 5.50 
Weight gain during infancyb     
   On target   3.10 <0.001 
   Slow  2.93 
	
186	
   Rapid  4.20 
   Extremely rapid  5.20 
Gestational Age   
   <34 weeks 12.94 <0.001 3.51 0.50 
   ≥34 to <37 weeks 28.83 4.10 
   ≥37 weeks 41.37 4.40 
Sex     
   Girls 42.44 <0.001 
 
4.83 0.004 
   Boys 31.62 3.56 
Breast feedingb     
   Bottle only   4.43 0.94 
   Both bottle and breast 
feeding 
 4.24 
   Only breast feeding  4.28 
aAGA: Appropriate for gestational age, SGA: Small for gestational age, LGA: Large for gestational 
age 
bCord blood leptin levels were not calculated for postnatal variables (breastfeeding and weight 





















Supplemental Table 5-2: Determinants of weight gain pattern during infancy  
 







gain p value 
Gestational age (%) <0.001 
   Term 177 (39.86) 66 (14.86) 87 (19.59) 114 (25.68)   
   Late preterm 10 (12.35) 4 (4.94) 7 (8.64) 60 (74.07)   
   Early preterm 0 (0.0) 0 (0.0) 1 (2.08) 47 (97.92)   
Birth weight for gestational agea (%)  <0.001 
   AGA 152 (33.12) 45 (9.80) 81 (17.65) 181 (39.43)   
   SGA 12 (19.35) 3 (4.84) 13 (20.97) 34 (54.84)   
   LGA 23 (44.23) 22 (42.31) 1 (1.92) 6 (11.54)   
Maternal BMI (%) 0.01 
   <25 92 (34.98) 26 (9.89) 37 (14.07) 108 (41.06)   
   ≥25 to <30 67 (37.43) 20 (11.17) 30 (16.76) 62 (34.64)   
   ≥30 28 (21.37) 24 (18.32) 28 (21.37) 51 (38.93)   
Maternal diabetes (%) 0.03 
   No GDM/DM 174 (34.05) 57 (11.15) 81 (15.85) 199 (38.94)   
   GDM/DM 13 (20.97) 13 (20.97) 14 (22.58) 22 (35.48)   
Maternal obesity + Diabetes (%) 0.001 
  No Obesity & 
Diabetes 150 (36.95) 41 (10.10) 59 (14.53) 156 (38.42)   
  Obesity or Diabetes 33 (23.40) 21 (14.89) 30 (21.28) 57 (40.43)   
  Obesity & Diabetes 4 (15.38) 8 (30.77) 6 (23.08) 8 (30.77)   
 








Supplemental Table 5-3: Sensitivity Analyses on the association between birth weight for 
gestational age, rapid weight gain during first year of life and subsequent ASD risk in BBC 
using stringent controlsa 
 





n OR 95% CI p value OR 95% CI 
p 
value 
Model 1: Birth weight for gestational ageb  
  AGA 276 36 Ref     Ref     
  SGA 39 5 0.98 0.36, 2.67 0.97 1.22 0.39, 3.75 0.79 
  LGA 35 6 1.38 0.54, 3.55 0.51 1.28 0.39, 4.20 0.69 
Model 2: Birth weight for gestational ageb 
  AGA 276 36 Ref     Ref     
  SGA 39 5 0.98 0.36, 2.67 0.97 1.29 0.41, 4.06 0.66 
  LGA 35 6 1.38 0.54, 3.55 0.51 1.47 0.44, 4.94 0.53 
Model 3: Weight gain during infancyc  
  On target 102 9 Ref     Ref     
  Slow 44 5 1.32 0.42, 4.21 0.63 1.43 0.42, 4.87 0.56 
  Rapid weight gain 51 6 1.38 0.46, 4.11 0.57 1.73 0.51, 5.86 0.38 
  Extremely rapid 
weight gain 
133 26 
2.51 1.12, 5.63 0.03 3.21 1.36, 7.60 0.008 
Model 4: Weight gain during infancy c 
  On target 102 9 Ref     Ref     
  Slow 44 5 1.32 0.42, 4.21 0.63 1.21 0.33, 4.41 0.77 
  Rapid weight gain 51 6 1.38 0.46, 4.11 0.57 1.93 0.55, 6.78 0.31 
  Extremely rapid 
weight gain 
133 26 
2.51 1.12, 5.63 0.03 3.51 1.44, 8.56 0.006 
Model 5: Weight gain during infancy c 
  On target 102 9 Ref     Ref     
  Slow 44 5 1.32 0.42, 4.21 0.63 1.45 0.43, 4.94 0.55 
  Rapid weight gain 51 6 1.38 0.46, 4.11 0.57 1.60 0.47, 5.44 0.45 
  Extremely rapid 
weight gain 
133 26 
2.51 1.12, 5.63 0.03 2.08 0.81, 5.36 0.13 
Model 6: Weight gain during infancy c 
  On target 102 9 Ref     Ref     
  Slow 44 5 1.32 0.42, 4.21 0.63 1.01 0.26, 3.96 0.97 
  Rapid weight gain 51 6 1.38 0.46, 4.11 0.57 1.79 0.49, 6.60 0.38 
  Extremely rapid 
weight gain 
133 26 




a Stringent control defined as exclusion of children with any of the following conditions – 
Conduct disorder (312.0 - 312.9), Emotional disturbances of childhood or adolescence including 
Oppositional Defiant Disorder (313.0 - 313.9), Congenital Anomalies (740 - 759.9) 
b Birth weight for gestational age defined as appropriate for gestational age (AGA) (≥10th – 90th 
percentile);  Small for gestational age (SGA) (<10th percentile), and Large for gestational age 
(LGA) (>90th percentile) 
c Weight gain during infancy defined as the change in weight-for-age z-scores from birth until 
the target time-point and was categorized into the following groups: slow (weight gain z-score 
<-0.67), on track (−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely rapid (>1.28) 
 
Model 1: Adjusted for maternal age at delivery, parity, smoking, education, maternal BMI, 
maternal diabetes status, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, follow-up time and breastfeeding status 
Model 4: Adjusted for Model 3 + birth weight for gestational age pattern 
Model 5: Adjusted for Model 3 + gestational age 






























Supplemental Table 5-4: Sensitivity Analysis on the association between birth weight for 
gestational age, rapid weight gain during first year of life and subsequent ASD risk in the BBC 
using cases that were diagnosed at least twice and by a specialist 
 





n OR 95% CI p value OR 95% CI 
p 
value 
Birth weight for gestational agea  
Model 1   
  AGA 476 29 Ref     Ref     
  SGA 64 3 0.76 0.22, 2.56 0.66 0.58 0.15, 2.15 0.41 
  LGA 56 4 1.19 0.40, 3.51 0.76 0.90 0.26, 3.14 0.86 
Model 2   
  AGA 476 29 Ref     Ref     
  SGA 64 3 0.76 0.22, 2.56 0.66 0.62 0.16, 2.36 0.48 
  LGA 56 4 1.19 0.40, 3.51 0.76 1.00 0.28, 3.56 1.00 
Weight gain during infancyb 
Model 3   
  On target 187 7 Ref     Ref     
  Slow 69 3 1.17 0.29, 4.65 0.83 1.37 0.33, 5.68 0.66 
  Rapid weight gain 95 5 1.43 0.44, 4.63 0.55 1.40 0.39, 5.08 0.61 
  Extremely rapid weight 
gain 
219 20 
2.58 1.07, 6.26 0.04 3.03 1.21, 7.57 0.02 
Model 4 
          On target 187 7 Ref     Ref     
  Slow 69 3 1.17 0.29, 4.65 0.83 1.44 0.34, 6.05 0.62 
  Rapid weight gain 95 5 1.43 0.44, 4.63 0.55 1.37 0.38, 5.01 0.63 
  Extremely rapid weight 
gain 
219 20 
2.58 1.07, 6.26 0.04 2.99 1.20, 7.50 0.02 
Model 5 
          On target 187 7 Ref     Ref     
  Slow 69 3 1.17 0.29, 4.65 0.83 1.41 0.34, 5.89 0.64 
  Rapid weight gain 95 5 1.43 0.44, 4.63 0.55 1.30 0.36, 4.76 0.69 
  Extremely rapid weight 
gain 
219 20 
2.58 1.07, 6.26 0.04 1.68 0.60, 4.71 0.32 
Model 6 
          On target 187 7 Ref     Ref     
  Slow 69 3 1.17 0.29, 4.65 0.83 1.16 0.27, 4.93 0.84 
  Rapid weight gain 95 5 1.43 0.44, 4.63 0.55 1.02 0.26, 3.95 0.98 
  Extremely rapid weight 
gain 
219 20 




a Birth weight for gestational age was defined as appropriate for gestational age (AGA) (≥10th – 
90th percentile);  Small for gestational age (SGA) (<10th percentile), and Large for gestational age 
(LGA) (>90th percentile) 
b Weight gain during infancy defined as the change in weight-for-age z-scores from birth until 
the target time-point and was categorized into the following groups: slow (weight gain z-score 
<-0.67), on track (−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely rapid (>1.28) 
 
Model 1: Adjusted for maternal age at delivery, parity, smoking, education, maternal BMI, 
maternal diabetes status, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, follow-up time and breastfeeding status 
Model 4: Adjusted for Model 3 + birth weight for gestational age pattern 
Model 5: Adjusted for Model 3 + gestational age 

































Supplemental Table 5-5: Association between cord blood, early childhood leptin and ASD 
(categorized as continuous and categorical variables) 
 
      Unadjusted Adjusted 
  
Total 
n ASD n OR 95% CI 
p 
value OR 95% CI 
p 
value 
Cord leptin a                 
Leptin, continuous 655 39 0.77 0.58, 1.03 0.08 0.90 0.66, 1.24 0.52 
Tertiles                 
   Q1 216 14 Ref     Ref     
   Q2 216 15 1.08 0.51, 2.29 0.85 1.55 0.67, 3.57 0.31 
   Q3 223 10 0.68 0.29, 1.56 0.36 0.88 0.35, 2.24 0.79 
Quintiles                 
   Q1 131 10 Ref     Ref     
   Q2 131 6 0.58 0.20, 1.65 0.31 0.82 0.26, 2.62 0.74 
   Q3 131 12 1.22 0.51, 2.93 0.66 2.14 0.79, 5.80 0.14 
   Q4 131 8 0.79 0.30, 2.06 0.63 1.02 0.35, 2.98 0.98 
   Q5 131 3 0.28 0.08, 1.06 0.06 0.45 0.10, 1.96 0.29 
Early childhood leptin b                 
Leptin, continuous 652 36 1.58 1.15, 2.17 0.005 1.80 1.25, 2.60 0.002 
Tertiles                 
   Q1 215 7 Ref     Ref     
   Q2 215 8 1.15 0.41, 3.22 0.79 1.22 0.41, 3.61 0.72 
   Q3 222 21 3.10 1.29, 7.46 0.01 3.66 1.43, 9.36 0.007 
Quintiles                 
   Q1 130 3 Ref     Ref     
   Q2 131 4 1.33 0.29, 6.08 0.71 1.45 0.31, 6.92 0.64 
   Q3 130 7 2.41 0.61, 9.53 0.21 2.85 0.67, 12.01 0.16 
   Q4 131 9 3.12 0.83, 11.81 0.09 3.62 0.89, 14.68 0.07 
   Q5 130 13 4.70 1.31, 16.92 0.02 6.62 1.69, 26.00 0.007 
a Model 1: Adjusted for maternal characteristics such as age at delivery, parity, smoking, 
education, race, child's gender, maternal BMI, maternal diabetes, follow-up time 











Supplemental Table 5-6: Sensitivity Analysis on the association between cord, early childhood 
leptin and subsequent ASD risk in BBC using stringent controls a 
 
      Unadjusted Adjusted 
Cord Leptin                  
Model 1 
Total 
n ASD n OR 95% CI p value OR 95% CI 
p 
value 
  Leptin (continuous) 372 39 0.77 0.57, 1.03 0.08 0.99 0.70, 1.39 0.95 
Model 2 
           Leptin (continuous) 372 39 0.77 0.57, 1.03 0.08 1.00 0.67, 1.50 0.99 
Early childhood leptin  
        Model 3 
           Leptin (continuous) 384 36 1.58 1.15, 2.18 0.005 1.83 1.23, 2.72 0.003 
Model 4 
           Leptin (continuous) 384 36 1.58 1.15, 2.18 0.005 1.86 1.24, 2.79 0.003 
Model 5 
          Leptin (continuous) 384 36 1.58 1.15, 2.18 0.005 1.69 1.03, 2.76 0.04 
Model 6 
  
        Leptin (continuous) 384 36 1.58 1.15, 2.18 0.005 1.79 1.19, 2.70 0.005 
 
a Stringent control defined as exclusion of children with any of the following conditions – ADHD 
(314.0 - 314.9), Conduct disorder (312.0 - 312.9), Emotional disturbances of childhood or   
adolescence including Oppositional Defiant Disorder (313.0 - 313.9), Developmental Delay (315.0 - 
315.9), Intellectual Disability (317 – 319), Congenital Anomalies (740 - 759.9) 
 
Model 1: Adjusted for maternal characteristics such as maternal age at delivery, parity, smoking, 
maternal BMI, maternal diabetes status, education, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, age of leptin measurement, follow-up time and 
breastfeeding status 
Model 4: Adjusted for Model 3 + gestational age 
Model 5: Adjusted for Model 3 + cord leptin levels 













Supplemental Table 5-7: Sensitivity Analysis on the association between cord, early childhood 
leptin and ASD risk in the BBC (in children that were diagnosed at least twice and by a specialist) 
 
      Unadjusted Adjusted 





n OR 95% CI p value OR 95% CI 
p 
value 
   Leptin (continuous) 653 31 0.77 0.56, 1.06 0.11 0.87 0.62, 1.22 0.42 
Model 2 
           Leptin (continuous) 653 31 0.77 0.56, 1.06 0.11 0.96 0.64, 1.43 0.83 
Early childhood leptin 
Model 3 
           Leptin (continuous) 654 26 1.40 0.97, 2.02 0.08 1.49 0.99, 2.26 0.06 
Model 4 
           Leptin (continuous) 654 26 1.40 0.97, 2.02 0.08 1.50 0.98, 2.28 0.06 
Model 5 
          Leptin (continuous) 654 26 1.40 0.97, 2.02 0.08 1.38 0.85, 2.24 0.20 
Model 6 
  
        Leptin (continuous) 654 26 1.40 0.97, 2.02 0.08 1.41 0.93, 2.14 0.10 
 
Model 1: Adjusted for maternal characteristics such as maternal age at delivery, parity, smoking, 
maternal BMI, maternal diabetes status, education, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, age of leptin measurement, follow-up time and 
breastfeeding status 
Model 4: Adjusted for Model 3 + gestational age 
Model 5: Adjusted for Model 3 + cord leptin levels 




Supplemental Table 5-8: Association between birth weight for gestational age, Weight gain 




n ASD n HR 95% CI 
p 
value 
Birth weight for gestational agea 
Unadjusted           
  AGA 478 36 Ref     
  SGA 64 5 0.99 0.39, 2.53 0.99 
  LGA 57 6 1.39 0.58, 3.30 0.46 
Model 1           
  AGA 478 36 Ref     
  SGA 64 5 0.77 0.29, 2.05 0.60 
  LGA 57 6 1.15 0.45, 2.95 0.77 
Model 2 
       AGA 478 36 Ref     
  SGA 64 5 0.84 0.31, 2.25 0.73 
  LGA 57 6 1.26 0.49, 3.26 0.63 
Weight gain during infancyb 
Unadjusted           
  On target 187 9 Ref     
  Slow 70 5 1.48 0.50, 4.42 0.48 
  Rapid weight gain 95 6 1.30 0.46, 3.66 0.62 
  Extremely rapid weight gain 221 26 2.35 1.10, 5.04 0.03 
Model 3           
  On target 187 9 Ref     
  Slow 70 5 1.49 0.49, 4.50 0.48 
  Rapid weight gain 95 6 1.32 0.44, 3.98 0.62 
  Extremely rapid weight gain 221 26 2.63 1.21, 5.71 0.01 
Model 4 
       On target 187 9 Ref     
  Slow 70 5 1.35 0.43, 4.28 0.61 
  Rapid weight gain 95 6 1.41 0.46, 4.31 0.55 
  Extremely rapid weight gain 221 26 2.80 1.27, 6.16 0.01 
Model 5 
       On target 187 9 Ref     
  Slow 70 5 1.54 0.51, 4.64 0.45 
  Rapid weight gain 95 6 1.28 0.43, 3.87 0.66 
  Extremely rapid weight gain 221 26 1.97 0.84, 4.60 0.12 
Model 6 
       On target 187 9 Ref     
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  Slow 70 5 1.27 0.42, 3.85 0.67 
  Rapid weight gain 95 6 1.04 0.33, 3.23 0.95 
  Extremely rapid weight gain 221 26 2.67 1.22, 5.83 0.014 
 
a Birth weight for gestational age was defined as appropriate for gestational age (AGA) (≥10th – 
90th percentile);  Small for gestational age (SGA) (<10th percentile), and Large for gestational age 
(LGA) (>90th percentile) 
b Weight gain during infancy defined as the change in weight-for-age z-scores from birth until the 
target time-point and was categorized into the following groups: slow (weight gain z-score <-0.67), 
on track (−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely rapid (>1.28) 
 
Model 1: Adjusted for maternal age at delivery, parity, smoking, education, maternal BMI, 
maternal diabetes status, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, follow-up time and breastfeeding status 
Model 4: Adjusted for Model 3 + birth weight for gestational age 
Model 5: Adjusted for Model 3 + gestational age 





























Supplemental Table 5-9: Association between cord, early childhood plasma leptin levels and 




n ASD n OR 95% CI 
p 
value 
Cord leptin           
Unadjusted 
        Q1 164 10 Ref     
   Q2 163 11 1.12 0.48, 2.65 0.79 
   Q3 164 11 1.09 0.46, 2.57 0.84 
   Q4 164 7 0.69 0.26, 1.81 0.45 
Model 1           
   Q1 164 10 Ref     
   Q2 163 11 1.50 0.61, 3.66 0.38 
   Q3 164 11 1.61 0.65, 3.97 0.30 
   Q4 164 7 1.09 0.38, 3.09 0.88 
Model 2 
        Q1 164 10 Ref     
   Q2 163 11 2.11 0.79, 5.60 0.14 
   Q3 164 11 2.53 0.90, 7.14 0.08 
   Q4 164 7 1.62 0.53, 4.99 0.40 
Early childhood leptin 
     Unadjusted 
        Q1 163 3 Ref   
   Q2 163 8 2.77 0.73, 10.44 0.13 
   Q3 163 10 3.50 0.96, 12.72 0.06 
   Q4 163 15 4.56 1.32, 15.81 0.02 
Model 3 
        Q1 163 3 Ref   
   Q2 163 8 3.32 0.87, 12.66 0.08 
   Q3 163 10 4.10 1.10, 15.26 0.04 
   Q4 163 15 6.19 1.74, 22.00 0.005 
Model 4 
        Q1 163 3 Ref   
   Q2 163 8 3.17 0.83, 12.11 0.09 
   Q3 163 10 4.35 1.16, 16.32 0.03 
   Q4 163 15 6.26 1.76, 22.24 0.005 
Model 5 
        Q1 163 3 Ref   
   Q2 163 8 3.84 0.76, 19.36 0.10 
   Q3 163 10 4.35 0.85, 22.24 0.08 




        Q1 163 3 Ref   
   Q2 163 8 3.42 0.90, 13.02 0.07 
   Q3 163 10 4.48 1.21, 16.68 0.03 
   Q4 163 15 5.61 1.58, 19.98 0.008 
 
 
Model 1: Adjusted for maternal characteristics such as maternal age at delivery, parity, smoking, 
maternal BMI, maternal diabetes status, education, race, child's sex and follow-up time 
Model 2: Adjusted for Model 1 + gestational age 
Model 3: Adjusted for child's sex, race, age of leptin measurement, follow-up time and 
breastfeeding status 
Model 4: Adjusted for Model 3 + gestational age 
Model 5: Adjusted for Model 3 + cord leptin levels 
























Supplemental Figure 5-1: Flowchart of initial enrollment and postnatal follow-up of the BBC and 







































Eligible mother-infant pairs 
Enrollment period: 1998-2013 
Site: Boston Medical Center (BMC)	
N=2,932 
Children that received pediatric care 
at BMC	
N=5,007  
Excluded because postnatal pediatric 
care was not at BMC 	
N=1,589 
No cord or early childhood leptin  
 	
N=1,343 
Children with cord or early childhood 
leptin measure	
N=599 (ASD=47) 




Children with 1st year 
weight gain measure	
N=652 (ASD=36) 
Children with early 
childhood leptin measure	
N=655 (ASD=39) 
Children with cord leptin 
measure	
N=822 
Children included in the final analysis 
N=521 (ADHD =191; DD=330) 
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Emerging research suggests that adiponectin, a cytokine produced by adipose tissue, may be 
implicated in ASD. In this prospective birth cohort study, we assessed the association between 
cord, early childhood plasma adiponectin and the risk of developing ASD. ASD was defined 
based on ICD codes of physician diagnosis in the Electronic Medical Record. Cord adiponectin 
levels were inversely associated with ASD risk (aOR: 0.50; 95% CI: 0.33, 0.77), independent of 
preterm birth, early childhood adiponectin and other known ASD risk factors. Early childhood 
adiponectin, assessed prior to ASD diagnosis was associated with lower risk of ASD, which 
attenuated after adjusting for cord adiponectin, indicating the relative importance of cord 
adiponectin in ASD risk. Further research is warranted to confirm our findings and elucidate 
biological mechanisms.   





Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by 
impairments in social interaction and communication, and by the presence of restrictive, 
repetitive behaviors and interests (1, 2). Recent epidemiological studies suggest that 
approximately 1% of children are diagnosed with ASD (3, 4). While genetic, environmental, and 
prenatal/perinatal factors have been implicated in ASD (5, 6), the etiology of the disorder 
remains largely unknown and no convincing biomarkers of ASD have been identified (1, 2, 7).  
Disturbances in immunoinflammatory factors and adipocytokines have been observed in 
subjects with ASD (7, 8).  Aberrant immune activity during vulnerable periods of 
neurodevelopment could potentially play a role in neural dysfunction associated with ASD (9). 
Emerging evidence suggests that immune dysfunction and neuroinflammation may be a 
common thread across the individual ASD risk factors (10). 
Beyond its energy storing capabilities, adipose tissue has emerged as an endocrine 
organ that orchestrates inflammatory response through the production of adipocytokines (11-
13). The family of adipocytokines includes a variety of highly active molecules including 
interleukin (IL)-6, tumor necrosis factor (TNF)-α, leptin, adiponectin, resistin and vistafin, all of 
which are known to play a critical role in the regulation of inflammatory responses (11, 12).  
Adiponectin is the most abundant adipocytokine, mainly produced by brown and white adipose 
tissues (11).  
The role of adiponectin in ASD deserves attention for at least two important reasons. 
First, as an anti-inflammatory cytokine, adiponectin functions as a mediator of inflammatory 
response and has a protective role against metabolic disturbances (12, 14, 15). Emerging 
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evidence shows that adiponectin is implicated in neurological conditions (16-19). A few studies 
have reported altered adiponectin levels in children with ASD (15, 20, 21), but this has not been 
studied prospectively. Limited sample size, lack of adjustment of numerous confounders, and 
cross-sectional study designs have precluded elucidation of the role of adiponectin in the 
development of ASD. 
Second, preterm birth is an established risk factor for ASD (22-27). Lower serum 
adiponectin levels are noted in mothers who had preterm labor and delivery (12) as well as in 
children born preterm when compared to their term counterparts (28-35). While the role of 
adiponectin in prematurity is well characterized (28-35), existing research has not jointly looked 
at adiponectin and gestational age at birth in relation to ASD risk.  
To fill these gaps, we conducted a study to longitudinally assess the association between 
plasma adiponectin, measured in cord blood at birth and early childhood venous blood, and 
subsequent ASD risk. In addition, we set out to understand whether preterm birth and cord 
adiponectin had joint effects on ASD risk. We sought to clarify these questions by analyzing 
longitudinal data from the Boston Birth Cohort (BBC), a predominantly urban low-income 
minority birth cohort, enriched with preterm births.  
6.3 Methods 
6.3.1 Participants and data collection procedure 
 This study included 847 mother-child pairs from the BBC, of which 792 children were 
considered neurotypical and 55 received an ASD diagnosis. Supplemental Figure 6-1 outlines 
the enrollment, postnatal follow-up, inclusions and exclusions. Between 1998 and 2009, 
mothers who delivered a singleton live birth at the Boston Medical Center (BMC), were invited 
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to participate in this study. After obtaining informed consent, mothers were interviewed 24-72 
hours after delivery using a standardized postpartum questionnaire. Exclusion criteria for the 
initial enrollment were multiple-gestation pregnancies, chromosomal abnormalities, major 
birth defects and preterm deliveries as a result of maternal trauma.  Children that continued to 
receive pediatric care at the BMC were included in this study, and they were followed-up until 
2015 (Supplemental Figure 6-1). The study was approved by the Institutional Review Boards of 
the Johns Hopkins Bloomberg School of Public Health and the Boston University Medical 
Center.   
6.3.2 Exposure measures 
Plasma adiponectin in the children was measured at two time points: (1) Umbilical cord 
blood sample, collected at delivery, and (2) early childhood venous blood, collected during a 
pediatric visit (median time of measurement: 19.03 months). Plasma samples were stored in a 
freezer at −80°C.  Adiponectin was measured using an immunoassay (ELISA) and had an inter-
assay variation of <5.8% (36). The assays were run according to the manufacturer’s 
recommendation. Children that had adiponectin assessed after ASD diagnosis were excluded 
from the analysis. Adiponectin levels that were greater than 3SD above the mean were re-
assigned the value of 3 SD. 
Gestational age at birth was characterized based on the first day of the last menstrual 
period data and early ultrasound data (37, 38). Children with gestational age ≥ 37 completed 
weeks of gestation were categorized as full-term and those <37 weeks were grouped into late- 
(≥ 34 to <37 weeks) and early-preterm (<34 weeks).  
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6.3.3 Outcome measure 
Electronic Medical Records (EMR) data were used to identify children with ASD. Children 
were classified as an ASD case if they were ever diagnosed with autism (ICD-9 code 299.00), 
Asperger syndrome (299.80) and/or pervasive developmental disorder not otherwise specified 
(299.90). Children that were never diagnosed with ASD, ADHD (314.0 - 314.9), intellectual 
disabilities (317 – 319) or other developmental disabilities (315.0 - 315.9) were classified as 
‘neurotypical.’ When children with ASD also had ADHD, intellectual disabilities, or other 
developmental disabilities, they were still categorized as ASD. Two separate sensitivity analyses 
were performed using the following criteria: 1) a stringent ASD definition that included only 
those that were diagnosed with ASD on two separate occasions, and had at least one visit with 
a specialist such as a developmental behavioral pediatrician, pediatric neurologist or child 
psychologist; and 2) a stringent definition for neurotypical children which excluded those with 
competing diagnoses such as ADHD (314.0 - 314.9), intellectual disabilities (317 – 319), other 
developmental disabilities (315.0 - 315.9), Conduct Disorder (312.0 - 312.9), emotional 
disturbances of childhood or adolescence including Oppositional Defiant Disorder (313.0 - 
313.9) and Congenital Anomalies (740 - 759.9). 
6.3.4 Covariates 
Based on the existing literature and our earlier work in the BBC, we selected the 
covariates for adjustment a priori (36, 38-40), including maternal pre-pregnancy BMI, maternal 
diabetes status, maternal race/ethnicity, maternal age at the time of delivery, smoking during 
pregnancy (ever smoked 3 months before pregnancy/during pregnancy vs. not smoked during 
preconception/ pregnancy), parity (not including the index pregnancy), maternal education 
(high school or less vs. some college or more), child’s sex (female vs. male), year of baby’s birth 
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(1998-2006 vs. 2007-2013), mode of feeding (formula only, both formula and breast feeding 
and breastfeeding only), age at which early childhood blood was drawn and follow up time for 
each participant. Maternal pre-pregnancy weight and height were collected using a 
standardized questionnaire 2-3 days after delivery, which was used to calculate maternal BMI, 
defined as weight in kilograms divided by height in meters squared. Mother’s diabetes status 
was categorized into the following groups: 1) normal (without a pregestational or gestational 
diabetes diagnosis); 2) gestational diabetes (ever diagnosed with diabetes mellitus complicating 
pregnancy); and 3) pregestational diabetes (ever diagnosed with diabetes). Race/ethnicity was 
categorized into black, white, Hispanic and Other. Plasma insulin and leptin, in cord blood and 
in venous blood during childhood, were measured using a sandwich immunoassay and the 
interassay coefficient of variation was 4.0% and 4.5%, respectively (41). Adiponectin/leptin ratio 
was calculated and was log-transformed. Based on the WHO reference values, weight-for-age z-
score was used to calculate first year weight gain and was categorized into slow (weight gain z-
score <-0.67), on track (−0.67 to 0.67), rapid (>0.67 to 1.28), and extremely rapid (>1.28) (41).  
6.3.4 Statistical Analyses 
Distributional assumptions such as normality of cord and plasma adiponectin levels 
were assessed using the Shapiro-Wilk test. Since adiponectin distributions were skewed, they 
were log-transformed for both cord and early childhood adiponectin levels. Preliminary data 
analysis was conducted to compare neurotypical and ASD children using a chi-squared test for 
categorical variables and ANOVA for continuous variables.  Logistic regression was used to 
assess the relationship between log-transformed cord and early childhood plasma adiponectin 
levels (independent variables) and ASD (dependent variable), with adjustment for potential 
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confounders listed above. The results are presented as odds ratio. Baron and Kenny mediation 
analysis was used to explore the relationship between preterm birth, cord adiponectin and ASD 
risk. All statistical analyses were performed using STATA version 13.0 (StataCorp, College 
Station, TX). Differences were considered statistically significant if the p value was <0.05.  
6.4 Results 
The demographic and clinical characteristics of mothers and children in this study are 
presented in the Supplemental Table 6-1, and have also been documented in earlier studies 
from this cohort (36, 38-40, 42). We found that risk factors such as advanced maternal age, 
maternal diabetes, male sex and preterm birth were more common among children with ASD. 
In addition, ASD children were more likely to have lower birth weight and lower cord 
adiponectin levels (Supplemental Table 6-1).  Mean cord adiponectin levels were significantly 
different across groups defined by gestational age at birth, with early preterm children (8.29 
μg/mL) having the lowest levels, followed by late preterm (11.51 μg/mL) and term infants 
(16.90 μg/mL) (p value <0.001). Consistent with other studies (14, 32, 43-46), we observed that 
cord adiponectin was associated with the duration of gestation (Supplemental Table 6-2). 
Figure 6-1 shows the distribution of cord adiponectin by preterm status. As observed in panel A, 
the cord adiponectin distribution is shifted to the left for early preterm (<34 weeks) and late 
preterm (≥ 34 to <37 weeks) babies, when compared to term infants. However, there were no 
differences in the distribution of early childhood adiponectin levels based on gestational age at 
birth (Figure 6-2, panel B).  Cord adiponectin levels were also correlated with birth weight. 
Children with lower cord adiponectin levels were likely to have rapid or extremely rapid weight 
gain (Supplemental Table 6-3), but the association attenuated after adjusting for gestational 
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age at birth (data not shown). Correlation between cord and early childhood adiponectin was 
weak (r=0.18), although children whose cord adiponectin were in low, medium or high tertiles 
likely continued to stay in their respective categories at early childhood (Supplemental Figure 6-
2).  
6.4.1 Adiponectin and ASD risk 
A total of 674 children, including 634 neurotypical and 40 ASD children, were part of this 
analysis.  Figure 6-2 shows the distribution of cord and early childhood adiponectin levels by 
ASD status. The mean cord adiponectin level is reduced among children later diagnosed with 
ASD (Supplemental Table 6-1) and this is evident by the distinct lower cord adiponectin 
distribution observed in Figure 1, panel A. On the other hand, there was no difference in the 
mean early childhood adiponectin levels between neurotypical and ASD children (Figure 6-1, 
panel B).  
Table 6-1 presents the association between cord adiponectin and subsequent ASD risk. 
Higher cord adiponectin levels were associated with a lower risk of ASD (OR: 0.51; 95% CI: 0.35, 
0.75). When cord adiponectin levels were categorized into quartiles, an inverse dose-response 
relationship was observed. Compared to children with the lowest cord adiponectin levels 
(quartile 1), the highest cord adiponectin (ORquartile 4: 0.23, 95% CI: 0.08, 0.62) was associated 
with reduced risk of ASD in unadjusted analyses. This association persisted after adjustment for 
potential confounders (including child's sex, race, maternal education, maternal age, parity, 
smoking status, pre-pregnancy BMI, maternal diabetes status and follow-up time), (aORquartile 4: 
0.14, 95% CI: 0.04, 0.46; model 1). Sequentially adjusting for additional covariates including 
gestational age (model 2), cord insulin (model 3), cord leptin (model 4) and weight gain during 
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first year of life (model 5) did not alter the association between cord adiponectin and ASD 
(Table 6-1). This finding was also robust to how adiponectin was categorized (tertiles, quintiles, 
extreme levels) (Supplemental Table 6-4).  Finally, further adjusting for early childhood 
adiponectin did not alter the association. 
 A total of 638 children had data on early childhood adiponectin, of which 36 were 
subsequently diagnosed with ASD. As seen in Supplemental Figure 6-3, there was no difference 
in the timing of adiponectin measurement between neurotypical children and those that had 
ASD. In an unadjusted model, early childhood adiponectin was not associated with ASD risk 
(OR: 0.71; 95% CI: 0.45, 1.13) (Table 6-2). After adjusting for potential confounders (including 
maternal age, diabetes status, pre-pregnancy BMI, sex, race, preterm birth, age of 
measurement, follow-up time and breastfeeding status; model 1), higher early childhood 
adiponectin levels were inversely associated with the risk of ASD (aOR: 0.54; 95% CI: 0.33, 0.90). 
Similar to cord adiponectin, when early childhood adiponectin was categorized as quartiles, 
those with the highest levels (quartile 4) were associated with the lowest ASD risk (aORquartile 4: 
0.29; 95% CI: 0.09, 0.94).  The association persisted when adjusting for early childhood insulin 
(model 3), early childhood leptin (model 4) and weight gain during first year of life (model 5) 
and approached significance when adjusted for gestational age at birth (model 2). However, 
after adjusting for cord adiponectin levels (model 6), the association between early childhood 
adiponectin and ASD was no longer significant. We repeated the analysis by categorizing early 
childhood adiponectin as tertiles, quintiles and extreme values, and observed similar findings 
(Supplemental Table 6-5).  
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Sensitivity analyses using stringent ASD case and neurotypical definitions yielded 
consistent and stronger associations for both cord and early childhood adiponectin 
(Supplemental Tables 6-9). Repeating the analysis using ASD subjects that were diagnosed >2 
years did not alter the findings. 
Since leptin is linked to ASD in several studies (20, 21, 47-49), including ours, and 
adiponectin-leptin ratio is considered as a marker of metabolic syndrome (50), we assessed the 
association between log-transformed adiponectin-leptin ratio and subsequent ASD risk. We 
conducted this analysis for both cord and early childhood ratios (Supplemental tables 6-10 and 
6-11). While the associations were statistically significant, the ratio did not predict ASD risk 
beyond the independent effects of leptin and/or adiponectin.   
Next, the joint effects of preterm birth and adiponectin levels on the risk of ASD were 
assessed. Children that had term birth (≥37 completed weeks of gestation) and high cord 
adiponectin levels (defined as ≥50th percentile) were the reference group (Table 6-3).  After 
adjusting for confounders, the risk of ASD was not different between preterm (<37 completed 
weeks of gestation) and term children, as long as they had high cord adiponectin. ASD risk was 
elevated among term children with low adiponectin (defined as < 50th percentile) in both 
unadjusted and adjusted models (aOR: 3.06; 95% CI: 1.27, 7.40). Among preterm children with 
low adiponectin, the ASD risk was significantly higher than the reference group in the 
unadjusted model and approached statistical significance, after adjusting for confounders (aOR: 
2.62; 95% CI: 0.99, 6.99).  
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6.4.2 Mediation analysis: An exploration 
 Since the temporal ordering of preterm birth and altered adiponectin levels is unclear 
(12), mediation analysis was explored in two ways: 1) Cord adiponectin as a mediator in the 
relationship between preterm birth (independent variable) and ASD risk (dependent variable); 
and 2) Preterm birth as a mediator in the relationship between cord adiponectin (independent 
variable) and ASD risk (dependent variable). As seen in Supplemental Table 6-10, early preterm 
(independent variable) was associated with ASD risk (dependent variable) (step 1), both early 
and late preterm birth was associated with adiponectin (mediator) (step 2), and cord 
adiponectin was associated with ASD risk (step 3). In the last regression model (step 4), the 
association attenuated suggesting that cord adiponectin mediated the relationship between 
early preterm birth and ASD risk (Supplemental Table 6-12). In the second mediation analysis, 
preterm birth was considered as mediator in the association between cord adiponectin levels 
and ASD. Here, cord adiponectin was associated with ASD risk (step 1), preterm birth was 
associated with cord adiponectin (step 2) and early preterm birth was associated with ASD risk 
(step 3). In the regression model, adjusting for preterm birth did not alter the association 
between cord adiponectin and ASD risk, suggesting that there was no mediation (Supplemental 
Table 6-13). The role of early childhood adiponectin mediating the association between 
preterm birth and ASD risk is presented in Supplemental Table 6-14.   
6.5 Discussion 
 To our knowledge, this is the first study to prospectively assess adiponectin levels in 
cord blood (a proxy of fetal adiponectin) and in early childhood venous blood in relation to ASD 
risk. We find cord blood adiponectin levels to be inversely associated with the risk of ASD. In 
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comparison, the association between early childhood adiponectin and ASD was less robust and 
was further weakened after adjustment of cord adiponectin. These associations remained 
consistent after additional analyses, including sequential adjustment for potential confounders 
and other metabolic biomarkers (such as leptin, insulin) and after more stringent ASD and 
neurotypical classifications of outcome. 
Our findings are in line with the observations of Fujita-Shimizu et al. who noted that 
adiponectin levels are lower in subjects with ASD (15). Specifically, they reported a negative 
correlation between adiponectin and social development in children, characterized by the 
Autism Diagnostic Interview Revised (15). Consistent with these findings, Rodrigues et al., noted 
that adiponectin levels were inversely correlated with the severity of autism symptoms (21). 
Lisik et al. showed that adiponectin levels were lower in those with Fragile X Syndrome (16). 
These findings suggest that adiponectin may have a larger role to play in neurodevelopmental 
processes, rather than merely regulate energy expenditure or serve as a biomarker for the 
onset of metabolic syndrome (51, 52). 
 Adiponectin is detected in cord serum as early as 24 weeks of gestation, after which the 
concentration rises 20-fold until term (30). This increase during third trimester mirrors the 
increase in adiposity (14) and is in stark contrast with children and adults in whom adiponectin 
concentration is inversely associated with body fat percentage (30, 35). Cord adiponectin does 
not correlate with maternal adiponectin suggesting the fetal origins of cord adiponectin (14, 28, 
53-55). In the fetus, adiponectin is secreted by muscle and vascular cells, in addition to 
adipocytes (56).  
	
	214	
While cord adiponectin is associated with ASD, it is intriguing that early childhood 
adiponectin demonstrates a less robust association. Adiponectin expression and its relationship 
to growth parameters and fat distribution seem to evolve temporally, from birth to childhood 
(51, 57, 58). At birth, adiponectin is positively correlated with growth parameters and fat mass 
(51, 58-61). Subsequent to this initial time window, there is possibly a shift in this relationship 
noting an inverse association between adiponectin and fat mass (43, 51, 58, 62). Taken 
together, these findings suggest that the role of adiponectin in utero may be fundamentally 
different than early childhood adiponectin (43, 57).  The discrepancy between adiponectin at 
different time points has been hypothesized to the differential origination of adiponectin, 
variation in fat storage, secretion and modulation of adiponectin (43, 56). While the evidence 
discussed here is in the context of obesity, adiponectin’s effect may not be different for 
neurodevelopmental outcomes such as ASD.  
Adiponectin has been previously shown to be altered in preterm babies, however, for 
the first time we jointly assessed adiponectin and preterm birth in the context of ASD and 
showed that lower adiponectin levels could increase ASD risk, irrespective of the gestational 
age. As a next step, we conducted a preliminary mediation analysis. Given the uncertainty in 
the biological temporal relationship between preterm birth and cord adiponectin (meaning 
whether preterm birth alters adiponectin levels, or changes in adiponectin triggers preterm 
birth) (12), our analysis assessed both as mediators. In this exploratory analysis, cord 
adiponectin mediated the relationship between preterm birth and ASD; whereas, preterm birth 
did not seem to mediate the association between cord adiponectin and ASD. These findings are 
preliminary and suggestive of a potential mediating role of adiponectin in relationship between 
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preterm birth and ASD. More research in animal models and human studies is warranted to 
further clarify this finding.  
6.5.1 Biological plausibility 
Several lines of evidence support the biological plausibility of adiponectin’s role in ASD. 
Adiponectin suppresses the macrophage production of pro-inflammatory cytokines such as 
TNF- α, IL-6 (53), Interferon (IFN)-γ (12), which are noted to be elevated in children with ASD (4, 
63, 64). Consistent findings suggest that IL-6 was significantly increased in the anterior 
cingulated gyrus, frontal cortices and cerebellum(64) and TNF was increased almost 50 times in 
the cerebrospinal fluid (26).  Similarly, IFN-γ is elevated in the brain of ASD subjects, when 
compared to controls (64). Adiponectin signaling inhibits NF-κB, an essential transcription factor 
that mediates and regulates inflammatory and stress-related protein expression (13), which is 
aberrantly expressed in subjects with ASD (65).  
Beyond its role in influencing other cytokines, emerging evidence suggests that 
adiponectin may be implicated in brain functions (66). Adiponectin enters the brain from 
circulation and directly targets neurons (66-70). Its receptors are widely expressed in the 
dentate gyrus of hippocampus (68), hypothalamus, cortex and pituitary glands (53, 66). Given 
this broad distribution of adiponectin receptors in different brain regions, adiponectin’s role 
may be broader than the regulation of metabolic homeostasis and could plan an important role 
in the ‘adipocyte-brain cross-talk’ (66).  Adiponectin is involved in neurogenesis, dendritic spine 
remodeling, hippocampal neural stem cell proliferation and dentate gyrus neuronal excitability 
(67-70). It also promotes adaptive neuroplasticity and may possess cerebra-protective role, 
likely mediated through the eNOS signal pathway (53, 66, 71). Abnormal development of 
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dentate gyrus of hippocampus, an important center for learning and memory, is likely 
implicated in the pathophysiology of ASD (3). Adiponectin may also possess higher brain 
functions. For example, diminished adiponectin levels are associated with clinically significant 
affective episodes and subjects with major depressive symptoms are known to have lower 
adiponectin levels (71). Adiponectin knockout mice have exhibited depressive-like behavior 
(67). Further, hypoadiponectinemia is thought to increase sympathetic nervous system activity 
– which is observed in depression (72).  
6.5.2 Limitations and strengths 
There are limitations to highlight. First, only total adiponectin and not the distinct forms 
such as low-molecular weight trimmers, medium-molecular-weight hexamers and high-
molecular-weight oligomers (HMW) was examined. It is possible that these individual 
components could have different roles and should be further explored in the context of ASD 
(12).  However, research in pediatric populations has found no difference in the role of total vs. 
HMW adiponectin (57). Second, ASD assessment relied on EMR data, which can introduce 
outcome misclassification in unpredictable ways. However, the results of our sensitivity analysis 
showed consistent associations when using more stringent outcome classification for both 
cases and neurotypical children. Third, because of the relatively small sample of ASD children in 
the cohort, our estimates may be subject to random variation. Fourth, although well-known 
ASD risk factors were adjusted for, there is a possibility of residual confounding. Finally, this 
study consisted primarily of urban, low-income minority population with high risk for preterm 
births. Thus, the findings may not be generalizable to other U.S. populations with different 
characteristics, although, few ASD studies have focused on this important group.  
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Despite these limitations, this study has a number of strengths. This study is based on a 
well-designed prospective birth cohort in an urban under-represented minority population. This 
is one of the first longitudinal studies to measure adiponectin at two-time points (birth and 
early childhood) prior to ASD diagnosis. Among studies that have looked at adipocytokines in 
the context of ASD, most of them were cross-sectional, and very few have used cord and/or 
newborn samples (73). Additionally, using a preterm enriched cohort, this study was uniquely 
poised to explore a novel question on the joint effect and mediating role of adiponectin in 
explaining the relationship between preterm birth and ASD risk and highlighted research gaps 
that can be explored by future studies.  
 
6.6 Conclusions 
 In summary, our study found an inverse association between cord adiponectin levels 
and subsequent ASD risk in childhood. The effects of lower adiponectin on increased ASD risk 
were demonstrated independent of gestational age, early childhood adiponectin, and other 
important covariables. We would like to emphasize that our findings be regarded as hypothesis 
generating. Further research is required to elucidate whether cord and/or early childhood 
adiponectin can be used as a biomarker for identifying children that are at high risk for ASD and 
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Table 6-1 Association between cord plasma adiponectin levels and ASD risk in children  
 




OR  95% CI p value 
Unadjusted           
Continuous 674 40 0.51 0.35, 0.75 0.001 
Quartile           
   Q1 
674 40 
Ref     
   Q2 0.36 0.16, 0.85 0.02 
   Q3 0.32 0.13, 0.77 0.01 
   Q4 0.23 0.08, 0.62 0.004 
Model 1b           
Continuous 674 40 0.50 0.33, 0.77 0.002 
Quartile           
   Q1 
674 40 
Ref     
   Q2 0.39 0.15, 1.01 0.05 
   Q3 0.40 0.15, 1.10 0.08 
   Q4 0.14 0.04, 0.46 0.001 
Model 2c           
Continuous 674 40 0.51 0.32, 0.82 0.006 
Quartile           
   Q1 
674 40 
Ref     
   Q2 0.38 0.14, 1.03 0.06 
   Q3 0.38 0.13, 1.12 0.08 
   Q4 0.13 0.04, 0.45 0.001 
Model 3d           
Continuous 674 40 0.47 0.30, 0.74 0.001 
Quartile           
   Q1 
674 40 
Ref     
   Q2 0.41 0.16, 1.08 0.07 
   Q3 0.32 0.11, 0.95 0.04 
   Q4 0.14 0.04, 0.45 0.001 
Model 4e           
Continuous 674 40 0.46 0.29, 0.73 0.001 
Quartile           
   Q1 
674 40 
Ref     
   Q2 0.38 0.14, 1.01 0.05 




   Q4 0.13 0.04, 0.43 0.001 
Model 5f           
Continuous 674 40 0.51 0.32, 0.83 0.006 
Quartile           
   Q1 
674 40 
Ref     
   Q2 0.46 0.16, 1.34 0.16 
   Q3 0.44 0.15, 1.33 0.15 
   Q4 0.12 0.03, 0.48 0.003 
Model 6g      
Continuous 674 40 0.36 0.21, 0.62 <0.001 
Quartile      






Ref   
   Q2 0.32 0.11, 0.91 0.03 
   Q3 0.23 0.07, 0.77 0.02 
   Q4 0.08 0.02, 0.34 0.001 
aAdiponectin was entered as a continuous variable in one model and categorical variable in 
another model 
bModel 1: Adjusted for child's sex, race, maternal education, maternal age, parity, smoking 
status, pre-pregnancy BMI, diabetes status, follow-up time 
cModel 2: Model 1 + gestational age 
dModel 3: Model 1 + cord insulin 
eModel 4: Model 1 + cord leptin 
fModel 5: Model 1 + weight gain during first year of life 

























Table 6-2 Association between early childhood plasma adiponectin levels and ASD risk in 
children  
 




OR  95% CI p 
value 
Unadjusted           
Continuous 638 36 0.71 0.45, 1.13 0.15 
Quartile           
   Q1 638 36 Ref     
   Q2 0.70 0.27, 1.79 0.45 
   Q3 0.88 0.36, 2.13 0.78 
   Q4 0.61 0.23, 1.61 0.32 
Model 1b           
Continuous 638 36 0.54 0.33, 0.90 0.02 
Quartile           
   Q1 638 36 Ref     
   Q2 0.65 0.24, 1.77 0.40 
   Q3 0.68 0.25, 1.82 0.44 
   Q4 0.29 0.09, 0.94 0.04 
Model 2c           
Continuous 638 36 0.59 0.35, 0.99 0.05 
Quartile           
   Q1 638 36 Ref     
   Q2 0.71 0.25, 1.97 0.51 
   Q3 0.80 0.29, 2.19 0.66 
   Q4 0.31 0.09, 1.04 0.06 
Model 3d           
Continuous 638 36 0.53 0.32, 0.88 0.01 
Quartile           
   Q1 638 36 Ref     
   Q2 0.64 0.23, 1.76 0.39 
   Q3 0.68 0.25, 1.86 0.45 
   Q4 0.26 0.08, 0.87 0.03 
Model 4e           
Continuous 638 36 0.49 0.29, 0.83 0.008 
Quartile           
   Q1 638 36 Ref     
   Q2 0.64 0.23, 1.81 0.41 
   Q3 0.68 0.24, 1.89 0.46 
   Q4 0.23 0.06, 0.79 0.02 
Model 5f           




Quartile           
   Q1 638 36 Ref     
   Q2 0.63 0.20, 1.98 0.43 
   Q3 0.59 0.20, 1.72 0.34 
   Q4 0.27 0.08, 0.93 0.04 
Model 6g           
Continuous 638 36 0.67 0.34, 1.33 0.25 
Quartile           
   Q1 638 36 Ref     
   Q2 0.72 0.17, 2.95 0.65 
   Q3 0.81 0.22, 3.01 0.75 
   Q4 0.64 0.14, 2.99 0.58 
aAdiponectin was entered as a continuous variable in one model and categorical variable in 
another model 
bModel 1: Adjusted for maternal age, diabetes status, maternal BMI, sex, race, age of 
measurement, follow-up time and breastfeeding status 
cModel 2: Model 1 + gestational age at birth 
dModel 3: Model 1 + early childhood insulin 
eModel 4: Model 1 + early childhood leptin 
fModel 5: Model 1 + weight gain during first year of life 





























Table 6-3 Joint effects of preterm birth and cord adiponectin in predicting ASD risk  
 
Joint effects of preterm 
birtha and adiponectinb 




Full term + High adiponectin 309 Ref  Ref  
Preterm + High adiponectin  28 1.0 (0.12, 8.07) 1.0 1.22 (0.14, 10.87) 0.86 
Full term + Low adiponectin  221 2.26 (1.04, 4.92) 0.04 3.06 (1.27, 7.40) 0.01 
Preterm + Low adiponectin 116 2.84 (1.20, 6.74) 0.02 2.62 (0.99, 6.99) 0.05 
a – Full term defined as ≥ 37 completed weeks of gestation; preterm defined as <37 completed 
weeks of gestation 
b - High cord adiponectin – defined as ≥50th percentile; Low cord adiponectin – defined as <50th 
percentile 
c – Adjusted for child’s sex, maternal education, maternal age, parity, maternal BMI, maternal 

















Figure 6-1 describes the distribution of cord adiponectin in panel A and early childhood plasma adiponectin in panel B. The 
distributions in both these panels are categorized by gestational age: 1) Term (≥ 37 completed weeks of gestation); 2) Late preterm 
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Figure 6-2 Distribution of plasma adiponectin levels in cord blood and in early childhood venous blood, stratified by neurotypical 
children vs. those with ASD 
 
Figure 6-2 describes the distribution of cord adiponectin in panel A and early childhood plasma adiponectin in panel B. The 
distributions in both these panels are categorized by ASD status: 1) Neurotypical children; and 2) ASD children
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Supplement Table 6-1: Maternal and child characteristics by child's case status (neurotypical 
vs. ASD) in the Boston Birth Cohort 
 
  Neurotypical 
(n=792) 
ASD (n=55) p value 
Characteristics       
Mothers       
Age at birth (yrs), mean (SD) 28.19 (6.56) 30.35 (6.16) 0.02 
Parity (%)     0.89 
0 333 (42.05) 21 (38.18)   
1 or more 458 (57.83) 34 (61.82)   
Missing 1 (0.16) 0 (0.00)   
Mother's education (%)     0.85 
   High School or less 510 (64.39) 33 (60.00)   
   Some college or more 275 (34.72) 21 (38.18)   
   Missing 7 (0.88) 1 (1.82)   
Maternal BMI (%)     0.21 
   Underweight (<18.5) + Normal 
Weight (≥18.5-<25)  
385 (48.61) 20 (36.36)   
   Overweight (25-29.9) 245 (30.93) 19 (34.55)   
   Obesity (>=30) 162 (20.45) 16 (29.09)   
Diabetes (%)     0.04 
   No 718 (90.66) 47 (85.45)   
   Gestational 50 (6.31) 2 (3.64)   
   Diabetes mellitus 24 (3.03) 6 (10.91)   
Smoking during & 3 months prior to 
pregnancy (%) 
    0.45 
   No 677 (85.48) 42 (76.36)   
   Yes 109 (13.76) 12 (21.82)   
   Missing 6 (0.76) 1 (1.82)   
Child       
Gender (%)     <0.001 
   Male 337 (42.55) 40 (72.73)   
   Female 455 (57.45) 15 (27.27)   
Race-ethnicity (%)     0.83 
   Black 453 (57.20) 34 (61.82)   
   White 48  (6.06) 4 (7.27)   
   Hispanic 186 (23.48) 11 (20.00)   
   Other 100 (12.63) 6 (10.91)   
   Missing 5 (0.63) 0 (0.00)   
Gestational age (%)     0.04 




   Late preterm (≥34 - <37 weeks) 128 (16.16) 10 (18.18)   
   Early preterm (<34 weeks) 63 (7.95) 11 (20.00)   
Birth weight (g) 3017.85 (713.20) 2803.73 (886.24) 0.03 
Year of birth (%)     0.66 
   1998-2006 429 (54.17) 30 (54.55)   
   2007-2013 363 (45.83) 25 (45.45)   
Cord blood adiponectin (SD)a (μg/mL) 15.80 (10.84) 11.37 (88.27) 0.01 
Early childhood adiponectin (SD)b 
(μg/mL) 
10.67  (62.15) 10.11 (73.59) 0.61 
First year weight gain pattern (%)c     0.05 
   On target 182 (33.96) 9 (18.75)   
   Slow 65 (12.13) 6 (12.50)   
   Rapid weight gain 92 (17.16) 6 (12.50)   
   Extremely rapid weight gain 197 (36.75) 27 (56.25)   
Mode of feeding (%)     0.86 
   Formula 183 (23.11) 11 (20.00)   
   Both 549 (69.32) 37 (67.27)   
   Breastfeeding 54 (6.82) 6 (10.91)   
   Missing 6 (0.76) 1 (1.82)   
an=674 (Neurotypical n=634; ASD n=40) 
bn=638 (Neurotypical n=602; ASD n=36) 





























Supplemental Table 6-2: Prenatal and perinatal predictors of cord blood and early childhood 
adiponectin in the Boston Birth Cohort 
  Mean cord 
adiponectin 
(μg/mL) 





Maternal factors         
BMI   0.67   0.28 
   <25 15.53   10.72   
   ≥25 to <30 15.14   10.05   
   ≥30 16.21   11.12   
Diabetes   0.75     
   No 15.58   10.60 0.93 
   Yes 15.15   10.67   
Smoking   0.06   0.15 
   No 15.86   10.78   
   Yes 13.65   9.78   
Race   0.13   0.03 
   Black 15.06   10.05   
   White 14.50   12.17   
   Hispanic 17.35   11.62   
   Other 15.06   10.67   
Child Factors         
IUGR   0.13   0.07 
   AGA 16.02   10.35   
   SGA 12.99   11.34   
   LGA 15.19   12.40   
Weight gain during 1st yeara       0.68 
   On target     10.84   
   Slow     10.94   
   Rapid     11.06   
   Extremely Rapid     10.21   
Gestational age   <0.001   0.14 
   <34 weeks 8.29   9.51   
   ≥34 to <37 weeks 11.51   9.96   
   ≥37 weeks 16.90   10.89   
Sex   0.57   0.99 
   Boys 15.28   10.60   
   Girls 15.75   10.61   
Breast feedinga       0.57 
   Bottle only     10.76   





   Only breast feeding     11.45   
 a Cord blood leptin levels were not calculated for postnatal variables (weight gain during 1st 




Supplemental Table 6-3: Predictors of cord adiponectin (categorized into quartiles) in the 
Boston Birth Cohort 
 
  Cord adiponectin   
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value 
Gestational age (%)         <0.001 
   ≥ 37 weeks 94 (17.74) 127 (23.96) 155 (29.25) 154 (29.06)   
   ≥ 34 to <37 weeks 45 (45.00) 32 (32.00) 11 (11.11) 12 (12.00)   
   < 34 weeks 28 (63.64) 11 (25.00) 3 (6.82) 2 (4.55)   
In utero growth (%)         0.23 
   AGA 86 (77.68) 93 (76.23) 99 (79.84) 104 (81.89)   
   SGA 17 (15.32) 10 (8.20) 12 (9.68) 10 (7.87)   
   LGA 8 (7.21) 19 (15.57) 13 (10.48) 13 (10.24)   
Birth weight (%)     <0.001 
   Normal (≥ 2500 g) 106 (63.47) 135 (79.88) 157 (92.90) 161 (95.83)  
   Low (<2500 g) 61 (36.53) 34 (20.12) 12 (7.10) 7 (4.17)  
Weight gain (%)         0.001 
   On track 31 (28.70) 36 (32.73) 54 (45.76) 45 (36.59)   
   Slow 6 (5.56) 17 (15.45) 17 (14.41) 17 (13.82)   
   Rapid  19 (17.59) 12 (10.91) 22 (18.64) 27 (21.95)   
   Extremely rapid 52 (48.15) 45 (40.91) 25 (21.19) 34 (27.64)   
Maternal pre-pregnancy BMI (%)  0.92 
   <25 85 (50.90) 80 (47.06) 78 (46.15) 82 (48.81)   
   ≥ 25 to <30 52 (31.14) 57 (33.53) 58 (34.32) 49 (28.17)   
   ≥ 30 30 (17.96) 33 (19.41) 33 (19.53) 37 (22.02)   
Diabetes (%)         0.55 
   No 151 (90.42) 148 (87.06) 152 (89.94) 154 (91.67)   
   Yes 16 (9.58) 22 (12.94) 17 (10.06) 14 (8.33)   
Maternal obesity & diabetes  0.99 
   No obesity & 
diabetes 80 (68.38) 76 (67.86) 73 (68.22) 79 (66.95)   
   Obesity or diabetes 34 (29.06) 34 (30.36) 32 (29.91) 35 (29.66)   
   Obesity & diabetes 3 (2.56) 2 (1.79) 2 (1.87) 4 (3.39)   
Early child adiponectin     <0.001 
   Quartile 1 34 (32.69) 26 (21.31) 22 (19.30) 21 (15.56)  
   Quartile 2 33 (31.73) 37 (30.33) 21 (18.42) 23 (17.04)  
   Quartile 3 23 (22.12) 36 (29.51) 41 (35.96) 26 (19.26)  
   Quartile 4 14 (13.46) 23 (18.85) 30 (26.32) 65 (48.15)  
Mean maternal age 






Supplemental Table 6-4: Association between cord adiponectin levels (tertiles, quintiles, extreme values) and ASD risk in children in the 
Boston Birth Cohort (n=674 including ASD (n=40)) 
 Unadjusted Model 1 Model 2 Model 3 Model 4 Model 5 
  OR  95% 
CI 
p  OR  95% 
CI 
p  OR  95% 
CI 
p  OR  95% 
CI 
p  OR  95% 
CI 
p  OR  95% CI p  
Tertile  
Q1 Ref     Ref     Ref     Ref     Ref     Ref     
Q2 0.43 0.20, 
0.93 
0.03 0.50 0.21, 
1.19 














Q3 0.33 0.14, 
0.75 



















Q1 Ref     Ref     Ref     Ref     Ref     Ref     
Q2 0.30 0.11, 
0.77 
0.01 0.36 0.13, 
1.02 














Q3 0.41 0.17, 
0.98 
0.04 0.49 0.18, 
1.30 














Q4 0.15 0.04, 
0.51 
0.002 0.20 0.05, 
0.74 














Q5 0.25 0.09, 
0.69 










































































Model 1: Adjusted for child's sex, race, maternal education, maternal age, parity, smoking status, pre-pregnancy BMI, diabetes status, 
follow-up time 
Model 2: Model 1 + gestational age 
Model 3: Model 1 + cord insulin 
Model 4: Model 1 + cord leptin 








Supplemental Table 6-5: Association between early childhood adiponectin levels (tertiles, quintiles, extreme values) and ASD risk in 
children in the Boston Birth Cohort 
 
   Unadjusted Model 1 Model 2 Model 3 




OR  95% CI p 
value 
OR  95% CI p value OR  95% CI p 
value 
OR  95% CI p value 
Tertile                             
Q1 638 36 Ref     Ref     Ref     Ref     
Q2 1.14 0.53, 2.46 0.74 0.88 0.38, 2.04 0.76 1.03 0.43, 2.45 0.95 1.19 0.38, 3.76 0.77 
Q3 0.57 0.23, 1.41 0.22 0.26 0.09, 0.75 0.01 0.28 0.09, 0.85 0.03 0.39 0.10, 1.59 0.19 
Quintile                             
Q1 638 36 Ref     Ref     Ref     Ref     
Q2 0.17 0.04, 0.76 0.02 0.19 0.04, 0.92 0.04 0.19 0.04, 0.95 0.04 0.17 0.02, 1.62 0.12 
Q3 1.06 0.45, 2.51 0.89 0.88 0.34, 2.27 0.79 1.14 0.42, 3.09 0.80 1.58 0.43, 5.82 0.49 
Q4 0.41 0.14, 1.23 0.11 0.22 0.06, 0.75 0.02 0.24 0.07, 0.86 0.03 0.11 0.01, 0.91 0.04 
Q5 0.51 0.18, 1.44 0.20 0.29 0.09, 0.96 0.04 0.33 0.09, 1.12 0.08 0.68 0.14, 3.39 0.64 
Extreme values (percentile)           
<20th  638 36 Ref     Ref     Ref     Ref     
>=20th to 
<80th  
0.54 0.25, 1.16 0.11 0.42 0.18, 1.00 0.05 0.48 0.20, 1.16 0.10 0.49 0.15, 1.58 0.23 
>=80th 0.51 0.18, 1.44 0.20 0.30 0.09, 1.00 0.05 0.33 0.10, 1.13 0.08 0.69 0.15, 3.23 0.63 
Model 1: Adjusted for maternal age, diabetes status, maternal BMI, sex, race, age of measurement, follow-up time and breastfeeding status 
Model 2: Model 1 + gestational age 









Supplemental Table 6-6: Sensitivity Analysis on the association between cord adiponectin 
and subsequent ASD risk in the Boston Birth Cohort using cases that were diagnosed at 
least twice and by a specialista 
 




OR  95% CI p 
value 
Unadjusted           
Continuous 674 30 0.41 0.27, 0.62 <0.001 
Quartile           
Q1 674 30 Ref     
Q2 0.38 0.15, 0.94 0.04 
Q3 0.16 0.05, 0.55 0.004 
Q4 0.16 0.05, 0.56 0.004 
Model 1           
Continuous 674 30 0.40 0.25, 0.66 <0.001 
Quartile           
Q1 674 30 Ref     
Q2 0.40 0.15, 1.10 0.08 
Q3 0.18 0.05, 0.70 0.01 
Q4 0.13 0.04, 0.50 0.003 
Model 2           
Continuous 674 30 0.44 0.26, 0.74 0.002 
Quartile           
Q1 674 30 Ref     
Q2 0.41 0.14, 1.18 0.10 
Q3 0.19 0.04, 0.79 0.02 
Q4 0.14 0.03, 0.54 0.005 
Model 3           
Continuous 674 30 0.39 0.23, 0.64 <0.001 
Quartile           
Q1 674 30 Ref     
Q2 0.42 0.15, 1.17 0.1 
Q3 0.18 0.04, 0.70 0.01 
Q4 0.13 0.03, 0.49 0.002 
Model 4           
Continuous 674 30 0.38 0.23, 0.64 <0.001 
Quartile           
Q1 674 30 Ref     
Q2 0.40 0.14, 1.11 0.08 
Q3 0.16 0.04, 0.67 0.01 
Q4 0.12 0.03, 0.47 0.002 




Continuous 674 30 0.38 0.22, 0.66 0.001 
Quartile           
Q1 674 30 Ref     
Q2 0.43 0.14, 1.34 0.15 
Q3 0.18 0.04, 0.76 0.02 
Q4 0.09 0.02, 0.44 0.003 
aAdiponectin was entered as a continuous variable in one model and categorical variable in 
another model 
Model 1: Adjusted for child's sex, race, maternal education, maternal age, parity, smoking 
status, pre-pregnancy BMI, diabetes status, follow-up time 
Model 2: Model 1 + gestational age 
Model 3: Model 1 + cord insulin 
Model 4: Model 1 + cord leptin 

































Supplemental Table 6-7: Sensitivity Analysis on the association between early childhood 
adiponectin and subsequent ASD risk in the Boston Birth Cohort using cases that were 
diagnosed at least twice and by a specialista 
 
  Total n ASD n OR  95% CI p value 
Unadjusted           
Continuous 638 28 0.61 0.37, 1.00 0.05 
Quartile           
Q1 638 28 Ref     
Q2 0.46 0.15, 1.40 0.17 
Q3 0.87 0.34, 2.26 0.78 
Q4 0.47 0.15, 1.43 0.18 
Model 1           
Continuous 638 28 0.46 0.27, 0.79 0.005 
Quartile           
Q1 638 28 Ref     
Q2 0.40 0.12, 1.29 0.13 
Q3 0.64 0.22, 1.86 0.41 
Q4 0.20 0.05, 0.78 0.02 
Model 2           
Continuous 638 28 0.49 0.28, 0.87 0.02 
Quartile           
Q1 638 28 Ref     
Q2 0.43 0.13, 1.45 0.17 
Q3 0.75 0.25, 2.27 0.61 
Q4 0.21 0.05, 0.88 0.03 
Model 3           
Continuous 638 28 0.45 0.26, 0.78 0.004 
Quartile           
Q1 638 28 Ref     
Q2 0.40 0.12, 1.30 0.13 
Q3 0.65 0.22, 1.91 0.43 
Q4 0.19 0.05, 0.76 0.02 
Model 4           
Continuous 638 28 0.42 0.24, 0.74 0.003 
Quartile           
Q1 638 28 Ref     
Q2 0.40 0.12, 1.33 0.14 
Q3 0.62 0.21, 1.85 0.39 
Q4 0.16 0.04, 0.68 0.01 




Continuous 638 28 0.42 0.24, 0.75 0.003 
Quartile           
Q1 638 28 Ref     
Q2 0.47 0.13, 1.76 0.26 
Q3 0.61 0.19, 1.95 0.41 
Q4 0.20 0.05, 0.86 0.03 
Model 6           
Continuous 638 28 0.46 0.22, 0.96 0.04 
Quartile           
Q1 638 28 Ref     
Q2 0.31 0.07, 1.50 0.15 
Q3 0.50 0.12, 2.03 0.33 
Q4 0.22 0.03, 1.44 0.12 
aAdiponectin was entered as a continuous variable in one model and categorical variable in 
another model 
Model 1: Adjusted for maternal age, diabetes status, maternal BMI, sex, race, age of 
measurement, follow-up time and breastfeeding status 
Model 2: Model 1 + gestational age 
Model 3: Model 1 + early childhood insulin 
Model 4: Model 1 + early childhood leptin 
Model 5: Model 1 + weight gain during first year of life 

























Supplemental Table 6-8: Sensitivity Analysis on the association between cord adiponectin 
and ASD risk in the Boston Birth Cohort using stringent neurotypical subjectsa 
 
  Total n ASD n OR  95% CI p value 
Unadjusted           
Continuous 389 40 0.48 0.31, 0.72 <0.001 
Quartile           
Q1 389 40 Ref     
Q2 0.32 0.13, 0.76 0.01 
Q3 0.31 0.12, 0.78 0.01 
Q4 0.19 0.07, 0.52 0.001 
Model 1           
Continuous 389 40 0.48 0.29, 0.79 0.004 
Quartile           
Q1 389 40 Ref     
Q2 0.34 0.12, 0.98 0.05 
Q3 0.51 0.17, 1.51 0.22 
Q4 0.11 0.03, 0.39 0.001 
Model 2           
Continuous 389 40 0.48 0.28, 0.81 0.006 
Quartile           
Q1 389 40 Ref     
Q2 0.32 0.11, 0.95 0.04 
Q3 0.49 0.16, 1.52 0.22 
Q4 0.10 0.02, 0.37 0.001 
Model 3           
Continuous 389 40 0.42 0.25, 0.72 0.001 
Quartile           
Q1 389 40 Ref     
Q2 0.37 0.12, 1.12 0.08 
Q3 0.37 0.12, 1.20 0.10 
Q4 0.10 0.03, 0.36 0.001 
Model 4           
Continuous 389 40 0.39 0.22, 0.68 0.001 
Quartile           
Q1 389 40 Ref     
Q2 0.30 0.10, 0.92 0.04 
Q3 0.33 0.10, 1.06 0.06 
Q4 0.08 0.02, 0.32 <0.001 
Model 5           




Quartile           
Q1 389 40 Ref     
Q2 0.39 0.12, 1.30 0.13 
Q3 0.63 0.19, 2.09 0.45 
Q4 0.09 0.02, 0.38 0.001 
aAdiponectin was entered as a continuous variable in one model and categorical variable in 
another model 
Model 1: Adjusted for child's sex, race, maternal education, maternal age, parity, smoking 
status, pre-pregnancy BMI, diabetes status, follow-up time 
Model 2: Model 1 + gestational age 
Model 3: Model 1 + cord insulin 
Model 4: Model 1 + cord leptin 


































Supplemental Table 6-9: Sensitivity Analysis on the association between early childhood 
adiponectin and ASD risk in the Boston Birth Cohort using stringent neurotypical subjectsa 
 
  Total n ASD n OR  95% CI p 
value 
Unadjusted           
Continuous 378 36 0.71 0.44, 1.13 0.15 
Quartile           
Q1 378 36 Ref     
Q2 0.58 0.22, 1.52 0.27 
Q3 0.78 0.32, 1.95 0.60 
Q4 0.55 0.20, 1.50 0.25 
Model 1           
Continuous 378 36 0.43 0.24, 0.78 0.005 
Quartile           
Q1 378 36 Ref     
Q2 0.51 0.17, 1.55 0.23 
Q3 0.43 0.14, 1.34 0.15 
Q4 0.14 0.04, 0.55 0.005 
Model 2           
Continuous 378 36 0.47 0.25, 0.87 0.02 
Quartile           
Q1 378 36 Ref     
Q2 0.55 0.17, 1.75 0.31 
Q3 0.50 0.15, 1.64 0.26 
Q4 0.17 0.04, 0.68 0.01 
Model 3           
Continuous 378 36 0.45 0.25, 0.81 0.01 
Quartile           
Q1 378 36 Ref     
Q2 0.51 0.16, 1.56 0.24 
Q3 0.48 0.15, 1.49 0.20 
Q4 0.15 0.04, 0.60 0.007 
Model 4           
Continuous 378 36 0.40 0.21, 0.75 0.004 
Quartile           
Q1 378 36 Ref     
Q2 0.50 0.16, 1.58 0.24 
Q3 0.47 0.15, 1.53 0.21 
Q4 0.13 0.03, 0.55 0.005 
Model 5           




Quartile           
Q1 378 36 Ref     
Q2 0.80 0.22, 2.93 0.75 
Q3 0.41 0.12, 1.43 0.16 
Q4 0.15 0.04, 0.63 0.01 
Model 6           
Continuous 378 36 0.44 0.19, 1.01 0.05 
Quartile           
Q1 378 36 Ref     
Q2 0.61 0.12, 3.04 0.55 
Q3 0.41 0.09, 1.91 0.26 
Q4 0.22 0.04, 1.32 0.10 
aAdiponectin was entered as a continuous variable in one model and categorical variable in 
another model 
Model 1: Adjusted for maternal age, diabetes status, maternal BMI, sex, race, age of 
measurement, follow-up time and breastfeeding status 
Model 2: Model 1 + gestational age 
Model 3: Model 1 + early childhood insulin 
Model 4: Model 1 + early childhood leptin 
Model 5: Model 1 + weight gain during first year of life 











Supplemental Table 10: Association between cord adiponectin leptin ratio and ASD risk in the Boston Birth Cohorta 
   Unadjusted Model 1 Model 2 Model 3 




OR  95% CI P 
value  
OR  95% CI p 
value 
OR  95% CI p 
value 




642 38 0.88 0.66, 1.18 0.40 0.75 0.55, 1.03 0.08 0.71 0.51, 0.97 0.03 0.65 0.45, 0.95 0.03 
Tertile  
Q1 642 38 Ref     Ref     Ref     Ref     
Q2 1.00 0.45, 2.21 1.00 0.97 0.40, 2.37 0.95 0.94 0.38, 2.30 0.89 0.70 0.25, 1.95 0.50 
Q3 0.89 0.40, 2.00 0.78 0.61 0.24, 1.54 0.29 0.47 0.17, 1.25 0.13 0.38 0.12, 1.18 0.09 
Quartile 
Q1 642 38 Ref     Ref     Ref     Ref     
Q2 0.99 0.42, 2.36 0.99 1.00 0.39, 2.62 0.99 0.98 0.37, 2.55 0.96 0.69 0.23, 2.07 0.51 
Q3 0.71 0.28, 1.82 0.48 0.46 0.16, 1.33 0.15 0.43 0.14, 1.28 0.13 0.21 0.06, 0.81 0.02 
Q4 0.71 0.28, 1.81 0.47 0.43 0.15, 1.28 0.13 0.34 0.11, 1.04 0.06 0.26 0.07, 0.93 0.04 
Quintile  
Q1 642 38 Ref     Ref     Ref     Ref     
Q2 0.88 0.35, 2.26 0.80 0.75 0.26, 2.15 0.59 0.74 0.26, 2.12 0.57 0.53 0.16, 1.81 0.32 
Q3 0.58 0.20, 1.65 0.31 0.45 0.14, 1.47 0.19 0.45 0.14, 1.49 0.19 0.29 0.08, 1.11 0.07 
Q4 0.68 0.25, 1.84 0.44 0.39 0.12, 1.24 0.11 0.35 0.11, 1.14 0.08 0.23 0.06, 0.89 0.03 









0.71 0.33, 1.55 0.39 0.52 0.21, 1.27 0.15 0.50 0.20, 1.24 0.13 0.34 0.12, 0.95 0.04 
>=80t
h ptile 




Model 1: Adjusted for child's sex, race, maternal education, maternal age, parity, smoking status, pre-pregnancy BMI, diabetes 
status, follow-up time 
Model 2: Model 1 + gestational age 






Supplemental Table 6-11: Association between early childhood adiponectin/leptin ratio and risk of ASD in children in the Boston 
Birth Cohort 
   Unadjusted Model 1 Model 2 Model 3 




OR  95% CI p  OR  95% CI p  OR  95% CI p  OR  95% CI p  
Log AL 
ratio 
636 36 0.66 0.51, 0.85 0.001 0.51 0.36, 0.71 <0.00
1 
0.50 0.36, 0.71 <0.001 0.53 0.35, 0.80 0.003 
Tertile                             
Q1 636 36 Ref     Ref     Ref     Ref     
Q2 0.39 0.18, 0.86 0.02 0.28 0.11, 0.67 0.004 0.23 0.10, 0.59 0.002 0.20 0.06, 0.66 0.008 
Q3 0.20 0.07, 0.55 0.002 0.12 0.04, 0.36 <0.001 0.11 0.04, 0.35 <0.001 0.14 0.04, 0.51 0.003 
Quartile 
Q1 636 36 Ref     Ref     Ref     Ref     
Q2 0.67 0.30, 1.53 0.35 0.48 0.19, 1.20 0.12 0.45 0.17, 1.18 0.11 0.54 0.16, 1.76 0.30 
Q3 0.47 0.18, 1.19 0.11 0.32 0.11, 0.93 0.04 0.29 0.10, 0.88 0.03 0.40 0.11, 1.49 0.17 
Q4 0.26 0.08, 0.80 0.02 0.15 0.04, 0.53 0.003 0.15 0.04, 0.51 0.003 0.20 0.05, 0.89 0.04 
Quintile  
Q1 636 36 Ref     Ref     Ref     Ref     
Q2 1.10 0.47, 2.56 0.82 0.70 0.27, 1.83 0.47 0.60 0.22, 1.62 0.31 1.23 0.35, 4.35 0.74 
Q3 0.46 0.16, 1.28 0.14 0.28 0.09, 0.89 0.03 0.24 0.07, 0.81 0.02 0.30 0.06, 1.54 0.15 
Q4 0.25 0.07, 0.91 0.04 0.13 0.03, 0.53 0.004 0.12 0.03, 0.52 0.004 0.31 0.06, 1.55 0.15 









0.59 0.28, 1.26 0.18 0.36 0.15, 0.86 0.02 0.32 0.32, 0.78 0.01 0.60 0.19, 1.94 0.40 
80th 
ptile 




Model 1: Adjusted for child's sex, race, age of measurement, breast feeding status, follow-up time  
Model 2: Model 1+ gestational age 








Supplemental Table 6-12: Exploratory mediation analysis using Baron and Kenny - Cord adiponectin mediating the association 
between preterm birth and ASD (n=674) in the Boston Birth Cohort 
 
 Unadjusted (OR) Adjusted
a
 (OR) 
Step 1: Association between preterm birth and ASD 
Full term Ref Ref 
Late preterm 1.14 (0.46, 2.84); p=0.77 0.83 (0.31, 2.24); p=0.72 
Early preterm 2.83 (1.10, 7.26); p=0.03 3.71 (1.19, 11.56); p=0.02 
Step 2: Association between cord adiponectin and preterm birthb 
Adiponectin in full term Ref Ref 
Adiponectin in late preterm -0.83 (-1.12, -0.53); p<0.001 -0.82 (-1.13, -0.50); p<0.001 
Adiponectin in early 
preterm 
-1.37 (-1.76, -0.97); p<0.001 -1.49 (-1.91, -1.06); p<0.001 
Step 3: Association between cord adiponectin and ASD 
Cord adiponectin 
(continuous) 
0.51 (0.35, 0.75); p=0.001 0.50 (0.33, 0.77); p=0.002 
Step 4: Association between preterm and ASD, after adjusting for cord adiponectinc 
Full term Ref Ref 
Late preterm 0.89 (0.35, 2.25); p=0.81 0.57 (0.20, 1.65); p=0.30 
Early preterm 1.73 (0.63, 4.74); p=0.28 1.91 (0.54, 6.70); p=0.31 
a
 – Adjusted for child's sex, maternal education, maternal age, parity, maternal BMI, maternal smoking status, diabetes, race 
ethnicity and follow-up time 
b
 – Coefficients in step 2 are not log transformed 
c








Supplemental Table 6-13: Exploratory mediation analysis using Baron and Kenny – Preterm birth mediating the association 
between cord adiponectin and ASD (n=674) in the Boston Birth Cohort 
 
 Unadjusted (OR) Adjusteda (OR) 
Step 1: Association between cord adiponectin and ASD 
Cord adiponectin 
(continuous) 
0.51 (0.35, 0.75); p=0.001 0.50 (0.33, 0.77); p=0.002 
Step 2: Association between preterm and cord adiponectinb 
Full term Ref Ref 
Late preterm -0.42 (-0.56, -0.27); p<0.001 -0.41 (-0.56, -0.26); p<0.001 
Early preterm -0.80 (-1.01, -0.59); p<0.001 -0.82 (-1.03, -0.61); p<0.001 
Step 3: Association between preterm and ASD 
Full term  Ref Ref 
Late preterm 1.14 (0.46, 2.84); p=0.77 0.83 (0.31, 2.24); p=0.72 
Early preterm 2.83 (1.10, 7.26); p=0.03 3.71 (1.19, 11.56); p=0.02 
Step 4: Association between cord adiponectin and ASD, after adjusting for pretermc 
Cord adiponectin 
(continuous) 
0.54 (0.36, 0.81); p=0.003 0.51 (0.32, 0.82); p=0.006 
a
 – Adjusted for child's sex, maternal education, maternal age, parity, maternal BMI, maternal smoking status, diabetes, race 
ethnicity and follow-up time 
b
 – Coefficients in step 2 are not log transformed 
c






Supplemental Table 6-14: Exploratory mediation analysis using Baron and Kenny – Early childhood adiponectin mediating the 
association between preterm birth and ASD (n=638) in the Boston Birth Cohort 
 
 Unadjusted (OR) Adjusted
a
 (OR) 
Step 1: Association between preterm birth and ASD  
Full term Ref Ref 
Late preterm 0.71 (0.24, 2.10); p=0.54 0.59 (0.19, 1.86); p=0.37 
Early preterm 3.19 (1.36, 7.50); p=0.008 3.94 (1.47, 10.52); p=0.006 
Step 2: Association between early childhood adiponectin and preterm birthb 
Adiponectin in full term Ref Ref 
Adiponectin in late 
preterm 
-0.15 (-0.45, 0.16); p=0.34 -0.20 (-0.52, 0.13); p=0.23 
Adiponectin in early 
preterm 
-0.26 (-0.65, 0.14); p=0.20 -0.32 (-0.73, 0.09); p=0.12 
Step 3: Association between early childhood adiponectin and ASD  
Early childhood 
adiponectin (continuous) 
0.71 (0.45, 1.13); p=0.15 0.54 (0.33, 0.90); p=0.02 
Step 4: Association between preterm and ASD, after adjusting for early childhood 
adiponectinc  
Full term Ref Ref 
Late preterm 0.70 (0.24, 2.06); p=0.51 0.58 (0.19, 1.83); p=0.36 
Early preterm 3.08 (1.31, 7.27); p=0.01 3.42 (1.23, 9.46); p=0.02 
 
a 
- Adjusted for child's sex, race, follow-up time, age of biomarker measurement, breastfeeding status, maternal age, pre-pregnancy 
BMI and maternal diabetes status  
b
 – Coefficients in step 2 are not log transformed 
c
 – In step 4 unadjusted model, early childhood adiponectin was included. In the adjusted model, all covariates listed above cord 




Supplemental Figure 6-1: Flowchart of initial enrollment and postnatal follow-up of the BBC 













































Eligible mother-infant pairs 
Enrollment period: 1998-2013 
Site: Boston Medical Center (BMC)	
N=2,932 
Children that received pediatric care 
at BMC	
N=5,007  
Excluded because postnatal pediatric 
care was not at BMC 	
N=1,546 
No cord and/or early childhood 
adiponectin measure  
 	
N=1,386 
Children with cord and/or early childhood 
adiponectin measure 	
N=674 (ASD=40) 
Children with cord 
adiponectin measure	
N=638 (ASD=36) 
Children with early childhood 
adiponectin measure	
N=847 
Children included in the final analysis 
N=539 (ADHD =203; DD=336) 
Had other competing diagnosis 
 	
N=475 (ASD=31) 
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Median age of measurement in neurotypical children: 18.83 mo





0 50 100 150
Age of early childhood adiponectin measurement in neurotypical children














































 This chapter begins with discussing the public health and clinical implications on the role 
of nutritional and metabolic factors in ASD, followed by a section on research implications. 
7.1 Public health and clinical implications: Nutrition perspective 
7.1.1 Folate, the double-edged sword 
Mandatory folic acid fortification of grain products has been hailed as possibly “the 
most important science-driven intervention in nutrition and public health in decades” (1). In the 
U.S., folic acid fortification has led to 26-47% reduction in NTD rates (2-5) with the current 
incidence of 3.0-6.3 per 10,000 live births (6). Despite the success of the fortification efforts, 
there has been lingering concerns that folic acid intake may be insufficient among some sub-
groups of U.S. women (7). In response to this concern, FDA recently approved corn masa flour 
fortification to improve folate status among Hispanic population (6, 8).  
At the other end of the spectrum, there have been some apprehensions about exposing 
population to too much folic acid and the long-term health consequences associated with it (9, 
10). These concerns include masking of vitamin B12, tumor progression, aberrant DNA 
methylation, diminished natural killer cell cytotoxicity (11), aberrant embryonic development, 
insulin resistance (12), adverse neurocognitive development (13, 14), increased risk of asthma 
and respiratory infections (4, 15, 16). Trends overtime suggests that serum folate levels in the 
U.S. have increased 2.5 times, since fortification and the prevalence of low folate levels has 
plummeted to ≤1%, across all demographic subgroups (5). Several studies have shown that 
unmetabolized folic acid (UMFA) is detected in the entire U.S. population, including maternal 
and fetal circulation and this has been attributed to high levels of synthetic folic acid from 
supplements and/or fortified foods (4, 9, 17, 18). There is growing interest about the potential 
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long-term effects of folic acid consumption in the population (19, 20), which had prompted the 
NIH’s Office of Dietary Supplements and National Institute of Environmental Health Sciences to 
convene an expert panel to identify the research needs around safe use of high intakes of folic 
acid (21).  
7.1.1.1 Sources of folic acid intake in pregnant population 
The US Preventative Task Force (USPSTF) recommends women to consume 400-800 μg 
of folic acid per day. Despite this range, most women in the U.S. generally consume higher 
doses of folic acid from supplements (≥800 μg/day), rather than a lower standard multivitamin 
dose of 400 μg/day (22, 23). Recent estimates from a nationally representative sample suggest 
that U.S. women consume 817 μg/day of folic acid from dietary supplements (22). This is 
equivalent to 1,389 μg of dietary folate equivalents (DFE), after accounting for 1.7 times greater 
bioavailability of folic acid when compared to dietary folate (21). Diet continues to be another 
important source with women receiving ~575 μg DFE from the dietary sources, including 
natural folate and fortified and enriched foods (24). Taken together, some sub-groups of 
pregnant women may be consuming folic acid, in excess of 1000 μg/day, which is the FDA’s safe 
upper level (UL) of daily intake (25). While ensuring that women receive adequate folic acid 
from at least from one of the sources (supplement or fortified foods), it is possible that some 
sub-groups of women may unintentionally be exposed to high levels of folic acid. This is 




7.1.1.2 Future policy considerations 
First, there is an urgent need to review and update the UL based on the current state of 
science, which was originally meant to be updated within a decade (26). When establishing the 
safe UL, it may be important to develop population sub-group specific UL based on their ability 
to metabolize and absorb folic acid (27).  The UL of 1000 μg/day (or 1 mg/day) for folate was 
proposed primarily for those individuals with vitamin B12 deficiency in whom excess folate may 
exacerbate neurological damage (26, 27). Hence, it is unclear if it is appropriate to use the same 
UL as a universal cut-off for all conditions across all populations (27, 28). Further, the DRI/IOM 
set the UL for folate before studies questioning the safety of folic acid were published (4, 11, 
15, 26, 27, 29).  
Second, there is no consensus on upper plasma folate levels (10, 30) and time is ripe for 
authoritative agencies to determine the upper level threshold taking into consideration the 
pregnancy state, and other individual and assay specific factors (17, 31). Although the WHO has 
proposed a cut-off of 45.3 nmol/L for elevated levels, it was based on assay’s upper limit 
capabilities and not on biological implications for health (32). It is notable that in our study we 
did not find adverse effects when considering the WHO cut-off, but we observed effects in the 
extreme tail (≥ 60.3 nmol/L). Studies like ours underscore the need to have cut-offs that 
captures not only deficiency and normal range, but also excess and most importantly extreme 
levels (33).  
Third, maternal folate exposure has been beneficially and detrimentally linked to a 
number of conditions in the offspring, including neural tube defects (NTD), congenital 
anomalies, insulin resistance, neurodevelopmental condition (12-14, 34). In the U.S., folate 
levels are not clinically monitored, although there is a desire to do so, at least prior to and 
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during pregnancy (33). The rationale for monitoring folate levels is to ensure that women are 
not folate deficient, at the same time are not exposed to exceptionally high levels, thus 
minimizing the harm across the range of perinatal outcomes (33). 
Finally, there is a need to investigate whether it is essential to continue prenatal 
supplements beyond first trimester. This is especially relevant given that repeated consumption 
of small amount of folic acid, over the course of pregnancy, can result in accumulation in serum 
as well as in cerebrospinal fluid (9, 28). Although, the USPSTF recommends folic acid 
supplementation for preconception to first trimester only (35), a majority of women however 
continue to use multivitamin supplements until the last trimester (22). It is paradoxical that 
women in their third trimester are more likely to use supplements than those in their first 
trimester (22). Thus, it is not only the dosage, but the duration of exposure of folic acid may 
also matter (28). 
7.1.1.3 Considering the context while comparing study findings 
 In the past decade, studies have been published on prenatal folic acid supplementation 
and ASD (36-40). While these findings may seem disparate at the face value, understanding the 
context may provide a better perspective on some of these differences. This section lays out 
important contextual factors that one shall consider when comparing findings across studies. 
• Folate-replete vs. folate-deplete population: Over 80 countries including the U.S., and 
Canada have mandatory folic acid fortification (41). While liberal voluntary fortification 
policies are in place in countries like Ireland, others limit (e.g. Netherlands) or even 
prohibit (e.g. Denmark) folic acid fortification (41, 42). Folate status is found to be 
lowest in populations without access to fortified foods and highest in countries with 
	
	 261	
mandatory folic acid fortification (41). It is interesting to note that many studies that 
reported beneficial effects of folic acid supplementation in the context of ASD were 
conducted in countries that did not have mandatory fortification. For example, in the 
Norwegian study, the authors reported that none of the foods that the participants 
consumed were folic acid fortified and the only source of synthetic folic acid were from 
supplements with a dosage of ≤400 μg/day (39). Another recent study that showed a 
protective effect of folic acid supplementation was conducted in Israel, a country 
without mandatory folic acid fortification. In fact, the study reported a prevalence of 
folate deficiency in pregnant women (36). Thus, the population’s underlying folate 
status and fortification policies in the country in which the study was conducted, should 
be taken into account when interpreting and comparing study findings.   
• Genetic differences: One of the important factors in elucidating the relationship 
between folic acid and ASD risk is the underlying prevalence of 
methylenetetrahydrofolate reductase (MTHFR) gene polymorphism. As mentioned in 
chapter 2, every population has MTHFR polymorphism, but the prevalence may vary 
based on the race/ethnicity. In the California based CHARGE study, the authors noted an 
inverse association between folic acid exposure during preconception and early 
pregnancy and ASD risk.  Interestingly, they reported that the association between folic 
acid and ASD risk was observed only when the mother and/or child had MTHFR variant 
genotype (38). However, we did not observe a similar protective effect in this study. 
One of the reasons might be that majority of the subjects in our cohort were blacks, 
who are reported to have the lowest frequency of 677T (<2%) (43). Also, our hypothesis 
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is in line with the conclusion of a meta-analysis that stated that relationship between 
folic acid and ASD risk is contingent on the MTHFR genotype and differences in the 
genotype could explain some of the variation in the study findings (44).  
• Race/ethnic differences in folate metabolism: Blacks in the U.S. have traditionally lower 
serum and RBC folate concentrations; paradoxically, they also have the lowest NTD 
rates, when compared to other racial ethnic groups (17). A recent NHANES study noted 
that non-Hispanic blacks (NHB) are also likely to have higher levels of UMFA, probably 
indicating a mismatch between folic acid supply and demand (17). This may be 
suggestive of lower folic acid requirements or genetic differences in the ability to 
metabolize folic acid in NHB when compared to other sub-groups (17). Similarly, 
NHANES data noted that NHB have higher levels of vitamin B12, when compared to 
whites and Hispanics (45). Although we did not find differences in ASD risk by 
race/ethnicity, it is nevertheless important to consider these different aspects while 
interpreting study findings.  
7.1.2 Vitamin B12 
Another nutrient considered in this dissertation is vitamin B12. Although vitamin B12 is 
intricately involved in one carbon metabolism along with folate, the latter has received a lot 
more attention from a national and international policy perspective. Recently, there has been a 
proposal to implement flour fortification of vitamin B12 in the U.S. (28, 46, 47).  The driver for 
such a proposal has been the following – 1) emerging evidence that there is an association 
between vitamin B12 and NTD, 2) exacerbation of the symptoms of vitamin B12 deficiency with 
folic acid fortification (48), and 3) high prevalence of vitamin B12 deficiency in elderly (47).  
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Considering that vitamin B12 fortification may somewhat be similar to the past 
fortification efforts, much can be learnt from those experiences. Below are some of the 
contextual issues that are worth considering before embarking on another fortification 
program.  
1. Vitamin B12 deficiency in the U.S. is limited to a sub-set of the population (e.g. elderly) 
(48).  This raises the question whether entire population should be exposed to meet the 
needs of a small section of the population (48).  
2. High prevalence of vitamin B12 deficiency is often due to poor absorption of vitamin 
B12, rather than deficiency per se. Further, much of the deficiency is sub-clinical and 
rarely manifests as a notable morbidity (46).  
3. Stability of cyanocobalamin, most commonly used vitamin B12 form in supplements, is 
rather questionable. They can form cobalamin analogues that can interfere with normal 
vitamin B12 metabolism and transport (48). Even though the synthetic form of vitamin 
B12 (cyanocobalamin) is readily converted to the active form in the body, substantial 
accumulation of non-physiologic cobalamin has been noted under certain circumstances 
(49). 
4. Vitamin B12 is tightly regulated in the body. This may be because of the diminished 
nutrient supply or exposing to large quantities might potentially be harmful (46). 
Emerging research suggests that elevated levels of vitamin B12 is associated with 
systemic inflammation, venous thromboembolism, increased cancer risk and higher 
mortality risk, mainly in elderly (50-52). With studies like ours (and others) are showing 
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adverse effects, gaining a thorough understanding on vitamin B12 metabolism may be 
important before initiating fortification efforts.  
5. Optimum dosage for vitamin B12 that is effective, yet not toxic is unknown (48). The 
IOM/DRI has not established a UL for vitamin B12 because of its low potential for 
toxicity (53). With the emergence of new knowledge, it may be time to revisit the UL for 
vitamin B12.  
6. Similar to plasma folate, there is no consensus on the upper bound cut-off for plasma 
vitamin B12. The cut-off for excess plasma vitamin B12 has ranged widely in the 
literature (anywhere from 500 pg/mL to 1084 pg/mL) (50, 54-56).  
7. There have been no clinical trials that have shown that vitamin B12 administration 
prevents NTD or improves outcome in elderly population. Without well-established 
clinical trials to prove one way or the other, it may be too premature to embark on a 
population wide effort.  
7.2 Public health and clinical implications: Metabolic perspective 
7.2.1 Potential for ASD biomarkers 
Traditionally, ASD diagnosis has been based on symptom clusters (57); however, precise 
diagnosis in young children before 3 years is challenging considering the etiological 
heterogeneity and substantial clinical variations. Unlike other conditions, there are no reliable 
biomarkers for ASD diagnosis (58, 59). However, recently numerous biomarkers including 
biochemical, morphological, immunological, hormonal, neurophysiological, neuroanatomic and 
neuropsychological markers have been proposed (58). Among these, adipokines have received 
increased attention, mainly because of its potential to identify at least sub-groups of ASD 
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individuals who may have some form of immune system dysregulation (58). This study, for the 
first time, has suggested that cord adiponectin and early childhood leptin can potentially serve 
as a predictive biomarker of ASD. In addition, our study was able to hint at some of the 
metabolic pathways in which these adipokines may be involved. This may expand the possibility 
of considering adiponectin as a stand-alone biomarker or leptin, in combination with early life 
growth indicators (such as rapid weight gain).  
While this early work is promising, several steps should be taken before possibly 
considering these biomarkers at a clinical or population level. Briefly, it is important to 
understand the role of leptin and adiponectin in different ASD sub-types (58). Our study 
findings require additional confirmation by other independent studies. If the evidence is 
consistent, it will be useful for intervention studies to assess these adipokines in order to 
understand if the interventions are altering or targeting these metabolic biomarkers (57).  
Ultimately, clinical trials should be conducted to evaluate if an active intervention can result in 
a favorable clinical response (58).  
7.2.2 Managing catch-up growth in ASD  
Encouraging postnatal catch-up growth has been controversial (60). Traditionally, 
clinicians in the NICU have done all they could to promote postnatal growth so that the IUGR or 
preterm babies become comparable to that of an uncompromised fetus of an equal 
postmenstrual age (61). However, promoting accelerated postnatal growth has been 
questioned and has lately been a subject of debate (62, 63). The Latin America SGA consensus 




The conundrum is that lack of postnatal catch-up growth is a significant risk factor for 
cognitive impairments and can exacerbate motor, language and developmental delays (65, 66).  
However, our study (including many others) has shown that accelerated growth during first 
year of life may be associated with an increased ASD risk. In addition, infants with postnatal 
rapid catch-up growth, have other adverse outcomes such as more central fat distribution by 5 
years of age (67), greater propensity to later cardiovascular disease, insulin resistance, leptin 
resistance, obesity and high blood pressure as adults (63, 68). Somatic overgrowth in the 
postnatal period may not be deterministic of ASD; yet, in the context of neurodevelopment, 
should catch-up growth be promoted or not? And, if acceleration of growth (including head 
circumference) is an adaptive or compensatory response, can altering the growth trajectory 
have an impact on ASD etiology? Clearly, more research is needed to answer these questions. If 
further studies provide evidence for this association, gender-specific clinical guidance on 
optimum postnatal growth that could maximize health benefits at the same time minimize any 
potential risk of neurological development can be considered.  
7.3. Research Implications 
 
This dissertation has addressed several important questions on the role of nutritional 
and metabolic factors in ASD. Since this study is one of the first prospective birth cohort studies 
to show some of the associations, more research in diverse populations is needed to validate 
our findings. During the course of this dissertation, many more questions have emerged that 
were not tackled in this study for a variety of reasons including project scope, availability of 
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time, resources and data. Nevertheless, they are important research gaps worthy of future 
investigation and have been elaborated below - 
7.3.1 Folate, vitamin B12 and ASD 
 
1. Across all three specific aims, outcome was assessed based on physician diagnosis using 
EMR. However, future studies could consider tools such as Autism diagnostic interview-
revised (ADI-R) and Autism diagnostic observation schedule (ADOS), which are 
considered to be the ‘gold standard’ for ASD diagnosis (59). 
2. Most studies conducted thus far, have solely assessed multivitamin supplement intake 
as the exposure (36, 38, 39) and have often not considered dietary folate (including 
fortified, enriched foods and natural folate from the diet). In a country like the U.S., diet 
contributes a significant amount of folate/folic acid and incomplete exposure 
ascertainment could preclude studies from observing the associations. Future studies 
should consider maternal dietary folate intake from all sources as well as biomarkers 
when assessing ASD risk in children.  
3. Unmetabolized folic acid (UMFA), which is ubiquitously detected in the U.S. population 
(17), is speculated to impact folate metabolism and is thought to be responsible for 
adverse effects (4, 10). However, none of the studies, thus far, have assessed UMFA in 
the context of ASD and is an important research question to address.  
4. Our study was conducted in a population that is mostly folate replete, with possibly 
lower folate requirements (based on preliminary knowledge on folate metabolism in 
blacks (17) and low prevalence of MTHFR C677T polymorphism). It will be interesting to 
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replicate our study in another population without mandatory fortification and/or higher 
prevalence of MTHFR polymorphism. 
5. To our knowledge, ours is the only study that assessed third trimester maternal plasma 
folate and vitamin B12 and its association with ASD in offspring. Studies that measured 
supplement intake or biomarkers during second trimester reported no association (39) 
(37, 69). Interestingly, some of these studies reported a protective effect earlier during 
pregnancy (37, 39). Based on these findings, it can be speculated that there may be 
unique window of opportunities, during which folate may play a role in ASD (36, 69, 70); 
however, this has not been systematically examined. Hence, there is a critical research 
need to understand the relationship between folate and vitamin B12 status at different 
time points (including preconception, first, second and third trimesters) and subsequent 
ASD risk. 
6. In addition to the ones mentioned already, below are some mechanistic research 
questions, if explored could provide additional insights on the pathways involving 
folate/folic acid. 
a. Our study demonstrated the joint effect of elevated folate and vitamin B12 in 
adversely affecting ASD risk. Although it is well known that folate and vitamin 
B12 are intricately involved in the one-carbon metabolism, the underlying 
mechanism that may exacerbate ASD risk is unknown and is worth investigating.  
b. Animal models have suggested that high folic acid supplementation during 
gestation modulates gene expression and alter brain development and behavior 
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in offspring (70-72). These findings need to be replicated in humans to 
understand if similar epigenetic alterations occur.   
c. Animal models that assess individual nutrient’s effect (folate, vitamin B12) on 
brain development may be required to unravel the role of each one carbon 
metabolite during various stages of neurodevelopment (73).  
7.3.2 Leptin, Adiponectin and ASD 
1. This dissertation presents a new finding that leptin and adiponectin, prior to ASD 
diagnosis, are independently associated with ASD. However, there is a lack of clarity 
whether abnormal levels of these adipokines is deterministic of ASD or is it merely 
associated with the underlying condition (57).  
2. There is an urgent need to conduct additional studies to further understand the impact 
of these adipokine levels on neurological consequences (74), as well as the mechanism 
behind the role of adipokines in mediating these relationships.   
3. Several studies, including ours, have suggested immune system aberrations in ASD. But 
there is limited understanding on the relationships between immune profiles and ASD 
symptoms and severity (58, 75). In addition, it may also be worthwhile to explore if 
abnormalities in adipokines are observed commonly in the presence of certain co-
morbidities (e.g. gastrointestinal dysfunction, sleep disorder) (58) or other inflammatory 
cytokine aberrations.  
4. Based on the findings from this study, we have theorized the possibility of considering 
leptin and adiponectin as early life biomarkers of ASD with full cognizance about the 
critical steps that are required to validate leptin and/or adiponectin as a useful 
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biomarker of ASD.  If additional studies support our findings, research can be 
undertaken to validate these biomarkers.   
5. Many studies, including ours, have demonstrated that catch-up growth during infancy is 
associated with subsequent ASD diagnosis. If catch-up growth is important, does timing 
or magnitude of catch-up growth matter in the context of ASD? Also, can rapid weight 
gain (or other auxological parameters) individually or in combination with leptin reliably 
predict ASD? 
6. Adiponectin circulates in multiple forms, with high-molecular weight adiponectin 
considered to be the active form (76). Although this study assessed total adiponectin, it 
has been suggested that the biological effects may vary by multimeric complex (77). The 
role of these multimeric adiponectin complexes has not been assessed in the context of 
ASD and is an important research gap to pursue. 
 
The research gaps or questions stated above are just examples of future research 
possibilities that are informed and stimulated by this dissertation. At present, one of the biggest 
challenges in this current research is the inability to temporally attribute neurobehavioral 
outcomes to early nutritional exposures or metabolic imbalances that may have happened 
years ago. There are multiple levels between the actual insult (be it genetic, epigenetic or 
environment alteration) and the behavioral manifestation, with no direct evident link in 
between each layer. Further, anatomic, spectroscopic or functional neuroimaging techniques 
are not sensitive enough to detect subtle alterations in brain structure due to sub-optimal 
nutritional exposures or immunological aberration (78, 79).  One option to circumvent these 
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challenges is for researchers to rely on a layered, multidisciplinary approach (as proposed in 
chapter 2) using developmentally appropriate pre-clinical models to provide the plausible 
biological proof for the role of sub-optimal nutrition or adipokine alteration in neurobehavioral 
manifestation in ASD (78-80). I foresee that the coming decade will be an exciting time to 
further the understanding of the ASD etiology, by leveraging the rapid advancement in 
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 This concluding chapter provides a summary of the key findings and reviews the 
strengths and limitations of the dissertation.  
8.1 Summary of Findings 
 This dissertation prospectively investigated the relationship between nutritional and 
metabolic factors and risk of ASD, using a life-course framework. The analysis was organized 
around three aims: 
1. To evaluate the associations between maternal multivitamin supplement intake, B-
vitamin biomarkers (plasma folate and vitamin B12) and ASD risk in children 
2. To evaluate the association between cord blood, early childhood plasma leptin, fetal 
growth and first year weight gain pattern, and risk of ASD in children 
3. To evaluate the association between cord blood, early childhood plasma adiponectin 
and risk of ASD in children 
To address these aims, I used data from the BBC, a large well-established prospective birth 
cohort drawn from urban, low-income minority population seeking obstetric and pediatric 
health care at the BMC. The BBC is an ASD enriched-cohort due to oversampling of babies born 
preterm. The findings from this study have relevance to high risk, low-income population in 
Boston and elsewhere in the U.S. with similar characteristics. 
8.1.1 Key Findings 
 The analyses for Specific aim 1 explored the association between maternal multivitamin 
supplement intake, maternal plasma folate and vitamin B12 measured at delivery and risk of 
ASD in the offspring. There was a “U shaped” relationship between multivitamin supplement 
intake during pregnancy and ASD risk in children. Mothers with moderate multivitamin 
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supplement intake (3-5 times/week) during pregnancy were associated with the lowest risk of 
ASD. Using this as the reference group, the risk of ASD in children was elevated among those 
mothers that had low (≤2 times/week) or high levels (>5 times/week) of multivitamin 
supplement intake. Maternal folate levels, categorized using the WHO cut off (<13.5 nmol/L – 
possible deficiency; 13.5-45.3 nmol/L – normal range; >45.3nmol/L – elevated) was not 
associated with an altered ASD risk. However, very high maternal plasma folate (≥60.3 nmol/L) 
at delivery was associated with an increased ASD risk, compared to those that had plasma 
folate in the middle 80th percentile. Elevated plasma vitamin B12 (≥536.8 pmol/L) was also 
associated with an increased ASD risk.  
 The analyses for Specific aim 2 assessed the association between leptin, early life 
growth and ASD and whether leptin mediated the relationship between early life growth and 
ASD. When compared to those whose growth was on track, infants with extremely rapid weight 
gain (weight gain z score >1.28) during first year of life was associated with a greater ASD risk. 
Similarly, early life elevated plasma leptin levels, prior to ASD diagnosis, were associated with 
an increased ASD risk. However, fetal growth and cord leptin levels did not predict ASD risk in 
this study. Early childhood plasma leptin levels mediated the association between rapid weight 
gain in infancy and ASD risk. Our findings are consistent with the previous studies that have 
reported that children with ASD subjects experience rapid growth in early life. In addition to 
prospectively reporting the association between early childhood leptin and ASD, this study 
provided a mechanistic insight on the role of leptin in mediating the relationship between 
accelerated infant weight gain and ASD.  
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 The analyses for Specific aim 3 assessed the relationship between cord and early 
childhood adiponectin and subsequent ASD risk in children. In this study, we showed that cord 
adiponectin, an anti-inflammatory cytokine was associated with ASD risk. Specifically, a dose-
response relationship was observed and children with highest cord adiponectin levels at birth 
had the lowest subsequent ASD risk. Early childhood adiponectin, prior to ASD diagnosis, was 
associated with ASD risk; but this association disappeared after adjusting for cord adiponectin, 
possibly suggesting a tracking of adiponectin levels from birth to early childhood. The 
association between cord adiponectin and ASD risk was independent of preterm birth, early 
childhood plasma adiponectin and many other known risk factors.  
8.1.2 Major Contributions to autism research 
 This dissertation, for the first time, assessed and demonstrated an association between 
elevated maternal plasma folate and ASD risk in offspring. From a public health perspective, 
this is an important topic to address, given that at least a fraction of women of reproductive 
age in the U.S. may consume surplus amounts of folic acid from multiple sources (e.g. prenatal 
supplement intake, foods fortified and enriched with folic acid), in addition to the natural folate 
from the diet. We also addressed a novel question on the association between maternal plasma 
vitamin B12 and ASD risk in children, which, to our knowledge, has never been reported before. 
Additionally, we showed that a combination of elevated maternal plasma folate and plasma 
vitamin B12 further increased ASD risk in children. This dissertation was uniquely poised to 
study ASD risk by assessing both prenatal supplement intake and maternal biomarkers of B 
vitamins, which provides complementary measures of maternal folate and B12 nutritional 
status during preconception and each trimester of pregnancy.  
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 Emerging research suggests that leptin, a pro-inflammatory cytokine, may be altered in 
children with ASD; however, this was based on findings from cross-sectional studies. In this 
dissertation, we were able to extend the existing knowledge by prospectively considering leptin 
at two time points (at birth and early childhood, before ASD diagnosis). We also confirmed the 
previous findings that accelerated weight gain during infancy is linked to increased ASD risk. 
Although the role of adipokines in ASD has been speculated, our study for the first time 
provided evidence that leptin may mediate the relationship between accelerated infant growth 
and increased ASD risk.   
 Finally, adiponectin’s role in ASD has not been longitudinally assessed. This is the first 
study to demonstrate that cord adiponectin, an anti-inflammatory cytokine, was associated 
with lower risk of ASD in a dose-response fashion, which is independent of preterm birth, 
postnatal plasma adiponectin levels, and other known risk factors of ASD.  Our research has 
also paved way for future studies to explore the possibility of considering leptin and 
adiponectin as early predictive biomarkers of ASD and as therapeutic targets.   
8.2 Limitations and Strengths 
8.2.1 Limitations 
Generalizability: The study population consists mainly of urban low-income minority women in 
Boston, MA. Due to the unique nature of demographic, environmental, and health service 
access to this population, caution has to be exercised when generalizing the findings of this 
study to other U.S. populations with different characteristics. Further, biological differences 
associated with race-ethnicity (e.g. difference in allele frequency of MTHFR gene 
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polymorphisms between non-Hispanic whites, Hispanics and non-Hispanic blacks) has to be 
considered when interpreting the results and generalizing the study findings.  
Selection bias and differential follow-up: The initial participation rate in the BBC was high, but 
only a subset continued to receive pediatric care at the BMC and they were the ones that were 
followed in this cohort. Differential follow-up might have occurred for some participants due to 
a variety of reasons including – 1) children missing their regular health checkup because of their 
optimum health status, 2) parents’ ignorance, 3) migration and 4) changing of hospitals. The 
latter option is unlikely because majority of families (>90%) in this cohort qualify for Medicaid 
(1) and BMC is the primary health care provider of Medicaid in Boston. To understand the 
impact of differential follow-up, analyses were conducted in this cohort comparing children 
included and excluded from current analyses in terms of characteristics at baseline and the 
results did not show statistically significant differences (2).   
Residual confounding: This study examined the prospective association between independent 
variables (such as maternal plasma folate; vitamin B12; cord and early childhood leptin and 
adiponectin; fetal growth and first year weight gain) and risk of ASD.  Despite the evidence of 
temporal and dose-response relationships, it is important to regard our findings as associations 
rather than indication of causality. Although the analyses in this study controlled for potential 
confounders based on key covariates identified in the literature, there might still have been 
other unmeasured variables that could have influenced the outcome. One example is that fat 
mass was not directly assessed at the time when leptin was measured and this could have 
resulted in some residual confounding.  
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Measurement of key exposure variables: Maternal plasma folate and vitamin B12 were 
measured 24-72 hours after delivery, which may be reflective of maternal biomarker levels 
during the third trimester, at best. Plasma folate is a marker of recent dietary intake exposure 
and may not reflect the long-term status. Due to the cost of biomarker assay, we only 
measured folate and B12 level in a subset of the study sample. Not including dietary data (such 
as folate from natural foods as well as those that are fortified and enriched with folic acid) 
along with supplement intake and biomarker data for the entire sample could be viewed as a 
limitation.  
Additionally, metabolic biomarkers – leptin and adiponectin levels were random, non-
fasting measurements and this could have introduced noise and could have biased the results 
towards null (3, 4). The models for leptin and adiponectin accounted for breastfeeding vs. 
formula feeding, but more research is required to examine the influences of perinatal nutrition 
on these biomarkers. Our study measured total adiponectin and not the distinct forms such as 
the low-molecular weight trimmers, medium-molecular-weight hexamers and high-molecular-
weight oligomers. These individual forms of adiponectin could possess diverse roles, and this 
needs further exploration in the context of ASD. Finally, maternal BMI was calculated based on 
self-reported height and weight and may have been subjected to reporting bias (4).  
Identification of ASD cases: Case and neurotypical development classification was based on 
physician diagnosis as documented in EMR, which could have possibly resulted in outcome 
misclassification in unpredictable ways. However, additional sensitivity analyses yielded 
consistent results when using more stringent outcome classification for both cases and 
neurotypical children. The relatively small sample size of ASD subjects could have resulted in 
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imprecise estimates. In this study, ASD was defined using DSM-IV rather than newer DSM-5, 
since ICD-9 codes were used to diagnose autism. However, studies have shown that there is 
continuity between DSM-IV and DSM-5 and that the findings from DSM-IV would still be 
relevant (5).   
8.2.2 Strengths 
Study Design: The longitudinal design of the BBC allowed us to address the study hypotheses in 
a prospective fashion. Most of the studies that assessed metabolic biomarkers and ASD were 
cross-sectional and were conducted after ASD diagnosis. To our knowledge, this is the first time 
a study has prospectively assessed the relationship between cord leptin and adiponectin 
(assessed at two-time points) in the context of ASD. Further, assessing these metabolic 
biomarkers in cord blood and early childhood, prior to ASD diagnosis, helped understand how 
these biomarkers may be altered during different sensitive periods of development and 
whether this might influence its association with ASD.  
Multimethod data collection and availability of nutritional and metabolic biomarkers: The 
BBC combines different types of data collection including self-report, standardized 
questionnaire and biomarker data in mothers and children from prenatal, perinatal and 
postnatal periods. Triangulating data from multiple sources helped maintain data quality, 
tapped into the unique strengths of different assessment methods and possibly shedding light 
on different mechanisms, that can be further explored in animal models and human studies. 
For example, in the BBC, maternal nutritional status was assessed using self-reported 
multivitamin intake during pregnancy as well as using nutritional biomarker data measured at 
delivery, which complemented well with one another in providing a reasonable assessment of B 
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vitamin nutritional status. Early life longitudinal growth data along with leptin measurements 
provided mechanistic insights into metabolic pathways implicated in ASD. Similarly, considering 
adiponectin and preterm delivery together gave a unique perspective on their independent and 
joint roles in the etiology of ASD.  
Understudied US minorities: This dissertation focused on an understudied population in urban 
Boston, mainly comprised of blacks and Hispanics, who have high prevalence of maternal 
metabolic conditions, preterm deliveries and ASD. Given the dearth of research on this minority 
population, addressing key nutritional and metabolic factors from a life-course perspective has 
shed new light on ASD risk factors, which may have implications for research and prevention of 
ASD in this vulnerable population and beyond.   
8.3 Conclusion 
Since Leo Kanner first described autism 75 years ago, the field has made great strides in 
elucidating the underpinnings of ASD. Although notable progress has been made in ASD 
diagnosis and treatment (6), the cause is still elusive. In pursuit of understanding the etiology of 
ASD, this dissertation focused on three important, yet understudied questions. The findings 
from our study are not deterministic, but have contributed to the field in many ways. 
Specifically, some results confirmed previous research (e.g. accelerated growth during infancy 
and ASD, maternal supplement intake and ASD); others extended existing knowledge (e.g. cord 
adiponectin and early childhood adiponectin association with ASD), while others were 
completely new and cutting-edge (e.g. excessive plasma folate, vitamin B12 levels and ASD risk; 
leptin mediating the association of rapid infant weight gain and ASD; mechanistic role of 
adiponectin in preterm and ASD). This is an exciting time for autism research and the field of 
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early life origins of ASD is brimming with new research in this era of rapid advancement in 
biomedical research and biotechnology. The accumulating evidence and newer insights 
contributed by studies like ours and others will push the field forward and ultimately help to 
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